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ii Summary 
As  the  incidence  of  type  2  diabetes  rises  exponentially  in  the  early  part  of  the  21"'  century, 
the  global  healthcare  and  financial  burdens  associated  with  this  chronic  condition  rise  in 
tandem.  As  such,  it  becomes  increasingly  important  to  characterise  this  disease  further,  and 
unravel  the  molecular  mechanisms  which  lead  to  hyperglycaemia  and,  ultimately, 
premature  vascular  disease.  Insulin  resistance,  while  pathognomonic  of  type  2  diabetes,  is 
not  confined  to  this  condition.  It  has  become  clear  that  insulin  resistance  lies  at  the  centre  of 
a  constellation  of  cardiovascular  risk  factors,  which  include  hypertension,  obesity  and 
dyslipidaemia.  To  date  there  are  no  large  prospective  studies  that  have  examined  the  role  of 
insulin  sensitivity  in  the  development  of  vascular  disease,  however  epidemiological 
evidence  suggests  that  there  is  a  relationship.  Thus,  studies  exploring  the  factors  that 
determine  insulin  sensitivity  are  of  considerable  clinical  importance. 
In  this  thesis,  a  series  of  studies  is  described  which  were  designed  to  measure  insulin  action 
in  the  whole  body  and  in  isolated  tissues.  Insulin  sensitivity  was  measured  in  the  whole 
body  using  the  hyperinsulinaemic  euglycaemic  clamp,  though  also  in  adipose  tissue  by 
measuring  insulin-mediated  suppression  of  lipolysis  and  in  human  resistance  vessels  by 
measuring  insulin-mediated  vasodilation.  In  association  with  this,  the  effect  of  activation  of 
endogenous  hormonal  axes  that  may  influence  insulin  sensitivity  was  investigated,  not  only 
in  the  whole  body  but  also  in  individual  tissues. 
iii As  an  overview  of  the  experimental  chapters: 
i)  Insulin-mediated  suppression  of  lipolysis;  development  and  application  of  an 
assay  of  insulin  sensitivity 
In  chapter  3,  the  development  of  an  assay  designed  to  measure  insulin  sensitivity  in 
isolated  adipocytes  is  described.  Initial  experiments  are  described  that  establish  the 
fundamentals  of  this  assay,  which  is  based  on  insulin-mediated  suppression  of 
isoproterenol-induced  lipolysis.  There  follows  investigation  of  the  hypothesis  that 
insulin  sensitivity  in  isolated  adipocytes  reflects  the  phenotype  of  the  patient  from 
whom  they  are  obtained;  phenotype  characterisation  included  fasting  insulin,  blood 
pressure,  fasting  lipids  and  measurement  of  basal  metabolic  index.  In  addition  to 
demonstrating  a  reduction  in  insulin  sensitivity  in  obese  individuals,  a  continuous 
relationship  was  observed  between  insulin  sensitivity  and  BMI.  Thus,  there  was 
evidence  of  a  relationship  between  clinical  phenotype  and  the  response  to  insulin  at  a 
cellular 
fevel. 
ii)  Dietary  sodium  restriction  and  insulin  sensitivity 
The  hypothesis  that  modest  dietary  sodium  restriction,  by  activation  of  the  renin- 
angiotensin  system,  reduces  systemic  insulin  sensitivity  is  investigated.  This  study 
followed  previous  observations  that  severe  dietary  sodium  restriction  reduces  insulin 
sensitivity,  and  that,  in  keeping  with  this,  use  of  the  angiotensin  converting  enzyme 
inhibitors  may  improve  insulin  sensitivity.  Using  a  double-blind,  randomised,  placebo- 
controlled  crossover  trial,  an  11%  reduction  in  systemic  insulin  sensitivity  was 
demonstrated  in  association  with  modest  dietary  sodium  restriction  and  significant 
activation  of  the  circulating  renin  angiotensin  system.  Potential  explanations  for  the 
iv heterogeneity  of  previous  study  findings,  as  well  as  the  clinical  implications  of  the 
observed  fall  in  insulin  sensitivity,  are  discussed. 
iii)  Angiotensin  11  and  insulin  sensitivity  in  human  adipocytes 
In  chapter  5,  in  an  attempt  to  explain  the  findings  in  the  previous  chapter,  the 
hypothesis  that  angiotensin  II  may  have  a  direct  cellular  effect  on  insulin  action  is 
explored.  nis  may  be  explained  by  intracellular  crosstalk  between  second  messengers 
of  the  insulin  and  angiotensin  H  signalling  cascades.  Having  confirmed  the  presence  of 
angiotensin  H  binding  to  isolated  adipocytes,  no  effect  of  angiotensin  II  on  insulin- 
stimulated  glucose  transport,  insulin-mediated  suppression  of  lipolysis  or  glucose 
transport  in  the  absence  of  insulin  was  demonstrated.  The  conclusion  was  reached  that 
the  findings  in  chapter  4  might  be  explained  by  angiotensin  II  action  in  alternative 
tissue,  or  action  of  an  alternative  hormone  such  as  aldosterone.  There  was  no  evidence 
to  support  the  suggestion  that  angiotensin  H  contributes  to  insulin  resistance  in  human 
adipose  tissue. 
iv)  Glucocorticoids  and  insulin  sensitivity:  dissociation  of  insulin's  metabolic  and 
vascular  actions 
In  chapter  6,  the  effect  of  a  short  period  of  exposure  to  glucocorticoid  on  insulin 
sensitivity  is  investigated,  again  using  a  double-blind,  randomised,  placebo-controlled 
design.  In  this  study,  insulin  sensitivity  was  measured  both  systemically  and  again  in 
isolated  tissue,  though  on  this  occasion  in  small  resistance  vessels  dissected  from 
s.  ubjects  at  the  end  of  both  dexamethasone  and  placebo  phases.  As  anticipated,  systemic 
insulin  sensitivity  was  reduced  significantly  by  glucocorticoids  (mean  reduction  of 
29%),  however  there  was  no  difference  in  insulin  action  in  isolated  vessels  between 
V phases.  While  confirming  the  effect  of  glucocorticoids  on  insulin  sensitivity,  this 
observation  is  also  important  in  light  of  the  debate  regarding  the  coupling  of  insulin 
action  in  different  tissues.  Possible  explanations  for  the  dissociation  of  the  vascular  and 
metabolic  effects  of  insulin  in  this  model  are  discussed. 
Conclusions 
From  the  above  experimental  chapters,  several  conclusions  were  made 
i)  Insulin  sensitivity  in  isolated  human  adipocytes  is  reduced  in  obese,  though 
otherwise  healthy,  females  with  normal  fasting  plasma  glucose. 
ii)  Dietary  sodium  restriction  is  associated  with  a  reduction  in  systemic  insulin 
sensitivity. 
iii)  Intracellular  crosstalk  between  angiotensin  II  and  insulin  does  not  result  in 
insulin  resistance  in  human  adipocytes. 
iv)  Dexamethasone  treatment  is  associated  with  a  significant  reduction  in  systemic 
insulin  sensitivity,  though  no  change  in  insulin  action  in  the  vasculature. 
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xviii Chapter  1:  Introduction 
1.1  Overview 
Over  a  century  has  passed  since  the  concept  of  treating  diabetes  with  pancreatic  material 
was  proposed  by  Minkows1d  and  Von  Merings  in  the  University  of  Strasbourg  in  1889  (1). 
In  1923,  the  Nobel  Prize  in  physiology  and  medicine  was  awarded  to  Banting  and  McLeod, 
who  shared  the  award  with  Best  and  Collip  respectively,  for  the  discovery  of  insulin.  Very 
soon  afterwards,  insulin  was  widely  available  as  treatment  for  diabetes,  a  condition  with  a 
hitherto  appalling  prognosis.  Indeed,  Joslin  described  the  first  patients  receiving  insulin 
therapy  as  "near  resurrections". 
In  1936,  Himsworth  made  the  observation  (2)  that  there  was  differential  sensitivity  to 
insulin  in  patients  with  diabetes,  leading  to  the  realisation  that  although  insulin  acted  as  an 
efficient  blood  glucose-lowering  agent,  there  was  a  group  of  patients  with  diabetes  who 
seemed  less  sensitive  to  insulin  action.  Soon  after  insulin  assays  were  available,  it  became 
clear  that  this  less  insulin  sensitive  group  of  patients  did  not  in  fact  lack  circulating  insulin; 
indeed  there  was  an  abundance  (3).  As  such,  the  concept  of  insulin  resistance  was 
developed.  The  high  cardiovascular  mortality  associated  with  type  2  diabetes  and 
hyperinsulinaemia  (and  therefore  insulin  resistance),  in  conjunction  with  the  observation 
that  in  the  non-diabetic  population  there  were  associations  between  hyperinsulinaemia, 
hypertension  (4)  and  coronary  heart  disease  (5)  led  several  groups  to  speculate  that  insulin 
resistance  was  an  important  metabolic  variable  that  conferred  a  poor  cardiovascular 
prognosis. 
I The  series  of  studies  contained  in  this  thesis  describe  several  techniques  used  to  measure 
insulin  sensitivity  in  both  the  whole  body  and.  in  isolated  tissues,  and  the  relationship 
between  these  measurements  and  the  cardiovascular  phenotype  of  subjects.  In  addition,  I 
have  studied  the  influence  of  activity  of  other  endocrine  systems,  such  as  the  renin 
angiotensin  aldosterone  system  and  the  hypothalamic  pituitary  adrenal  axis,  on  insulin 
sensitivity.  Lastly,  I  have  considered  the  relationship  between  the  metabolic  sensitivity  to 
insulin  and  the  role  of  insulin  in  the  vasculature,  in  an  attempt  to  develop  a  direct  link 
between  insulin  resistance  and  vascular  disease. 
2 1.2  Insulin:  basic  biology  and  physiology 
1.2.1  Synthesis  and  secretion  of  insulin 
The  insulin  molecule  is  made  up  of  two  polypeptide  chains  (A  and  B),  which  are  linked  by 
disulphide  bonds.  Circulating  insulin  is  the  result  of  the  proteolytic  cleavage  of 
preproinsulin  to  proinsulin,  and  then  to  insulin  and  C-peptide,  which  are  released  from  9 
cells  in  the  Islets  of  Langerhan's  in  equimolar  amounts.  Small  amounts  of  the  structurally 
very  similar  proinsulin  are  also  secreted  in  this  process,  giving  rise  to  a  potential  source  of 
interference  with  non-specific  insulin  assays.  Insulin  is  secreted  in  response  to  various 
physiological  stimuli,  including  glucose,  arginine,  lysine,  ketone  bodies  and  free  fatty  acids 
(reviewed  in  (6)). 
1.2.2  Physiological  actions  of  insulin 
Insulin  binds  to  its  transmembrane  tyrosine  kinase  coupled  receptor  (see  section  1.7)  and, 
through  a  series  of  second  messenger  events,  stimulates  its  cellular  actions  (reviewed  in 
(6)),  the  exact  nature  of  which  depend  on  the  target  tissue  and  organ. 
e  Glucose  Uptake.  Insulin  stimulates  glucose  uptake  into  muscle  and  fat,  in  a  process 
involving  the  translocation  of  specific  insulin  responsive  glucose  transporters  to  the 
cell  surface. 
9  Glycogen  Synthesis.  Insulin  stimulates  the  storage  of  glucose  as  glycogen  in  skeletal 
muscle,  a  process  that  involves  the  activation  of  glycogen  synthase  by  glycogen 
synthase  Idnase. 
3 &  Lipogenesis  /  suppression  of  Upolysis.  Much  of  the  glucose  taken  up  into  adipose 
tissue  is  stored  as  triglyceride.  Insulin  activates  acetyl  coenzyme  A  (COA) 
carboxylase,  which  favours  the  diversion  of  acetyl  coenzyme  A  away  from 
oxidation  and  toward  lipid  synthesis.  This  may  be  mediated  by  activity  of  the 
adenosine  Y,  Y-cyclic  monophosphate  (cAMP)  dependent  protein  Idnase. 
e  Hepatic  glucose  output.  Amino  acids  derived  from  muscle  and  glycerol  released 
from  triglyceride  lipolysis  may  be  converted  into  substrates  for  gluconeogenesis. 
While  glucagon  facilitates  this  process,  insulin  inhibits  the  hepatic  production  of 
glucose.  The  breakdown  of  hepatic  glycogen,  an  additional  hepatic  source  of 
glucose,  is  again  regulated  by  the  balance  of  glucagon's  agonist  and  insulin's 
antagonist  action. 
9  Vasodilation.  In  addition  to  the  metabolic  actions  of  insulin,  it  has  become  clear  that 
insulin  acts  in  the  vasculature  as  a  vasodilator,  involving  the  endothelial-dependent 
release  of  vasoactive  substances  such  as  nitric  oxide.  This  is  discussed  later  in  this 
I 
thesis. 
Certain  common  conditions,  such  as  type  2  diabetes  and  essential  hypertension,  are 
characterised  by  a  reduction  in  the  ability  of  insulin  to  transport  glucose  into  cells  -  insulin 
resistance  (reviewed  in  (7-9) 
.  In  addition,  other  insulin-regulated  processes,  such  as 
suppression  of  lipolysis  and  possibly  insulin-mediated  vasodilation  may  also  be  attenuated. 
This  thesis  will  focus  on  the  mechanism  and  nature  of  insulin  resistance  measured  in  human 
tissue  and  in  the  whole  body.  In  order  to  do  so,  it  is  necessary  to  define,  more  specifically, 
what  insulin  resistance  implies  and  the  risks  that  it  may  carry. 
4 1.3  Insulin  resistance 
1.3.1  Definition 
Insulin  resistance,  like  other  syndromes  of  hormone  resistance,  may  be  defined 
conceptually  as  "a  subnormal  biological  response  to  insulin  at  physiological 
concentrations".  This  simple  definition  hides  the  complexity  of  the  biological  parameter 
that  it  attempts  to  summarise,  a  situation  that  becomes  clearer  when  attempts  are  made  to 
measure  this  variable. 
1.3.2  Measurement  of  whole  body  insulin  sensitivity 
A  variety  of  methods  employed  in  the  in  vivo  measurement  of  insulin  sensitivity  have  been 
described,  and  the  field  is  characterised  by  a  lack  of  standardisation.  These  methods  are  of 
varying  complexity,  ranging  from  simple  fasting  plasma  insulin  and  insulin  resistance 
index,  to  the  time  consuming,  though  more  direct,  euglycaemic  hyperinsulinaemic  clamp 
(10).  The  methods  of  measuring  insulin  sensitivity  are  detailed  below  (reviewed  in  (11)), 
and  summarised  in  table  1.1. 
0  Euglycaemic  hyperinsulinaemic  clamp(10):  A  primed,  then  constant, 
exogenous  insulin  infusion  suppresses  endogenous  pancreatic  0  cell  insulin 
secretion  and  hepatic  glucose  production,  while  glucose  is infused  at  a  variable  rate 
in  order  to  maintain  blood  glucose  at  a  predetermined  level.  At  the  steady  state  the 
glucose  infusion  rate  reflects  directly  the  rate  of  glucose  uptake  into  tissues,  i.  e. 
insulin  sensitivity.  Initial  clamp  studies  used  arterial  blood  samples  for  analysis  of 
serum  glucose  levels,  but  hand  warming  is  now  widely  used  to  "arterialise"  venous 
blood  (12).  Reproducibility  is  improved  when  a  three  hour  rather  than  two  hour 
clamp  is  performed  (13) 
5 0  Insulin  suppression  test:  Glucose  and  insulin  are  co-infused,  with  rates  held 
constant.  Steady  state  is  achieved  once  plasma  glucose  reaches  a  plateau. 
Endogenous  insulin  release  is  suppressed  using  somatostatin.  Steady  state  plasma 
glucose  is  used  as  an  index  of  insulin  sensitivity. 
0  Short  insulin  tolerance  test:  This  is  based  on  the  rate  at  which  plasma 
glucose  disappears  during  the  first  twenty  minutes  following  an  intravenous  bolus 
of  insulin. 
0  Serum  insulin:  Serum  insulin  has  been  used  as  a  surrogate  measure  of 
insulin  resistance,  based  on  the  assumption  that  compensatory  hyperinsulinaemia 
occurs  under  normal  circumstances  in  proportion  to  the  degree  of  insulin  resistance 
(this  may  not  be  the  case  in  the  context  of  pancreatic  failure).  Both  fasting  and  post- 
prandial  measurements  have  been  used  in  prospective  studies  of  insulin  resistance 
and  cardiovascular  disease  (14)  (15).  The  main  difficulties  in  interpreting  these 
values  are  variations  in  the  performance  of  assay  Idts  across  centres  and  differences 
in  the  specificity  of  insulin  vs.  its  precursor  molecules(16). 
0  Homeostatic  Modelling  Assessment  (HOMA)  and  Fasting  Insulin  Resistance 
Index  (FIRI):  These  simple  indices  are  derived  from  fasting  insulin  and  glucose 
levels  (17,18)  In  non-diabetic  populations,  positive  correlation  with  fasting  insulin 
is  almost  unity.  However,  in  datasets  from  which  diabetic  subjects  have  not 
formally  been  excluded,  these  may  provide  a  better  surrogate  measurement  of 
insulin  sensitivity  than  fasting  insulin(I  6). 
0  Frequently  sampled  iv  glucose  tolerance  test  with  minimal  model  analysis: 
This  technique,  in  which  up  to  22  glucose  samples  are  obtained  for  the 
mathematical  calculation  of  insulin  sensitivity,  has  been  reported  as  having  a  high 
6 degree  of  correlation  with  values  of  insulin  sensitivity  generated  using  the 
euglycaemic  hyperinsulinaemic  clamp  in  healthy  volunteers  (19).  In  subjects  with 
type  2  diabetes,  however,  the  correlation  is  less  strong,  particularly  when  the 
number  of  glucose  samples  is  reduced  to  12  (as  in  the  Insulin  Resistance  and 
Atherosclerosis  Study(20)).  As  such,  this  technique  is  best  employed  in  studies  of 
populations  with  normal  glucose  tolerance. 
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ORIGINAL 1.4  Insulin  resistance,  the  metabolic  syndrome  and  cardiovascular  disease 
Scientific  and  clinical  awareness  of  the  link  between  insulin  resistance  and  vascular  disease 
has  increased  exponentially  over  the  last  20  years.  A  relationship  between  atherosclerosis 
and  plasma  insulin  was  hypothesised  more  than  30  years  ago  (5),  based  on  the  presence  of 
hyperinsulinaemia  in  acute  myocardial  infarction.  More  recent  cross  sectional  studies, 
suggesting  that  plasma  insulin  is  associated  with  other  cardiovascular  risk  factors  (25), 
provided  firiner  evidence  on  which  to  base  larger  prospective  projects.  Reaven's 
description  of  Syndrome  X,  or  the  metabolic  syndrome,  in  1988  (26),  was  a  synthesis  of  his 
and  others'  data  that  offered  a  definition  of  the  metabolic  derangement  accompanying 
insulin  resistance.  His  hypothesis  states  that  insulin  resistance  lies  at  the  centre  of  a 
constellation  of  cardiovascular  risk  factors,  with  each  individual  component  associated  with 
vascular  disease,  however  these  factors  coexist  in  certain  individuals  more  than  could  be 
explained  by  chance.  Despite  insulin  resistance  per  se  being  a  prerequisite  of  the  syndrome, 
diabetic  levels  of  hyperglycaemia  were  not  an  absolute  requirement;  more  important  was 
resistance  t6  the  metabolic  effects  of  insulin,  with  secondary  hyperinsulinaemia.  Insulin 
resistance  is  a  continuous  biological  variable  with  wide  variability  throughout  the  non- 
diabetic  and  diabetic  populations;  up  to  a  ten  fold  variation  has  been  reported  in  subjects 
with  nonnal  glucose  tolerance  (27),  (28). 
The  baseline  characteristics  of  recruits  to  cohorts  such  as  the  Atherosclerosis  Risk  in 
Communities  study  (29)  and  the  San  Antonio  Heart  Study  (30)  demonstrate  clearly 
statistical  clustering  of  hypertriglyceridaemia,  low  concentrations  of  high  density 
lipoprotein  (HDL)-cholesterol,  hypertension,  diabetes  and  hyperuricaemia  with  fasting 
insulin,  basal  metabolic  index  (BMI)  and  waist  hip  ratio  (WHR).  Detailed  metabolic 
characterisation  of  a  population  of  nearly  3000  subjects  clearly  illustrates  the  co-clustering 
10 of  these  individual  risk  factors  (table  1.2)  (3  1).  The  prevalence  of  the  individual 
components  of  the  syndrome  in  isolation  was  far  less  than  in  combination,  while  even  in 
the  isolated  forms,  associations  with  hyperinsulinaernia,  implying  insulin  resistance,  were 
noted.  This  led  the  authors  of  this  analysis  to  hypothesise  that  insulin  resistance  lies  at  the 
centre  of  the  metabolic  syndrome. 
11 Table  1.2:  The  metabolic  syndrome:  prevalence  of  individual  components  in  a 
Western  population 
Component  Definition  Prevalence  in  Prevalence 
population  alone 
Obesity  BM>27kg/m2  54.3  29 
Type  2  diabetes  Fasting  glucose  ýýMmmol/l  9.3  1.3 
or  2h  glucose  Z!:  1  1.1  mmol/l, 
or  on  treatment 
Impaired  glucose  Fasting  glucose  <  7.8mmol/1  11.1  1.8 
tolerance  and  2h  glucose  7.8- 
11.1  mmol/I 
Hypertension  Diastolic  blood  pressure  -a  9.8  1.5 
95mmHg,  or  on  treatment 
Hypertriglyceridaemla  Serum  triglyceride  10.3  1 
>2.9mmol/I 
Hypercholesterolaemia,  Serum  total  cholesterol  9.2  1.7 
>6.5mmol/I 
12 1.4.1  Diagnostic  criteria  for  the  metabolic  syndrome 
Clearly  if  there  are  to  be  prospective  studies  of  the  metabolic  syndrome  and  its  attendant 
cardiovascular  risk,  strict  criteria  are  required  for  its  definition.  There  have  been  two  main 
attempts  to  define  these  diagnostic  criteria  (table  1.3).  Both  definitions  are  hampered  by  the 
lack  of  standardisation  in  the  measurement  of  the  individual  components  of  the  syndrome 
across  centres,  in  particular  the  specificity  of  insulin  assays  and  the  precise  protocol  for  the 
euglycaemic  hyperinsulinaemic  clamp  technique  are  highly  variable 
Though  the  constituents  are  similar  for  both  sets  of  guidelines,  there  are  notable  differences 
that  may  have  important  effects  on  projected  population  prevalence.  The  World  Health 
Organisation  (WHO)  criteria  (32)  require  either  proven  glucose  intolerance  or  the 
performance  of  a  euglycaemic  clamp.  In  the  European  Group  on  Insulin  Resistance  (EGIR) 
guidelines  (33),  the  blood  pressure  threshold  is  lower,  the  triglyceride  threshold  is  higher, 
the  diagnosiý  of  central  obesity  does  not  require  a  measurement'of  hip  circumference  and 
microalbuminuria  is  not  included.  When  the  WHO  set  of  criteria  is  applied  to  the  EGIR 
database  of  1500  non-diabetic,  normotensive  European  adults  (34),  a  prevalence  of  15.6% 
(WHO)  (35)  is  derived.  Subsequent  application  of  diagnostic  guidelines  to  other  datasets 
has  yielded  prevalence  of  between  7%  and  30%  using  WHO  criteria  and  between  1%  and 
22%  using  EGIR  criteria  (33). 
13 Table  1.3:  Diagnostic  criteria  for  the  metabolic  syndrome 
WHO  1998(32)  EGIR  1999(") 
Name  "metabolic  syndrome"  "insulin  resistance  syndrome" 
Population  All  Non-diabetic 
Eligible 
Criteria  Diabetes  mellitus  or  impaired  Insulin  resistance  (euglycaemic 
glucose  tolerance  "  and/or  insulin  hyperinsulinaemic  clamp)  or  fasting 
resistance  (euglycaemic  f  hyperinsulinaemia, 
hyperinsulinaemic  clamp)  b 
Plus  Plus 
two  of  two  of 
"  BP  2:  160/90mmHg  0  BP  2:  140/90  mmHg  (or 
"  Triglycerides  treated) 
>1.7mmolA  '  0  Triglycerides;  >2.  Ommol/19 
"  WHR  >0.9  in  males/  a  Waist  circumference 
>0.85  in  females  d  2:  94cm  in  males/>_80cm  in 
"  Microalbuminuria  females 
a  Fasting  glucose 
2:  6.  ImmoUl  but 
<7.0mMol/l  h 
a)  according  to  WHO  criteria 
b)  lowest  quartile  of  glucose  disposal  for  background  population  under  study 
c)  and/or  HDL  <0.9mmoVI  in  males,  <I.  OmmoVI  in  females 
d)  and  /or  BNU>30kg/m' 
e)  Albumin  excretion  rate  2:  20gghnin  or  albumin:  creatinine  ratio  2:  20mg/g 
f)  Lowest  quartile  of  glucose  disposal  rate  or  highest  quartile  of  insulin  level 
g)  Or  HDL  <  1.0mmol/l  or  on  therapy 
h)  i.  e.  non-diabetic  fasting  hyperglycaernia 
14 1.4.2  The  metabolic  syndrome,  insulin  resistance  and  lipid  profile 
The  metabolic  syndrome,  insulin  resistance  and  type  2  diabetes  are  associated  with  an 
atherogenic  lipid  profile,  traditionally  consisting  of  raised  total  cholesterol,  low  HDL 
cholesterol  and  elevated  triglycerides.  Additional,  qualitative,  aspects  of  the  dyslipidaemia 
prevalent  in  insulin  resistance  have  become  apparent  in  recent  years.  In  males  with  type  2 
diabetes  and  hypertriglyceridaernia,  there  is  a  preponderance  of  small  dense  low-density 
lipoprotein  (LDL)  particles  and  an  associated  reduction  in  larger,  buoyant  particles  (36). 
This  relationship  is  also  applicable  to  subjects  without  diabetes;  analysis  of  the  San 
Antonio  Heart  Study  cohort  revealed  that  small  dense  LDL  was  associated  with  elevated 
triglycerides,  decreased  HDL,  hypertension  and  impaired  glucose  tolerance.  There  was  also 
an  association  between  increasing  numbers  of  these  individual  metabolic  disorders  and 
decreasing  LDL  size  (37).  The  smaller  LDL  subtype  is  in  addition  more  easily  oxidised  that 
its  larger  counterparts  (38),  and  again  there  is  evidence  demonstrating  an  association 
between  LDL  "oxidizability"  and  insulin  resistance  (39).  That  this  small,  dense,  partially 
oxidised  LDL  is  related  to  atherosclerosis  is  demonstrated  in  a  cross-sectional  study  of 
middle-aged  males,  in  whom  there  was  a  negative  relationship  between  LDL  particle  size 
and  intimal  media  thickness  of  the  internal  carotid  artery  (40). 
1.5  Cardiovascular  risk  associated  with  insulin  resistance:  are  insulin  resistance  and 
hyperinsulinaemia  cardiovascular  risk  factors? 
From  the  preceding  discussion  it  may  be  extrapolated  that,  given  the  traditional 
cardiovascular  risk  factors  encompassed  in  the  metabolic  syndrome,  as  a  syndrome  there 
will  be  an  association  with  cardiovascular  disease.  What  is  less  clear  is  whether  insulin 
resistance  per  se  is  an  independent  risk  factor  once  the  other  associated  factors  are 
accounted  for.  As  the  absolute  risk  of  cardiovascular  events  in  apparently  healthy  middle- 
15 aged  subjects  remains  small,  large  well-designed  prospective  studies  with  detailed 
metabolic  investigation  at  baseline'are  required  to  answer  this  fundamentally  important 
question.  All  but  a  very  few  studies  to  date  have  used  plasma  insulin  as  a  surrogate  marker 
of  insulin  sensitivity. 
1.5.1  Prospective  studies  of  insulin  as  a  cardiovascular  risk  factor 
Several  large  studies  have  examined  the  relationship  between  plasma  insulin,  either  fasting 
or  post-load,  and  while  a  detailed  review  of  this  literature  is  beyond  the  scope  of  this  thesis, 
I  have  considered  certain  important  aspects  of  these  studies;  while  some  have  suggested 
that  insulin  is  an  important  cardiovascular  risk  marker,  even  after  adjustment  for  other  risk 
factors,  others  have  found  no  relationship  whatsoever.  Several  factors  may  help  explain 
these  discrepancies. 
0  Age:  The  age  of  the  population  may  be  important.  For  instance,  in  the 
Busielton  study,  60-69  year  old  males  with  high  (values  in  the  upper  2& 
percentile)  one-hour  post  load  insulin  levels  had  a  risk  ratio  of  2.0  for  the  six-year 
incidence  of  coronary  heart  disease  (14)  and  a  risk  ratio  of  2.3  for  twelve-year 
coronary  heart  disease  mortality  (41)  after  adjustment  for  other  risk  factors.  No  such 
relationship  was  observed  in  the  younger  or  older  groups  studied. 
In  younger  populations,  it  may  be  that  the  risk  of  experiencing  a  cardiovascular 
event  during  follow-up  is  too  low  to  demonstrate  statistical  significance,  while  in 
older  populations  relevant  subjects  may  be  excluded  on  the  basis  of  already  having 
clinically  apparent  cardiovascular  disease.  In  addition,  studies  in  older  subjects  may 
be  focussing  on  "survivors"  that  are  not  representative  of  the  general  population. 
16 Duration  q  Follow  Up:  Several  prospective  studies  have  analysed  the 
relationship  between  serum  insulin  and  cardiovascular  disease  at  more  than  one 
time-point.  This  has  demonstrated  inconsistencies  in  insulin's  strength  as  a  risk 
factor.  In  the  first  follow  up  of  the  Paris  Prospective  Study  (mean  follow  up  63 
months,  mean  age  49)  (42),  fasting  serum  insulin  was  a  significant  risk  factor  after 
multivariate  analysis  for  the  development  of  coronary  heart  disease  (CHD)  (non- 
fatal  MI  and  coronary  related  deaths).  However,  in  the  15-year  follow  up  data  from 
the  same  cohort,  no  relationship  was  found  between  fasting  insulin  and  overall 
CHD  mortality.  Two  hour  post  load  insulin  levels  were  identified  as  an  independent 
risk  factor,  though  only  when  considered  as  a  categorical  variable  (below  or  above 
452  pmoVI  i.  e.  the  lower  limit  of  the  fifth  quintile  of  the  distribution)  (15). 
Similarly,  in  Helsinki  policemen  (n--982),  9.5  year  follow  up  (43)  revealed  that 
elevated  plasma  insulin  one  and  two  hours  following  a  glucose  load  was  an 
independent  risk  factor  for  CHD  (CHD  death  or  non-fatal  MI),  while  in  the  longer 
termý  follow  up  of  the  same  cohort,  (44)  only  an  association  between  one-hour 
insulin  (highest  area  under  the  curve  (AUC)  insulin  quintile  vs.  lower  four  quintiles) 
and  CHD  events  persisted,  and  with  less  strength  than  that  seen  initially  (  5-years 
hazard  ratio  2.36  (1.00-5.57  95%CD,  10-year  hazard  ratio  2.29  (1.31-4.02  95%CD, 
15-year  hazard  ratio  1.76  (1.09-2.82  95%CI)  and  22-year  hazard  ratio  1.32  (0-89- 
1.97  95%CI)  after  adjustment  for  other  factors). 
0  Assay  specificity:  It  has  been  argued  that  differential  cross-reactivity  of 
insulin  mdioinununoassays  with  insulin  precursor  molecules,  intact  insulin  and 
32,33  split  insulin  may  be  a  further  source  of  heterogeneity  between  studies.  It  is 
interesting  to  note  that  both  studies  which  have  used  specific  insulin  assays  (the 
17 British  Regional  Heart  Study  (45)  and  a  nested-case  control  study  of  Canadian 
males  (46))  have  found  serum  insulin  to  be  a  risk  factor  for  CHD  after  multivariate 
analysis. 
0  Ethnicity:  While  most  studies  have  focused  on  Caucasian  populations,  the 
evidence  for  serum  insulin  as  an  independent  cardiovascular  risk  factor  in  other 
populations  is  less  compelling.  Studies  of  the  insulin  resistant,  obese  Pima  Indians 
have  demonstrated  a  low  prevalence  of  cardiovascular  disease  (47),  while  fasting 
plasma  insulin  was  not  a  predictor  of  ischaemic  ECG  abnormalities  in  either 
diabetic  or  non-diabetic  members  of  this  ethnic  group  (48).  Similarly,  the 
relationship  between  plasma  insulin  and  blood  pressure  that  is  seen  in  some 
Caucasian  populations  is  less  strong  in  other  populations  (49). 
0  Cause  specific  outcomes:  One  factor  that  may  not  be  initially  obvious, 
thoujh  which  may  explain  apparent  discrepancies  amongst  studies,  is  the 
cardiovascular  endpoint.  For  example,  some  investigators-  have  focused  exclusively 
on  fatal  or  non-fatal  CHD,  while  others  have  used  composite  endpoints  of 
cardiovascular  disease  (CVD)  in  general.  Few  details  of  classification  of  sudden 
death  (i.  e.  CHD  or  otherwise)  are  given  by  some  investigators,  which  may  have  a 
considerable  bearing  on  risk  ratios. 
0  Adjustmentfor  other  riskfactors:  Perhaps  one  of  the  most  important  points 
in  this  debate  is  how  best  to  analyse  the  results.  In  univariate  analysis,  insulin  may 
be  associated  with  development  of  disease.  However,  after  adjustment  for  related 
IS risk'factors  (HDL-cholesterol,  obesity,  blood  pressure)  statistical  significance  is 
often  diminished  or  lost.  The  mathematics  of  multiple  regression  mean  that  the 
variable  that  is  most  accurately  and  reproducibly  measured  will  be  favoured  over 
related  variables  that  are  more  difficult  to  quantify.  Standard  statistical  approaches 
will  not  identify  a  phenotype  as  an  "independenf'  risk  marker  if  it  lies  on  a  chain  of 
definite  biological  causation  and  its  upstream  or  downstream  regulator  has  been 
included  in  the  model.  In  practice,  ýiose  risk  markers  that  are  fixed  (age/sex)  or  at 
least  partially  reversible  (obesity,  dyslipidaemia,  blood  pressure,  glycaemia)  will  be 
entered  into  models  in  preference  to  others. 
Factor  analysis  is  a  more  recent  approach  which  allows  for  biological  interactions 
amongst  variables.  Analysis  of  a  cohort  of  1069  Finnish  subjects  revealed  that  the 
"insulin  resistance"  factor  (reflecting  BMI,  VffR;  ý  triglycerides,  fasting  glucose  and 
insulin)  was  associated  with  a  hazard  ratio  of  1.33  (95%  CI  1.08-1.65)  for  the 
development  of  coronary  heart  disease  death  or  non-fatal  MI  at  seven  year  follow- 
up  in  men,  though  carried  no  increased  risk  in  women  (50).  Pyorala  et  al  ((5  1) 
applied  the  same  technique  to  the  Helsinki  Policeman  Study.  After  22-year  follow- 
up,  the  insulin  resistance  factor  (BMI,  subscapular  skinfold,  AUC  insulin  during 
oral  glucose  tolerance  test  (OGTT),  mean  blood  pressure  and  triglycerides)  was 
associated  with  an  age-adjusted  hazard  ratio  of  1.28  (1.10-1.50  95%  CD  for  CHD 
risk,  and  1.64  (1.29-2.08  95%  CD  for  stroke  risk. 
1.5.2  Insulin  as  a  cardiovascular  risk  factor:  a  meta-analysis 
Given  the  heterogeneous  methodology  and  the  apparently  contradictory  nature  of  the 
studies  of  insulin  as  a  cardiovascular  risk  marker,  a  meta-analysis  published  by  Ruige  et  al 
19 (52)  was  a  timely  addition  to  the  literature.  The  analysis  was  limited  to  prospective 
population-based  and  nested  case-control  studies  which  included  data  on  fasting  or  non- 
fasting  insulin  and  considered  cardiovascular  events  as  outcomes  (fatal/non  fatal  MI,  new 
ECG  abnonnalities).  Twelve  datasets  were  included  in  the  final  analysis.  Heterogeneity 
between  studies  was  noted,  mainly  with  regard  to  insulin  assays,  ethnic  composition  of 
study  groups  and  endpoints.  However,  an  overall  relative  risk  of  1.18  (1.01-1.29  95%  CI) 
for  an  increase  of  50pmol/I  in  fasting  insulin  concentration  was  derived.  Thus  it  was 
concluded  that  hyperinsulinaemia  is  indeed  associated  with  cardiovascular  risk,  although 
the  magnitude  of  the  risk  was  small  in  comparison  with  "establisheX'  risk  factors, 
especially  in  non-whites.  As  in  all  meta-analyses,  there  was  a  potential  for  publication 
bias. 
From  these  prospective  studies  of  insulin  (fasting  or  otherwise),  it  can  be  deduced  either 
that  insulin  resistance  is  not  a  strong  risk  factor  for  cardiovascular  disease,  or  that  plasma 
insulin  is  not  a  particularly  sensitive  or  specific  marker  of  insulin  resistance.  To  date,  there 
is  only  one  comparatively  small  prospective  study  in  which  insulin  resistance  was 
measured  at  baseline  (53).  In  this  study,  cardiovascular  end-points  occurred  in  the  most 
insulin  resistant  tertile  of  147  subjects  during  the  4.7-year  follow-up;  however,  these  end- 
points  included  peripheral  vascular  disease  and  hypertension  and  the  nature  (if  any)  of  the 
risk  associated  with  insulin  resistance  remains  unclear. 
1.5.3  Cross-sectional  studies  of  insulin  sensitivity  and  cardiovascular  disease 
Although  prospective  studies  provide  better  information  regarding  causation  in  the 
relationship  between  a  risk  factor  and  disease,  data  from  cross-sectional  studies  are  also  of 
considerable  value,  and  may  in  the  future  provide  prospective  data.  Furthermore,  some 
20 studies  have  measured  insulin  sensitivity  rather  than  serum  insulin  concentrations,  and  have 
characterised  larger  numbers  of  subjects  than  the  prospective  trials  described  above. 
In  a  cross  sectional  study  of  1,373  non-diabetic  Finnish  subjects  (54),  increasing  quintiles 
(I+IEI  vs.  HI+IV  vs.  V)  of  fasting  plasma  insulin  in  males  were  associated  with  an  increase 
in  the  age-adjusted  prevalence  of  CHD  (diagnosed  by  symptoms  or  ECG  changes).  No 
independent  relationship  was,  however,  present  between  insulin  and  CHD  after  adjustment 
for  other  cardiovascular  risk  factors. 
The  Insulin  Resistance  and  Atherosclerosis  Study  (IRAS)  investigators  (55)  chose  to  use  a 
more  direct  measurement  of  insulin  sensitivity  -  the  frequently  sampled  intravenous 
glucose  tolerance  test  with  minimal  model  analysis  -  rather  than  potentially  misleading 
surrogate  markers.  A  tri-ethnic  population  was  studied  in  an  attempt  to  clarify  the  role  of 
ethnicity  in  the  relationship  between  insulin  sensitivity  and  atherosclerosis.  In  all,  542 
white  non-Hispanic,  457  Hispanic  and  398  black  subjects  underwent  measurement  of 
insulin  sensitivity  and carotid  artery  intimal  media  thickness  (Mff),  the  prognostic 
significance  of  which  has  been  shown  in  a  healthy  population;  increasing  IMT  was 
associated  with  increased  incidence  of  myocardial  infarction.  and  stroke  at  six-year  follow- 
up  (56).  In  the  IRAS  study,  the  average  Mr  in  Hispanics  and  non-Hispanic  whites  was 
17/.  Lm  thinner  for  every  one-unit  increase  in  insulin  sensitivity,  once  corrected  for  other 
cardiovascular  risk  factors  and  glucose  tolerance.  The  important  finding  in  this  study  was 
that  asymptomatic  atherosclerosis  was  associated  with  insulin  resistance  in  Hispanic  and 
non-Hispanic  whites  (though  not  in  black  subjects);  this  was  only  partly  explained  by 
adjustment  for  traditional  cardiovascular  risk  factors,  glucose  tolerance,  fasting  insulin  and 
adiposity. 
21 1.6  Is  insulin  atherogenic? 
The  association  observed  between  plasma  insulin  levels  and  ischaernic  heart  disease  has  led 
some  investigators  to  suggest  that  insulin  itself  might  be  atherogenic  (57).  Proponents  of 
this  theory  suggest  that  insulin,  as  a  growth  factor,  stimulates  vascular  smooth  muscle  cell 
(vsmc)  proliferation  (58)  and  lipid  synthesis  (59).  Data  from  the  United  Kingdom 
Prospective  Diabetes  Study,  in  which  over  3000  subjects  with  type  2  diabetes  were 
randomised  to  receive  intensive  blood  glucose  lowering  treatment  modalities,  including 
insulin  therapy  in  approximately  30%,  may  have  refuted  this  hypothesis  (60)  in  that  the 
insulin  treated  group,  who  had  iatrogenic  hyperinsulinaemia,  did  not  suffer  excess 
cardiovascular  morbidity.  Reassuring  data  of  a  mechanistic  nature  are  also  provided  from  a 
study  of  patients  with  poorly  controlled  type  2  diabetes  who  underwent  in  vivo  tests  of 
endothelial  function  prior  to,  and  following,  six  months  of  insulin  therapy.  Insulin  therapy, 
in  association  with  a  fall  in  HbAlc,  triglycerides  and  free  fatty  acids,  resulted  in  an 
improvement  in  both  endothelium-dependent  and  -independent  vasodilation  (61). 
To  summarise  the  role  of  insulin  and  insulin  resistance  as  cardiovascular  risk  factors,  the 
present  lack  of  prospective  studies  of  insulin  sensitivity  and  cardiovascular  endpoints 
means  that  it  is  difficult  to  determine  the  magnitude  of  associated  cardiovascular  risk. 
While  there  are  data  examining  serum  insulin  as  a  predictor  of  cardiovascular  outcome,  the 
shortfalls  of  using  insulin  as  a  surrogate  marker  of  insulin  sensitivity  and  the  heterogeneity 
between  studies  limits  the  applicability  of  these  datasets  to  this  question.  Useful  data  does 
come  from  factor  analysis  studies,  where  the  relationship  between  clusters  of 
cardiovascular  risk  factors  and  endpoints  may  be  studied,  thus  overcoming  some  of  the 
limitations  of  multivariate  analysis.  The  IRAS  study  is  to  be  commended  in  its  use  of  a 
22 measure  of  insulin  sensitivity  (the  insulin  suppression  test),  and  has  shown  that  insulin 
sensitivity  is  associated  with  carotid  artery  atherosclerosis  in  a  cross  sectional  study.  To 
address  the  temporal  nature  of  this  relationship,  the  EGIR  investigators  have  co-ordinated 
the  pooling  of  clamp  data  from  20  European  research  centres  to  create  a  database  that  is 
large  enough  to  consider  important  epidemiological  issues.  The  group  proposes  a 
prospective  study  of  insulin  sensitivity  and  atherosclerotic  vascular  disease;  1,500  subjects 
will  have  detailed  metabolic  and  cardiovascular  profile  at  baseline,  then  undergo  follow  up 
assessments  to  examine  the  development  of  clinical  and  laboratory  markers  of 
atherosclerosis.  Clearly  this  will  enable  conclusions  to  be  drawn  regarding  the  nature  of  the 
relationship  between  insulin  resistance  and  cardiovascular  disease. 
23 1.7  Insulin-signalling  in  health  and  disease 
The  above  studies  have  focussed  on  whole  body  insulin  sensitivity  as  a  variable,  and 
considered  its  role  as  a  cardiovascular  risk  factor.  As  discussed  earlier,  the  generation  of 
such  a  value  must  take  into  consideration  a  complex  series  of  physiological  interactions.  As 
such,  only  limited  interpretations  can  be  made  on  the  action  of  insulin  at  the  tissue  and 
cellular  level.  Furthermore,  these  whole  body  insulin  sensitivity  values  may  be  influenced 
by  the  effect  of  changes  in  blood  flow  and  therefore  substrate  delivery  to  metabolically 
active  tissue  beds.  The  study  of  insulin  action  in  individual  tissue,  be  it  vascular  or 
metabolic  in  nature,  generally  requires  the  isolation  of  that  tissue.  By  examining  individual 
tissues,  both  in  tissue  culture  and  in  primary  isolates,  advances  have  been  made  in  the 
characterisation  of  the  intracellular  signalling  pathways  activated  in  response  to  insulin 
stimulation,  illustrated  in  figure  1.1.  These  events  are  outlined  below,  and  the  potential 
defects  in  the  pathway  are  considered  as  candidates  for  the  underlying  abnormality  in 
insulin  resistance.  It  must  be  emphasised  that,  despite  these  considerable  scientific 
advances  in  characterising  the  intracellular  action  of  insulin,  no  single  defect  has  been 
identified  in  population  studies  as  being  a  strong  candidate  to  underlie  the  majority  of  cases 
of  insulin  resistance  and  type  2  diabetes  seen  so  commonly  in  the  clinical  setting. 
24 Figure  1.1:  Insulin  signalling  in  metabolic  tissues 
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25 1.7.1  The  insulin  receptor 
The  insulin  receptor  is  present  in  nearly  all  tissues,  though  the  local  concentration  varies 
greatly  between  tissues.  The  insulin-like  growth  factor  -1  (IGF-1)  and  insulin  receptor- 
related  receptors  are  members  of  the  same  family,  with  considerable  homology  in  the 
intracellular  kinase  domain,  though  little  similarity  in  the  extracellular  binding  domain 
(62).  The  main  insulin  responsive  tissues,  namely  the  liver,  adipose  tissue  and  muscle,  have 
the  greatest  number  of  insulin  receptors. 
The  insulin  receptor  gene  is  found  on  the  short  arm  of  chromosome  19  (63).  The  receptor 
itself  consists  of  two  extracellular  a-subunits  and  two  intracellular  P-subunits  that  are 
linked  by  disulphide  bonds. 
Activation  of  the  insulin  receptor,  and  the  subsequent  intracellular  second  messenger 
events,  are  regulated  by  the  phosphorylation  of  tyrosine  residues.  Insulin  binding  to  the 
external  a-subunit  stimulates  the  intrinsic  tyrosine  kinase  activity  of  the  insulin  receptor, 
and  results  in  the  autophosphorylation  of  key  regulatory  tyrosine  residues.  When  the  insulin 
receptor  is  vacant,  there  is  tonic  inhibition  of  the  intrinsic  Idnase  activity.  Phosphorylation 
of  serine/threonine  residues  may  inhibit  insulin  receptor  activation,  thus  providing  a 
mechanism  for  fine  control  of  the  insulin  receptor  involving  ligand  binding,  and  the  balance 
of  serine  and  tyrosine  phosphorylation. 
The  insulin  receptor  also  has  a  role  in  the  internalisation  of  bound  insulin.  The  insulin- 
receptor  complex  is  internalised  by  endocytosis,  and  while  insulin  is  then  degraded,  the 
26 receptor  recycles  to  the  plasma  membrane.  Prolonged  insulin  stimulation  may  also  lead  to 
degradation,  and  so  down  regulation,  of  the  receptor  (64). 
1.7.1.1  Defects  in  the  insulin  receptor 
Insulin  receptor  gene  defects  underlie  the  severe  insulin  resistance  syndromes,  such  as 
leprechaunism,  the  Rabson-Mendenhall  syndrome  and  Type  A  insulin  resistance  (reviewed 
in  (65),  (66)).  These  are  characterised  by  acanthosis  nigricans,  glucose  intolerance  and 
abnormalities  of  growth  and  development.  These  receptor  abnormalities  lie  mainly  in  the 
absolute  number  of  receptors,  the  binding  of  insulin  (a-subunit)  or  in  the  activation  of 
tyrosine  kinase  activity  (P-subunit).  Since  the  description  of  the  first  insulin  receptor 
mutation  in  1988,  over  50  further  mutations  have  been  described  (reviewed  in  (67)). 
However,  though  small  reductions  in  receptor  number  and  binding  have  been  observed,  as 
well  as  defects  in  receptor  and  substrate  phosphorylation,  these  seem  unlikely  to  be  the 
primary  cause  of  the  insulin  resistance  seen  in  type  2  diabetes. 
The  application  of  gene  knockout  technology  to  the  area  of  insulin  action  has  offered  new 
insights  into  the  role  of  the  insulin  receptor  and  signalling  intermediates  in  insulin  action. 
Homozygous  insulin  receptor  knockout  mice  (IR-)  have  a  phenotype  characterised  by 
severe  insulin  resistance,  with  diabetes,  ketoacidosis,  hypertriglyceridaernia  and  growth 
retardation,  followed  by  death  within  one  week.  Mice  heterozygous  for  the  deletion, 
however,  have  no  dramatic  increase  in  the  incidence  of  type  2  diabetes.  From  a  mechanistic 
standpoint,  data  from  specific  tissue  knockouts,  where  the  insulin  receptor  may  only  be 
absent  in  one  tissue,  are  more  intriguing.  Muscle  specific  insulin  receptor  knockout  mice 
(MIRKO)  show  reduced  insulin-mediated  glucose  uptake  into  skeletal  rnuscle(68)- 
However,  these  animals  are  not  diabetic  and  have  normal  serum  insulin  concentrations. 
27 They  do  display  an  increase  in  fat  mass  and  triglycerides.  These  data  demonstrate  that  near 
total  insulin  resistance  in  skeletal  muscle  is  not  sufficient  to  cause  a  reduction  in  glucose 
tolerance,  and  suggest  that  glucose  uptake  into  other  metabolically  active  tissue,  such  as 
adipose  tissue,  must  be  considerable  and  may  even  compensate.  In  addition, exercise 
stimulated  glucose  uptake  into  skeletal  muscle  is  unaffected  in  MIRKO  mice,  implying  a 
distinct  pathway  for  this  process. 
The  insulin  receptor  may  also  have  a  sensing  role  in  the  pancreas,  as  pancreatic  insulin 
receptor  knockout  mice  lose  pancreatic  insulin  secretion  in  response  to  a  glucose  load(69). 
Lastly  liver  specific  insulin  receptor  knockout  mice  are  severely  insulin  resistant,  though  do 
not  display  fasting  hyperglycaemia  once  four  months  old(70) 
1.7.2.  Insulin  receptor  substrates 
The  main  substrates  of  the  insulin  receptor  are  the  insulin  receptor  substrates  1-4  (IRS  1-4), 
named  in  order  of  discovery.  Most  is  known  about  IRS-1  and  IRS-2,  however  the 
chromosomal  locations  of  all  the  IRS  genes  have  been  determined  -  IRS-1  on  chromosome 
1,  IRS-2  on  chromosome  8,  IRS-3  on  chromosome  5  and  IRS-4  on  the  X  chromosome. 
1.7.2.1  IRS-1/-2 
IRS-I  was  cloned  in  1991  (71),  and  is  a  180kDa  protein  that  resides  in  the  cytosol.  IRS-1 
contains  many  potential  sites  for  tyrosine  phosphorylation  by  the  activated  insulin  receptor. 
Once  phosphorylated,  these  residues  dock  proteins  that  contain  src  homology  2  (SH2) 
domains.  These  proteins  include  SH-PTP2,  Grb2,  Nck  and  the  regulatory  subunit  of  the 
lipid  kinase  P13'-kinase. 
28 IRS-2  was  purified  and  cloned  in  1995  (72).  In  comparison  with  IRS-1,  IRS-2  exhibits  a 
highly  conserved  amino  terminus  containing  a  pleckstrin  homology  (PH)  and 
phosphotyrosine-binding  (PTB)  domain,  though  there  is  less  homology  of  the  carboxy 
terminus.  IRS-2  is  also  tyrosine  phosphorylated  by  the  insulin  receptor,  and  binds  the 
regulatory  subunit  of  phosphatidylinositol  3'  kinase  (P13'-Idnase). 
1.7.2.2  IRS-3/4 
Initially  referred  to  as  pp60,  IRS-3  was  cloned  from  rat  adipocytes  by  Lienhard's  group 
(73)  in  1997.  A  60kDa  protein  was  identified  that  had  been  reported  to  be  tyrosine 
phosphorylated  and  activate  P13'-kinase  in  response  to  insulin.  IRS-3  shares  50%  structural 
homology  with  IRS-1  and  -2,  in  that  it  has  a  PH  domain,  a  PTB  domain  and  tyrosine 
phosphorylation  sites.  The  structurally  similar  IRS-4  is  a  160kDa  protein  that  was  cloned 
from  HEK  293  cells  by  Lienhard's  group  in  1997  (74),  and  later  from  the  mouse  (75).  IRS- 
3  and  -4  share  40-50%  homology  of  the  PH  and  PTB  domains  with  IRS-1  and  -2.  Like  the 
other  IRS  proteins,  IRS-4  is  activated  in  response  to  insulin  and  binds  P13'-Idnase.  Despite 
the  observation  made  in  over-expression  models  (76)  that  both  IRS-3  and  -4  translocate 
GLUT4  to  the  cell  surface  in  adipocytes,  Fantin  et  al  (75)  found  no  IRS4  protein  in 
adipose  tissue,  liver  or  skeletal  muscle,  raising  questions  about  its  absolute  importance. 
Unlike  IRS-1  and  -2,  which  reside  in  the  low-density  microsomal  (LDM)  fraction  of  the 
cell,  IRS-3  and  4  are  found  in  the  plasma  membrane  fraction  (77)  and  so  contribute  to  P13- 
kinase  activation  in  this  cellular  locale.  The  subcellular  distribution  of  these  proteins  may 
be  important  in  the  response  to  insulin,  as  it  appears  that  activation  of  P13'-kinase  in  the 
LDM  fraction  may  be  more  important  in  mediating  insulin  action  (78).  As  such,  the 
observations  that  in  IRS-3  null  mice  (79)  there  is  no  defect  in  growth  or  glucose  transport, 
29 and  that  in  32D  myeloid  progenitor  cells,  transfection  of  IRS-4  only  weakly  activates  P13'- 
kinase  (though  does  stimulate  protein  kinase  B)  are  all  the  more  interesting  (80).  In 
addition,  in  healthy  Danes,  (81)  IRS-4  polymorphisms  were  not  associated  with  insulin 
resistance  or  type  2  diabetes,  while  IRS-4  null  mice  show  only  mild  glucose  homeostatic 
defects  with  no  hyperinsulinaemia  or  hyperglycaernia  (82).  There  are  suggestions  that  IRS- 
3  may  play  a  more  important  role  in  liver  glucose  homeostasis  (83). 
1.7.2.3  Defects  in  the  insulin  receptor  substrates 
As  the  IRS  proteins  play  a  central  role  in  insulin-signalling,  any  deficiencies  in  their 
function  would  be  potential  candidates  in  the  pathogenesis  of  insulin  resistance. 
*  IRS-1 
It  is  unlikely  that  abnonnalities  of  IRS-1  are  responsible  for  type  2  diabetes.  Although 
polymorphisms  in  IRS-1  have  been  identified  in  insulin  resistant  populations,  such  as  Met 
614  Val  in  severe  insulin  resistance  (84)  and  Gly  972  Arg  in  type  2  diabetes  (85),  the  effect 
of  these  on  glucose  tolerance  is  not  clear.  The  latter  polymorphism  has  a  prevalence  of 
5.8%  in  normal  populations  and  10.7%  in  patients  with  type  2  diabetes.  This  defect  may 
lead  to  a  reduction  in  insulin-stimulated  IRS-1  activation  of  P13'-kinase  through  the  p85 
subunit.  Furthermore,  mice  homozygous  for  disruption  of  the  IRS-1  gene  (86),  while 
displaying  a  hypertensive,  dyslipidaemic  (hypertriglyceridaernia  with  low  HDL- 
cholesterol)  phenotype  with  reduced  endothelial  function,  are  not  diabetic,  and  have  normal 
levels  of  free  fatty  acids  (87).  Thus,  features  of  the  human  insulin  resistant  phenotype  are 
present  in  these  animals,  though  they  have  normal  levels  of  blood  glucose. 
Normoglycaemia  is  maintained  by  increased  pancreatic  insulin  secretion,  although  a 
heightened  intracellular  role  for  IRS-2  is  ýalso  proposed.  In  (IRS-14-)  knockout  models, 
reduced  insulin  stimulated  P13'-kinase  activity  is  seen  in  skeletal  muscle,  though  not  in 
30 liver.  Thus,  the  increase  in  the  amount  of  IRS-2-associated  P13'-kinase  activity  is  greater  in 
liver  than  in  skeletal  muscle.  In  keeping  with  these  observations,  adipocytes  from  diabetic 
humans  have  a  reduced  total  amount  of  IRS-1.  However,  in  diabetic  adipocytes  P13'-kinase 
is  nearly  entirely  associated  with  IRS-2  (88),  suggesting  that  while  IRS-1  may  be  the  main 
substrate  for  insulin  stimulation  and  activation  of  P13  kinase,  this  role  may  be  assumed  by 
IRS-2  or  perhaps  IRS-3  in  insulin  resistant  states  to  maintain  normal  cellular  insulin 
responsiveness. 
e  IRS-2 
In  contrast  to  IRS-1  knockouts,  IRS-2  deficient  mice  display  abnormalities  of  glucose 
tolerance  as  early  as  3  weeks  of  age,  and  by  10  weeks  are  diabetic  (89).  In  comparison  with 
the  (IRS-1  -/  )  mice,  far  less  severe  growth  retardation  is  observed,  suggesting  that  IGF-1 
may  preferentially  require  the  presence  of  IRS-1  for  signal  transduction.  In  neonates,  there 
is  no  difference  in  fasting  insulin  between  the  deleted  and  wild  type  animals,  although  their 
blood  glucose  is  elevated,  implying  insulin  resistance.  By  six  weeks  of  age,  however, 
plasma  insulin  is  greater  than  in  the  wild  type  animals,  and  the  response  to  the 
hypoglycaemic  action  of  insulin  is  reduced  (89).  The  use  of  clamp  studies  with 
measurement  of  hepatic  glucose  output  demonstrates  that  hepatic  and  muscle  insulin 
resistance  is  present.  In  addition,  and  contrary  to  the  (IRS-l")  mice,  the  IRS-2  deficient 
animals  show  a  lack  of  the  9-cell  hyperplasia  that  would  non-nally  accompany  peripheral 
insulin  resistance.  While  this  lack  of  insulin  secretory  capacity  is  not  sufficient  to  cause 
abnormalities  of  glucose  tolerance  at  birth,  over  the  next  10  weeks,  perhaps  in  association 
with  glucose  toxicity,  the  capacity  of  the  pancreas  to  overcome  peripheral  insulin  resistance 
falls.  Thus,  IRS-2,  normally  present  in  the  pancreatic  ductal  epithelium,  may  also  have  a 
role  in  pancreatic  growth.  While  these  observations  would  favour  a  major  role  for  IRS-2 
disruption  in  the  pathogenesis  of  insulin  resistance,  disruption  of  the  IRS-2  gene  was 
31 investigated  as  a  candidate  mechanism  for  insulin  resistance  in  the  Ashkenazi  Jews,  and  no 
major  role  for  this  gene  in  determining  susceptibility  to  type  2  diabetes  was  identified  (90). 
e  IRS-3 
IRS-34'  (79)  mice  display  normal  growth,  blood  glucose,  serum  insulin  and  adipocyte 
glucose  transport,  though  clearly  this  maintenance  of  homeostasis  may  be  the  result  of  IRS- 
1/2  compensation. 
9  IRS-4 
Again,  defects  in  this  gene  seem  unlikely  to  underlie  type  2  diabetes,  as  despite  there  being 
common  genetic  polymorphisms,  no  association  with  type  2  diabetes  or  insulin  resistance 
was  identified  in  a  Caucasian  population  (81). 
1.7.3  Phosphatidylinositol  3'  Idnase 
P13'-kinase  is  a  lipid  Icinase  with  two  functionally  defined  subunits-the  p85  regulatory 
subunit,  which  the  IRS  proteins  bind  to  via  a  SH2  domain  interaction,  and  the  catalytic 
(p  110)  subunit,  which  phosphorylates  the  D-3  position  of  the  inositol  ring  in  PI(3)P,  PI- 
(3,4)P2,  and  PI(3,4,5)P3.  Eight  polymorphisms  of  the  regulatory  subunit  have  been 
identified,  including  p85a,  p55q,  p5Oa,  p859  and  p55  P13'-kinase.  These  isoforms  are 
differentially  expressed  in  different  tissues,  and  this  may  be  important  in  determining 
individual  tissues  responses  to  insulin.  Activation  of  P13'-Idnase  is  necessary  (but  not 
sufficient)  for  the  translocation  of  GLUT4  to  the  cell  surface,  and  thereby  glucose  uptake, 
as  inhibition  with  wortmannin  or  LY294002  prevents  this  process  (91).  In  addition  to 
glucose  transport,  insulin-stimulated  activation  of  P13'-kinase  is  also  necessary  for  the 
suppression  of  lipolysis,  activation  of  glycogen  synthesis,  phosphorylation  of  protein  kinase 
B  and  stimulation  of  protein  synthesis. 
32 1.7.3.1  Abnormalities  of  P13'-  kinase 
Disruption  of  the  gene  encoding  the  p85a  subunit  is  associated,  counter-intuitively,  with 
increased  insulin  sensitivity  in  mice  (92).  This  may  be  due  to  the  increased  expression  of 
alternative  isoforms  of  this  subunit,  such  as  pSOm  A  polymorphism  of  the  p85  subunit  in 
which  methionine  is  replaced  by  isoleucine  has  been  identified,  however  the  prevalence  of 
this  polyrnorphism  is  not  geater  in  diabetic  than  non-diabetic  populations  (93). 
1.7.4  Phosphoinositide-dependent  protein  kinase  -1 
PI  (3,4,5)  P3  binds  to  and  activates  the  phosphoinositide-dependent  protein  Idnase  (PDK-1), 
which  then  activates  other  intermediates  such  as  PKB  and  various  isoforms  of  PKC  (u  and 
p  (94)  and  ý  (95)).  In  addition,  PDK-l  regulates  activity  of  the  p70S6  kinase,  a  regulator  of 
cell  proliferation,  through  PKC  t  activation  (96).  Emphasising  the  potential  importance  of 
PDK-1,  overexpression  of  PDK-1  in  rat  adipocytes  results  in  an  increase  in  activation  of 
PKC  t  and  an  increase  in  the  translocation  of  epitope  tagged  GLUT  4  to  the  cell  surface 
(97).  Expression  of  inactive  PDK-1  inhibits  both  of  these  processes. 
1.7.5  Protein  Idnase  B 
PKB  (also  known  as  akt)  is  activated  in  turn  by  P13'-kinase-induced  stimulation  of  PDK-I, 
and  is  involved  not  only  in  glucose  transport,  but  also  in  the  inhibition  of  glycogen  synthase 
kinase-3,  thereby  activating  glycogen  synthase.  The  processes  downstream  of  PKB 
activation  that  stimulate  the  translocation  of  GLUT4  from  storage  vesicles  to  the  cell 
surface  are,  as  yet,  unclear. 
33 1.7.5.1  Defects  in  protein  Idnase  B 
As  PKB  lies  downstream  of  P13'-Idnase,  any  defect  in  its  action  may  have  considerable 
importance.  In  a  comparison  of  six  healthy  volunteers  and  six  patients  with  type  2  diabetes 
(98),  the  diabetic  patients  showed  reduced  insulin  sensitivity,  measured  by  euglycaemic 
hyperinsulinaemic  clamp,  reduced  insulin  stimulated  glucose  uptake  into  isolated  skeletal 
muscle  strips  and  reduced  insulin-stimulated  activation  of  PKB,  despite  no  reduction  in 
expression  of  the  protein.  Studies  of  insulin-signalling  in  rat  skeletal  muscle  (99)  have 
revealed  that  activation  of  PKB  is  diminished  by  60%  in  media  containing  25mmol/I 
glucose,  compared  with  that  of  muscles  preincubated  in  a  glucose-free  medium. 
Importantly,  activation  of  P13'-Idnase  and  mitogen-activated  protein  (MAP)  kinase  is 
unaffected.  Similar  results  are  obtained  from  hyperglycaemic  Zucker  rats  (.  100),  in  which 
liver  PKB  activity  is  reduced  despite  normal  or  increased  P13'-kinase  activity.  These  data 
imply  that,  certainly  in  hyperglycaemia  induced  insulin  resistance,  reduced  activation  of 
PKB  may  be  of  primary  importance.  Against  this,  however,  are  data  from  Kim  et  al  (101), 
who  compared  vastus  lateralis  biopsies  from  lean,  obese  non-diabetic,  and  obese  type  2 
diabetic  patients.  They  found  that  insulin  activation  of  protein  Idnase  B  isoforms  is  normal 
in  muscle  of  obese  non-diabetic  and  obese  diabetic  subjects,  despite  decreases  of  50%  and 
39%  in  IRS-1-  and  IRS-2-associated  P13'-Idnase  activity,  respectively,  in  obese  diabetic 
subjects.  Thus  they  concluded  that  PKB  did  not  have  an  important  role  in  the  genesis  of 
insulin  resistance  in  human  skeletal  muscle.  A  later  study  from  this  group  (102)  also 
showed  that  in  obese  Zucker  rats,  the  reduction  in  insulin-stimulated  activation  of  P13'- 
kinase  is  greater  than  the  reduction  in  PKB  activity,  reinforcing  the  previous  study. 
34 1.7.6  Events  downstream  of  P13  Idnase/  PDK-1/PKB 
While  events  downstream  of  PKB  activation  are  not  fully  characterised,  it  is  clear  that  P13'- 
kinase  activation  alone  is  not  sufficient  to  stimulate  glucose  transport,  as  evidenced  by 
platelet  derived  growth  factor  induced  stimulation  of  P13  Idnase.  An  additional  signal,  or 
accessory  pathway,  may  need  to  be  activated  in  addition  to  the  generation  by  insulin  of 
PIP3  (reviewed  in  (65)) 
1.7.7c-CBL-associating  protein;  non-PIY-ý:  inase  dependent  insulin  signalling 
Observations  suggest  that  while  P13'-kinase  activation  is  necessary  for  insulin  action,  it  is 
not,  on  its  own,  sufficient.  This  has  led  to  the  concept  of  altemative,  or  parallel,  insulin- 
signalling  pathways.  One  such  pathway  involves  the  insulin-stimulated  translocation  of 
phospho-c-Cbl  to  lipid  rafts,  via  its  association  with  c-Cbl-associating  protein  (CAP). 
Blockade  of  this  pathway,  by  overexpression  of  a  dominant  negative  CAP  mutant,  blocks 
insulin-stimulated  glucose  transport  in  3T3-Ll  adipocytes  (103).  Further  characterisation  of 
this  novel  pithway  in  human  tissue  is  required. 
1.7.8  Contraction-induced  glucose  uptake 
While  it  is  appreciated  that  exercise  improves  insulin  sensitivity,  the  precise  mechanism 
underlying  this  remains  unclear.  Early  observations  in  rat  hindlimbs  demonstrated  that 
contraction-induced  glucose  uptake  may  not  involve  tyrosine  phosphorylation  of  the  insulin 
receptor,  suggesting  an  alternative  pathway  (104).  The  observation  that  obese  Zucker  rats 
display  resistance  to  insulin-stimulated  glucose  transport,  though  no  defect  in  contraction- 
induced  glucose  transport,  supported  the  notion  that  these  pathways  may  involve  different 
signalling  intennediates(105).  One  intermediate  in  the  contraction-induced  pathway  may  be 
nitric  oxide  (the  neuronal  form  of  nitric  oxide  synthase  is  expressed  in  skeletal  muscle 
35 (106)),  with  downstream  activation  of  cyclic  GMP  (107).  Activation  of  this  NO/cGMP 
pathway  occurs  during  skeletal  muscle  contraction,  as  demonstrated  in  rat  soleus  muscle 
using  the  NO  donor  sodium  nitroprusside  (10  8). 
Young  et  al  ((109))  used  soleus  muscle  from  lean  and  obese  Zucker  rats  to  investigate  this 
pathway  in  insulin  sensitive  and  resistant  models.  Incubation  with  a  cGMP 
phosphodiesterase  inhibitor  increased  cGMP  and  glucose  uptake  in  lean  though  not  obese 
rats.  Maximal  NOS  activity  was  also  reduced  in  the  obese  animals.  Lastly,  NO  donors 
(sodium  nitroprusside)  resulted  in  less  increase  in  cGMP  in  muscle  from  obese  than  lean 
animals.  These  data  demonstrate  a  reduction  in  NO/cGMP  activity  in  the  insulin  resistant 
animals. 
In  primary  vascular  smooth  muscle  cell  cultures  (110),  insulin  increases  expression  of 
mitogen-activated  protein  kinase  phosphatase  (MKP-1)  by  a  pathway  sensitive  to  NOS  and 
cGMP  inhibition,  and  also  wortmannin.  That  this  is  P13'-kinase  dependent  does  seem  to 
contradict  the  data  from  skeletal  muscle.  In  vascular  smooth  muscle  cells  from  insulin 
resistant  spontaneously  hypertensive  rats  (SHR),  insulin-stimulated  induction  of  MKP-1 
expression  is  reduced  due  to  a  decrease  in  insulin  stimulated  P13'-kinase  activity  and  so 
NOS  expression.  Thus  a  pathway  of  iNOS-cGMP-MKP-1,  downstream  of  insulin- 
stimulated  activation  of  P13'-kinase  was  proposed. 
These  data  suggest  that  there  may  be  at  least  one  non-insulin  mediated  signalling  pathway 
that  stimulates  glucose  uptake,  and  may  in  the  future  provide  additional  therapeutic  targets 
for  insulin-sensitising  agents. 
36 1.7.9  GLUT4:  translocation  and  trafflcking 
Insulin  stimulates  glucose  transport  by  the  translocation.  of  a  transport  protein  to  the  cell 
surface.  In  1989  the  protein  was  identified  as  GLUT  4,  one  a  family  of  seven  glucose 
transporters.  GLUT4  is  the  dominant  transporter  in  adipose  tissue  and  skeletal  muscle, 
particularly  in  red  muscle  fibres.  GLUT  1,  the  constitutively  active  glucose  transporter,  is 
also  present  in  both  of  these  tissue  types  (reviewed  in  (I  11)). 
While  there  is  a  reduction  in  the  number  of  GLUT4  transporters  in  adipose  tissue  from 
diabetic  patients,  there  is  no  equivalent  defect  in  skeletal  muscle,  and  as  such  this  defect 
alone  is  not  likely  to  account  for  the  resistance  to  insulin  stimulated  glucose  uptake.  There 
may,  however,  be  abnormal  translocation  of  GLUT4  to  the  cell  surface  in  association  with 
insulin  resistance,  as  demonstrated  in  muscle  biopsies  from  patients  with  type  2  diabetes 
and  normoglycaemic  insulin  resistant  subjects  (112).  Here,  in  both  the  basal  and  insulin- 
stimulated  state,  GLUT4  resided  in  a  more  dense  membrane  fraction  than  in  insulin 
sensitive  subjects.  The  tracking  of  GLUT4  in  its  storage  vesicles  has  been  aided  by  the 
identification  of  protein  markers  that  co-localise  with  these  vesicles,  such  as  the  insulin- 
regulated  membrane  aminopeptidases  (IRAP),  the  translocation  of  which  is  insulin- 
responsive  and  wortmannin-sensitive  (113,114). 
1.7.9.1  The  SNARE  hypothesis 
One  potential  defect  that  may  explain  mistargeting  of  GLUT4  in  response  to  insulin  lies  at 
the  level  of  the  SNARE  proteins  (soluble  NSF  (N-ethylmaleimide-sensitive  fusion  protein) 
attachment  protein  receptors).  It  is  proposed  in  the  SNARE  hypothesis  that  the  targeting  of 
specific  vesicles  to  specific  sites  involves  the  formation  of  a  complex  between  the 
membrane  SNARE  (t-SNARE)  and  the  vesicle  (v-SNARE).  This  has  led  to  the  elucidation 
37 of  several  such  membrane  (syntaxin-3)  and  vesicle  (vesicle  associated  membrane  peptide- 
2,  -3/cellulobrevin)  SNAREs,  and  the  suggestion  that  defects  in  the  function  or  expression 
of  these  may  result  in  resistance  to  insulin-stimulated  glucose  uptake  (reviewed  in  (115)). 
1.7.9.2  GLUT  4  knockout  models 
GLUT  4  --  mice  are  hyperinsulinaemic,  and  so  by  implication  insulin  resistant,  however 
they  are  not  diabetic(l  16).  These  mice  also  demonstrate  a  reduction  in  adiposity  and  in 
circulating  non-esterified  fatty  acids  (NEFA).  Once  these  mice  have  skeletal  muscle  GLUT 
4  restored,  glucose  metabolism  returns  to  normal,  but  the  defect  in  adipose  tissue 
metabolism  remains.  Heterozygous  mice  (GLUT  4  ')  (117)  develop  hyperinsulinaemia, 
hypertension  and  hyperglycaemia,  though  P  cell  function  remains  unaffected.  Peripheral, 
though  not  hepatic,  insulin  resistance  is  demonstrable  using  the  euglycaemic 
hyperinsulinaemic  clamp  (118).  The  restoration  of  skeletal  muscle  GLUT  4  expression  in 
these  animals  returns  whole  body  insulin  sensitivity  to  normal  (119),  and  prevents  the 
development  of  diabetes.  In  parallel  with  this,  specific  skeletal  muscle  GLUT  4  knockout 
mice  develop  hyperinsulinaemia  and  diabetes.  While  these  studies  demonstrate  the 
importance  of  glucose  uptake  into  the  skeletal  muscle  bed,  it  is  important  to  note  that  mice 
with  adipose-selective  reduction  in  GLUT  4  develop  liver  and  skeletal  muscle  insulin 
resistance.  Thus,  while  glucose  uptake  into  skeletal  muscle  has  clearly  an  important  role  in 
determining  systemic  insulin  sensitivity,  insulin  resistance  in  adipose  tissue  is  also  involved 
in  the  regulation  of  phenotype  and  may  play  a  part  in  the  development  of  systemic  insulin 
resistance  and  type  2  diabetes  (120) 
38 1.7.10  Genetic  knockout  models:  the  "two  hit"  hypothesis 
As  the  diabetic  phenotype  is  characterised  by  a  reduction  in  pancreatic  secretory  reserve  in 
association  with  peripheral  insulin  resistance,  Terauchi  et  al  created  a  model  to  mimic  this 
by  crossing  IRS-]  -1"  animals  with  mice  displaying  aP  cell  specific  glucokinase  (GK) 
deficiency  (resulting  in  reduced  glucose-stimulated  pancreatic  insulin  secretion)  (121). 
These  GKIIRS-I  mice  were  indeed  diabetic,  as  despite  the  pancreatic  hyperplasia,  the  GK 
deficiency  evidently  prevented  sufficient  insulin  production  to  overcome  the  severe 
peripheral  insulin  resistance. 
1.7.11  Obesity,  adipose  tissue  and  insulin  resistance 
In  obesity,  there  are  reports  of  reduced  insulin  receptor  number  and  tyrosine  kinase  activity 
in  skeletal  muscle  and  adipocytes  (122,123).  While  weight  loss  corrects  both  of  these 
defects  in  the  non-diabetic  population,  in  patients  with  obesity  and  type  2  diabetes,  weight 
loss  does  not  restore  insulin  sensitivity  to  normal,  suggesting  an  additional  defect  in  type  2 
diabetes.  It  does  seem  that  there  is  a  reduction  in  IRS-1  associated  P13'-kinase  activity  in 
obesity  and  type  2  diabetes(124);  IRS-2  may  however  be  able  to  compensate  (88)  and  the 
relevance  of  this  reduction  in  IRS-1  associated  P13'-kinase  is  not  clear. 
80%  of  patients  with  type  2  diabetes  are  obese;  the  strength  of  the  relationship  between 
obesity  and  insulin  resistance  suggests  that  there  may  be  a  direct  link  between  the  two, 
perhaps  mediated  by  factors  that  are  released  by  adipocytes.  Several  candidates  are 
proposed,  and  are  discussed  below. 
39 1.7.11.1  Adipose  tissue  cytokines 
Tumour  necrosis  factor-  a  (TNF-a)  and  interleukin  6  (IL-6)  are  cytokines  with  important 
roles  in  inflammation,  though  with  more  recently  appreciated  additional  metabolic  effects. 
Both  are  expressed  in  human  adipose  tissue,  with  circulating  levels  increased  in  obesity 
(125).  The  physiological  importance  of  this  elevation  in  circulating  cytokines  in  unclear, 
however  in  vitro  studies  of  TNF-  a  in  skeletal  muscle  show  reduced  insulin-stimulated  IRS- 
I  tyrosine  phosphorylation,  and  increased  serine/threonine  phosphorylation,  either  by  an 
increase  in  serine  kinase  or  a  reduction  in  serine  phosphatase  activity  (126).  Reduced 
expression  of  IRS-1  and  GLUT4  has  also  been  demonstrated  in  association  with  TNF-  a 
(127).  Elevated  IL-6  and  TNF-  a  may  also  reduce  insulin  action  by  increasing  basal 
intracellular  calcium,  which  has  a  negative  effect  on  GLUT  4-mediated  glucose  uptake 
(128).  Interleukin-6  regulates  the  release  of  hepatic  C-reactive  protein,  and  while  the  main 
source  of  IL-6  remains  the  activated  leucocyte,  cross-sectional  data  that  show  relationships 
between  CRP,  IL-6  and  TNF-  a  as  well  as  between  CRP,  insulin  resistance  and  obesity 
(129)  support  the  proposal  that  there  may  be  a  link  between  low  level  inflammation  and 
insulin  resistance  /  atherogenesis,  with  adipose  tissue  cytokine  secretion  playing  a  central 
role. 
Recently  two  additional  adipocytokines  have  been  reported.  Low  levels  of  adiponectin 
(130),  an  adipocytokine  which  is  reduced  in  obesity,  are  associated  with  insulin  resistance 
in  mice.  In  addition,  infusion  of  this  hormone  improves  insulin  sensitivity  in  lipoatrophic 
mice.  Mechanistically,  it  has  been  suggested  that  expression  of  this  hormone  may  be 
partially  regulated  by  a  peroxisome  proliferator  activated  receptor  (PPAP)-y  dependent 
pathway.  Contrasting  findings  are  reported  for  resistin,  the  gene  for  which  is  expressed 
during  adipocyte  differentiation,  though  is  downregulated  in  adipocytes  exposed  to  PPAP-7 
40 agonists.  Circulating  resistin  is  increased  in  obese  mice,  while  administration  of  resistin  to 
mice  impairs  insulin  action  and  glucose  uptake.  Future  studies  in  humans  are  keenly 
awaited  to  clarify  the  role  of  these  hormones  in  man 
1.7.11.2  Non-esterified  (free)  fatty  acids  and  insulin  resistance 
Over  30  years  ago,  Randle  (13  1)  hypothesised  that  high  circulating  levels  of  non-esterified 
fatty  acids  (NEFA)  may  induce  insulin  resistance,  possibly  by  competing  with  glucose  in 
intracellular  metabolism.  There  is  recent  evidence  to  suggest  that  NEFA  induce  cellular 
insulin  resistance;  using  the  model  of  intralipid  infusion  in  rats,  Magnan  et  al  (132) 
demonstrated  impaired  insulin-induced  glucose  disposal  during  a  clamp.  In  an  elegant 
series  of  studies  in  humans,  Dresner  et  al  (133)  investigated  the  mechanism  underlying 
NEFA  induced  insulin  resistance  in  human  skeletal  muscle.  Following  heparin  and  lipid 
infusion,  glucose  oxidation  and  glycogen  synthesis  fell  by  50-60%.  Insulin-stimulated  IRS- 
I  associated  P13'-kinase  activity  was  significantly  reduced  by  lipid  infusion,  implying  that 
NEFA  were  acting  at  the  level  of  intracellular  second  messengers.  Further  animal  studies 
demonstrated  similar  findings,  but  in  addition  showed  an  increase  in  protein  kinase  4 
activity  in  response  to  lipid  infusion,  which  the  authors  suggested  may  explain  the  defects 
in  the  insulin-signalling  cascade  by  the  process  of  serine  phosphorylation  (134). 
1.7.11.3  Cd  36  and  insulin  resistance 
In  1999,  Aitman  and  colleagues  (135)  identified  a  single  gene  that  was  defective  in  the 
spontaneously  hypertensive  rat  (SHR)  and  whose  protein  product  was  undetectable  in  the 
adipocyte  plasma  membrane  of  these  insulin  resistant  animals.  This  protein  was  U36,  also 
known  as  fatty  acid  translocase  (FAT)  and  has  been  shown  to  play  a  role  in  transmembrane 
long  chain  fatty  acid  transport  as  well  as  being  a  receptor  for  oxidised  low  density 
41 lipoprotein.  Humans  with  genetic  U36  deficiency  are  characterised  as  having  high  blood 
pressure,  insulin  resistance  and  hypertriglyceridaernia  (136).  The  prevalence  of  this 
genetic  defect  in  the  wider  population,  and  the  mechanism  through  which  it  is  related  to 
cellular  insulin  resistance,  remains  unknown. 
1.7.11.4  Peroxisome  proliferator  activated  receptor  (PPAR)  y 
The  recent  discovery  of  a  new  class  of  antidiabetic  drugs  -  the  thiazolidinediones  (TZDs)  - 
has  provided  a  new  insight  into  potential  intracellular  mechanisms  that  may  underlie 
obesity  and  insulin  resistance.  These  agents  act  on  PPAR  -f  receptors,  which  are  abundant 
in  adipocytes,  and  increase  insulin  sensitivity;  indeed  it  appears  that  the  presence  of  white 
adipose  tissue  is  necessary  for  TZDs  glucose  lowering  action(137),  while  a  preferential 
effect  in  subcutaneous  depots  may  explain  the  modest  weight  gain  associated  with  their 
use(I  3  8).  Patients  heterozygous  for  a  dominant-negative  PPAR  y  allele  are  insulin  resistant 
(139).  The  mechanism  linking  PPAR  y  with  insulin  sensitivity  is  unclear;  while  they 
increase  expression  of  Cd36(140),  it  has  also  recently  been  proposed  that  the  honnones 
resistin  (141)  and  adiponectin  may  play  a  role  (130). 
1.7.12  Hyperinsulinaemia  and  insulin  resistance 
As  hyperinsulinaemia  accompanies  insulin  resistance,  elevation  in  serum  insulin  may  be 
proposed  as  playing  a  part  in  the  development  of  cellular  insulin  resistance  by  reducing 
receptor  expression.  Though  reversal  of  hyperinsulinaemia  by  streptozotocin  administration 
may  return  insulin  receptor  expression  to  normal  (142),  insulin  secretion  increases  in 
response  to  insulin  resistance,  and  so  it  seems  more  likely  that  hyperinsulinaemia  is  a  result 
rather  than  a  cause  of  insulin  resistance. 
42 1.7.13  Counter-regulatory  hormones  and  insulin  resistance 
The  role  of  hormones  such  as  cortisol,  norepinephrine  and  glucagon  in  the  development  of 
the  metabolic  syndrome  and  type  2  diabetes  is  not  clear,  however,  insulin  resistance 
associated  with  glucocorticoid  action  is  discussed  below  and  explored  in  chapter  6. 
1.7.14  Glucose  and  Insulin  resistance 
Elevation  in  blood  glucose  is  known  to  impair  pancreatic  insulin  secretion,  but  glucose  may 
also  act  in  peripheral  tissues  to  reduce  insulin  sensitivity.  Glucose,  by  increasing 
intracellular  diacyl  glycerol  (DAG),  stimulates  intracellular  PKC,  which  in  turn 
phosphorylates  serine  residues  on  the  insulin  receptor  and  reduces  activation(143).  This 
process  of  serine  phosphorylation  may  be  a  more  generic  mechanism  through  which  an 
insulin  signal  may  be  "dampened"  by  reducing  the  association  of  the  insulin  receptor  with 
the  insulin  receptor  substrates  (144).  Indeed,  P13'-kinase  may  serine  phosphorylate  IRS-1, 
providing  a  mechanism  for  fine  control  and  self-limitation  of  the  insulin  signal  (145). 
Certainly  in  hyperglycaemic  animal  models,  reduction  in  blood  glucose  has  been  shown  to 
be  associated  with  an  improvement  in  insulin-stimulated  activation  of  signalling 
intermediates,  such  as  PKB  (146). 
1.8  Insulin  and  suppression  of  lipolysis 
In  addition  to  its  effects  on  glucose  transport,  insulin  is  also  involved  in  determining  the 
rate  of  lipolysis  in  adipocytes.  Lipolysis  is  the  breakdown  of  cellular  triacylglycerol 
(triglycerides)  into  its  constituent  parts-one  glycerol  and  three  long  chain  free  fatty  acids 
per  molecule  of  triglyceride  (reviewed  in(147,148)).  The  formation  and  breakdown  of 
43 triglyceride  in  the  cell  is  generally  the  result  of  a  balance  between  lipolytic  (e.  g. 
sympathetic  nervous  system)  and  anti-lipolytic  stimuli,  such  as  insulin. 
As  is  the  case  for  glucose  uptake,  insulin  stimulates  the  insulin  receptor  and  recruits  the 
IRS  proteins,  leading  to  the  activation  of  PIY-kinase;  this  step  is  necessary  for  the 
suppression  of  lipolysis,  as  in  rat  adipocytes  (149),  inhibition  of  PIY-kinase  by  wortmannin 
abolishes  both  insulin-stimulated  glucose  and  the  normal  suppression  by  insulin  of 
isoproterenol-induced  lipolysis  and  glycerol  release. 
Hormone  sensitive  lipase  (HSL),  the  rate-limiting  step  in  triglyceride  lipolysis  (150),  is 
activated  following  protein  kinase  A  (PKA)  mediated  phosphorylation.  While  P-adrenergic 
stimuli  increase  the  activity  PKA,  insulin  inhibits  it.  Again,  as  is  the  case  for  glucose 
transport,  the  insulin  pathway  downstream  of  P13'-kinase  is  not  well  characterised, 
although  stimulation  of  phosphodiesterase  3B  may  be  involved. 
1.9  Cellular  insulin  sensitivity:  variation  with  the  insulin  resistant  phenotype 
As  discussed  in  section  1.4,  the  insulin  resistance  or  metabolic  syndrome  has  a  classical 
phenotype  of  hypertension,  obesity  and  dyslipidaemia,  with  resistance  to  insulin  stimulated 
glucose  uptake  at  its  core.  In  the  WHO  and  EGIR  criteria  for  diagnosis  of  the  syndrome, 
whole  body  insulin  sensitivity,  measured  using  the  euglycaernic  hyperinsulinaernic  clamp, 
must  be  in  the  lowest  quartile  for  the  group  under  study.  While  it  is  appreciated  that  whole 
body  insulin  sensitivity  varies  greatly  between  subjects  (27),  it  has  proven  more  difficult  to 
study  the  sensitivity  of  individual  tissues  to  insulin;  it  would  be  anticipated  that  insulin 
response  at  the  tissue  level  would  reflect  the  phenotype,  however  there  are  few  studies  that 
have  examined  this  in  the  healthy  population. 
44 Kashiwagi  et  al  demonstrated  a  reduction  in  maximum  insulin  stimulated  glucose  uptake, 
glucose  utilisation  and  basal  glucose  transport  rates  in  adipocytes  isolated  from  patients 
with  type  2  diabetes  compared  with  normal  subjects  (151).  In  a  subsequent  publication 
(152),  comparison  of  lean,  moderately  obese  and  obese  Pima  Indians  revealed  increasing 
adipocyte  insulin  resistance  across  the  three  groups,  and  while  abnormalities  of  insulin 
binding  were  noted,  this  was  not  thought  to  be  the  sole  factor  in  the  pathogenesis  of  cellular 
insulin  resistance.  Foley  et  al  (153)  demonstrated  that  in  obese  Pima  Indians,  insulin 
stimulated  glucose  transport  and  antilipolysis  were  both  reduced  in  the  most  insulin 
resistant  subjects;  in  74  Southwest  American  (Pima)  Indians  with  normal  glucose  tolerance, 
the  ED50  of  insulin  for  glucose  transport  and  antilipolysis  correlated  with  fasting  insulin, 
two  hour  insulin  and  BMI.  Again  the  suggestion  was  that  the  cellular  defect  was  located 
downstremn  of  insulin  binding  to  it's  receptor,  opposing  the  findings  of  Ciamldi  (154),  who 
demonstrated  reduced  insulin  binding  in  subjects  with  impaired  glucose  tolerance  (IGT) 
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and  type  2  diabetes.  Foley  used  data  from  Pima  Indians  to  test  the  reproducibility  of  these 
techniques  for  measuring  insulin  sensitivity  in  subcutaneous  fat.  This  type  of  study  is 
difficult  as  the  nature  of  the  procedure  means  that  two  fat  samples  are  rarely  obtained  from 
the  same  subject,  though  here  the  needle  biopsy  technique  seemed  sufficiently  well 
tolerated  for  the  procedure  to  be  repeated.  The  coefficients  of  variation  for  the  ED5o  of 
insulin  for  glucose  transport  and  antilipolysis  were  33%  and  31%  respectively.  Resistance 
to  insulin  stimulated  glucose  uptake  and  antilipolysis  was  greater  in  obese  diabetic  and 
obese  non-diabetic  female  Pima  Indians  than  in  non-obese  controls  from  the  same  ethnic 
background.  No  difference  in  the  ED50  for  antilipolysis  was,  however,  seen  between  the 
obese  diabetic  and  obese  non-diabetic  groups,  suggesting  that  elevated  blood  glucose  plays 
45 only  a  minor  role  in  determining  insulin  sensitivity  in  adipocytes  (155).  In  this  study,  there 
was  no  difference  in  insulin  binding  between  diabetic  and  non-diabetic  obese  subjects. 
While  these  studies  in  Pima  Indians  illustrate  cellular  insulin  resistance,  it  must  be  borne  in 
mind  that  this  population  is  severely  obese  (mean  BMI  in  (155)  =35kg1m)  and  insulin 
resistant.  The  applicability  of  these  results  to  an  insulin  sensitive  Caucasian  population  has 
been  questioned,  and  though  in  a  comparison  of  10  obese  Pima  Indians  and  10  age  and 
weight  matched  Caucasians,  insulin  sensitivity  in  adipocytes  was  similar  (156),  in  the 
context  of  cardiovascular  risk,  the  metabolic  syndrome  in  Caucasians  and  Pima  Indians 
seem  quite  different(48).  Furthermore,  in  a  comparison  of  age  and  weight  matched  Pima 
and  Caucasian  children  (157),  Pima  children  had  a  higher  fasting  plasma  glucose  and 
insulin  in  association  with  larger  abdominal  adipocytes  than  the  Caucasian  children. 
In  two  groups  of  healthy  individuals  matched  for  age  and  weight  (158),  one  group  having  a 
family  history  of  type  2  diabetes  in  two  first-degree  relatives,  subcutaneous  adipose  tissue 
lipolysis  was  measured  using  microdialysis.  Clamp  studies  demonstrated  that  the  group 
with  a  family  history  of  diabetes  had  a  lower  insulin  sensitivity  index  than  those  without. 
During  insulin  infusion,  subcutaneous  adipose  tissue  glycerol  release  was  greater  in  the 
group  with  a  family  history  of  diabetes,  in  keeping  with  reduced  insulin  sensitivity. 
However,  fat  cells  obtained  by  needle  biopsy  prior  to  the  commencement  of  the  clamp 
showed  no  difference  between  groups  in  basal  or  insulin  stimulated  glucose  uptake  or 
suppression  of  lipolysis.  Thus  the  literature  remains  unclear  with  regard  to  the  presence  of 
cellular  insulin  resistance  in  insulin-resistant,  though  euglycaemic,  subjects. 
46 As  well  as  an  association  between  increases  in  BMI  and  insulin  resistance,  the  distribution 
of  fat  may  also  be  important.  A  high  waist:  hip  ratio,  representing  preferential  abdominal 
deposition  of  fat,  seems  more  closely  associated  with  insulin  resistance  in  obesity  than 
gluteofemoral  adiposity.  This  may  be  explained  by  the  observation  that  adipocytes  from 
visceral  and  abdominal  fat  deposits  are  more  prone  to  lipolysis  (159),  and  therefore  the 
release  of  NEFA  that  may  contribute  to  insulin  resistance.  In  a  study  of  930  obese  patients, 
higher  triglycerides,  glucose  and  insulin  were  observed  in  subjects  with  abdominal  obesity 
(highest  waist/hip  ratio)  vs.  a  more  peripheral  distribution  (160).  Landin  et  al  (161) 
demonstrated  that  in  obese  postmenopausal  women,  adipocytes  obtained  from  those  with  a 
high  WHR  were  larger  and  more  sensitive  to  isoproterenol  induced  lipolysis  than  cells  from 
obese  women  with  a  lower  WHR.  In  this  study,  there  was  no  difference  in  the  antilipolytic 
effect  of  high  dose  insulin  between  obese  and  lean  women. 
Most  lipolytic  stimuli  to  adipose  tissue  act  via  the  cell  surface  adrenoceptors. 
Catecholamines  stimulate  lipolysis  via  the  fll,  P2  and  fl3  and  inhibit  lipolysis  via  the  02 
adrenoceptors  (162).  Lonnqvist  et  al  (163)  compared  omental  adipose  tissue  from  obese 
and  lean  women,  and  found  that  norepinephrine-induced  lipolysis  was  twofold  greater  in 
the  obese  women.  These  women  also  had  greater  fl3  adrenoceptor  sensitivity,  which  has  its 
main  effect  in  visceral  adipocytes  (164),  and  reduced  a2  adrenoceptor  sensitivity.  Thus  the 
increase  in  NEFA  release  in  obesity  may  not  only  be  due  to  reduced  insulin  suppression  of 
lipolysis,  but  also  involve  increased  sensitivity  to  lipolysis  in  visceral  fat  that  may  increase 
portal  NEFA. 
Free  fatty  acid  turnover  is  not  only  important  in  adipose  tissue.  Bolinder  et  al  (165)  used 
the  technique  of  microdialysis  to  examine  glycerol  concentrations  in  skeletal  muscle, 
47 adipose  tissue  and  v'enous  plasma  in  lean  and  obese  volunteers.  Fasting  glycerol  in  all  three 
compartments  was  50%  higher  in  the  obese  group,  however  the  important  observation  was 
that  significant  amounts  of  glycerol  were  released  from  skeletal  muscle  as  well  as  adipose 
tissue. 
48 1.10  Insulin  as  a  vascular  hormone 
The  previous  section  focused  on  the  relationship  between  the  metabolic  effects  of  insulin  at 
a  cellular  and  whole  body  level.  However,  the  realisation  that  insulin  is  also  active  in  the 
vasculature  has  raised  questions  about  the  relationship  between  metabolic  and  vascular 
insulin  responsiveness.  It  has  been  suggested  that  a  defect  in  the  action  of  insulin  in  the 
vasculature  may  provide  a  more  direct  link  between  insulin  resistance,  hypertension  and 
vascular  disease. 
Though  insulin  increases  fluid  retention  and  facilitates  sympathetic  neurotransmission,  two 
models  of  hyperinsulinaemia  do  not  support  a  direct  relationship  with  hypertension;  in  dogs 
infused  with  high  physiological  doses  of  insulin  for  28  days,  no  elevation  in  blood  pressure 
was  observed  (166),  while  in  patients  with  insulinoma,  there  is  no  association  with 
hypertension  (167).  As  such,  insulin  may  have  a  direct  vasodilatory  effect,  preventing 
increases  in  blood  pressure  by  lowering  systemic  vascular  resistance.  Laakso  et  al  (168) 
demonstrated  that  insulin  caused  a  dose-dependent  increase  in  limb  blood  flow,  and  went 
on  to  show  that  in  obese  subjects  with  reduced  insulin-mediated  glucose  uptake  there  was 
an  associated  reduction  in  insulin-mediated  increments  in  limb  blood  flow.  Thus  the 
vascular  and  metabolic  actions  seemed  related.  Subsequent  studies  confirmed  that,  as  well 
as  in  obesity,  vascular  insulin  resistance  was  also  present  in  non-insulin  dependent  diabetes 
(169)  and  hypertension  (170). 
1.10.1  Insulin  as  a  vasodilator:  the  role  of  the  enclothelium 
The  above  early  studies  demonstrated  that  insulin  is  indeed  a  vasodilator,  however  they 
provided  no  mechanistic  information.  Insulin  may  vasodilate  by  modulating  vascular 
49 responsiveness  to  the  ot  and  j3  adrenoceptors  (17  1),  and  by  direct  effects  on  vascular  smooth 
muscle  membrane  ion  channels  involved  with  vasorelaxation. 
Most  interest  has  however  focussed  on  insulin's  action  as  a  vasodilator  involving  the 
endothelium,  a  cellular  monolayer  lining  the  vasculature.  Far  from  being  an  inert  barrier, 
the  endothelium  responds  to  a  wide  range  of  stimuli  by  secreting  biologically  active  agents 
involved  in  the  maintenance  of  vascular  tone,  platelet  aggregation,  vascular  thrombosis  and 
inflammation. 
One  such  agent  was  identified  as  the  endothelium-dependent  vasodilator-  nitric  oxide  (NO). 
NO  is  synthesised  in  the  endothelium  by  nitric  oxide  synthase  (NOS)  using  L-arginine  as  a 
substrate,  a  process  that  is  inhibited  by  the  addition  of  L-NMMA,  a  stereospecific  inhibitor 
of  NOS  that  competes  with  L-arginine. 
50 Figure  1.2:  Insulin-mediated  vasodflation,  the  endothelium  and  vascular  smooth 
muscle.  IRS,  insulin  receptor  substrate;  P13'-kinase,  phosphatidylinositol  3'  kinase;  PKB, 
protein  kinase  B;  eNOS,  endothelial  nitric  oxide  synthase;  GTP,  guanosine  triphosphate; 
cGNT,  cyclic  guanosine  monophosphate. 
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51 Acetylcholine  induced  vascular  relaxation  is  NO  mediated  (172),  and  requires  the  presence 
of  an  intact  endothelium,  (173),  implying  that  NO  is  endothelium  derived.  Insulin  induced 
vasodilation  is  similarly  endothelium.  dependent  and  at  least  partly  NO  mediated.  Steinberg 
(174)  found  that  in  normotensive,  non-diabetic  volunteers,  the  infusion  of  L-NMMA  into 
the  femoral  artery  resulted  in  a  20%  fall  in  leg  blood  flow  at  baseline,  and  a  40%  fall  during 
euglycaemic  hyperinsulinaemia,  essentially  returning  flow  to  baseline  levels.  These 
percentages  were  assumed  to  be  the  proportion  of  flow  that  was  NO  dependent  in  basal 
conditions  and  during  hyperinsulinaemia  respectively.  Importantly,  hyperinsulinaemia  had 
no  effect  on  sodium  nitroprusside  (endothelium  independent)  vasodilation.  Reinforcing 
insulin's  role  as  an  endotheliurn  dependent  vasodilator,  in  rat  cremaster  muscle  arterioles 
(175),  insulin-mediated  vasodilation  is  completely  abrogated  by  the  removal  of  the 
endothelium. 
In  disease  states  such  as  hypertension,  type  2  diabetes  and  obesity,  there  is  clearly 
resistance  to  the  metabolic  effects  of  insulin,  and  this  appears  also  to  be  the  case  for 
endothelial  insulin  sensitivity.  Laakso's  early  study  demonstrated  that  insulin-induced 
vasodilation  was  reduced  in  obesity,  though  did  not  prove  conclusively  that  this  was 
secondary  to  an  endothelial  defect.  However,  increases  in  leg  blood  flow  in  response  to 
methacholine  were  40%  lower  in  obesity  and  55%  lower  in  type  2  diabetes  compared  with 
controls(176).  The  methacholine  response  was  augmented  during  euglycaemic 
hyperinsulinaemia  only  in  the  lean  controls.  In  contrast,  the  sodium  nitroprusside 
vasodilatory  response  was  comparable  in  all  three  groups.  Further  evidence  relating 
metabolic  insulin  sensitivity  and  endothelial  function  came  from  the  observation  that  there 
was  a  correlation  between  metabolic  insulin  sensitivity  and  basal  nitric  oxide  production 
52 (measured  by  the  reduction  in  forearm  blood  flow  following  intra-arterial  infusion  of  L- 
NMMA)  (177). 
1.10.2  Endothelial  function  and  the  metabolic  syndrome 
Many  studies  have  exarnineý  the  association  of  endothelial  function  with  features  of  the 
insulin  resistant  phenotype 
e  Obesity  and  type  2  diabetes:  In  obesity  and  type  2  diabetes,  basal  methacholine 
induced  leg  blood  flow  is  reduced  compared  with  controls.  Additionally,  during 
euglycaemic  hyperinsulinaernia,  these  groups  have  no  augmentation  of 
methacholine  induced  leg  blood  flow,  while  sodium  nitroprusside  induced 
vasodilation  is  comparable  between  groups.  Thus,  obesity  and  type  2  diabetes  are 
associated  with  reduced  endothelial  dependent  vasodilation,  and  normal 
endothelium  independent  responses  (176). 
Not  all  studies  have  found  a  reduction  in  endothelial  function  in  association  with 
insulin  resistance  and  type  2  diabetes  (178)  however,  some  groups  demonstrating  no 
variation  from  normal  volunteers  in  the  vascular  effects  of  acetylcholine. 
0  Dyslipiddemia:  The  relationship  between  dyslipidaemia  and  the  endothelium  has 
been  studied  at  some  length.  Mechanistically,  a  dysfunctional  endothelium  may  be 
related  to  dyslipidaemia  via  the  local  expression  of  LDL  receptors  and  the  presence 
of  lipoprotein  lipase.  In  the  insulin  resistance  or  metabolic  syndrome,  there  is  an 
excess  of  easily  oxidised,  small,  dense  LDL,  which  reduces  NOS  expression 
in 
platelets.  HDL  cholesterol  may  offset  the  negative  effect  of  oxidised  LDL  on  the 
53 endothelium,  however  relative  amounts  of  this  lipoprotein  are  reduced  in  the 
metabolic  syndrome  as  discussed  earlier.  An  excess  of  free  fatty  acids  in  the 
systemic  circulation,  as  is  seen  in  insulin  resistance,  as  well  as  those  released  locally 
by  the  action  of  lipoprotein  lipase,  may  have  a  deleterious  effect  on  endothelial 
function  (179). 
*  Hypertension:  Endotheliurn  mediated  relaxation  is  reduced  in  hypertension,  as 
demonstrated  in  the  reduction  in  forearm  vasodilation  seen  in  response  to  intra- 
arterial  acetylcholine  in  hypertensive  patients  (180).  L-NMMA  infusion  into 
hypertensive  volunteers,  either  alone  or  in  combination  with  acetylcholine,  has  less 
effect  on  basal  forearm  vascular  flow  than  in  normotensives.  These  data  suggest 
that  both  basally  and  in  response  to  endothelium  dependent  vasodilators,  there  is  an 
abnormality  in  nitric  oxide  availability  in  hypertension  (181).  The  observation  that 
there  is  also  reduced  endothelial  response  to  bradyldnin,  another  endothelium 
derived  vasodilator,  in  hypertension,  implies  that  the  underlying  abnormality  is  not 
confined  to  a  particular  intracellular  pathway,  rather  that  the  endothelium  has  a 
general  defect  that  is  involved  in  mediating  the  response  to  many  extracellular 
stimuli  (182).  Furthermore,  there  does  not  seem  to  be  a  defect  in  the  availability  of 
nitric  oxide  substrate;  in  hypertensive  patients,  the  defect  in  endothelium-dependent 
vasodilation  is  not  reversed  by  L-arginine  infusion  (183)  Not  all  studies  concur 
with  these  findings  however;  some  studies  have  found  no  difference  in  forearm 
vascular  response  to  intra-arterial  acetylcholine  between  hypertensive  and 
normotensive  volunteers  (184). 
54 Thus,  metabolic  insulin  resistance  and  endothelial  function  seem  to  be  linked  in  the 
majority  of  studies.  It  is  more  difficult  to  uncover  the  temporal  relationship  between  these 
features,  which  would  allow  speculation  regarding  causality.  In  a  recent  study  (185) 
comparing  three  groups-  healthy  normotensives,  non  diabetic  hypertensives  and  type  2 
diabetics-  well  matched  for  age  and  lipid  profile,  no  difference  was  demonstrated  between 
the  three  groups  with  respect  to  insulin  sensitivity  or  endothelial  function.  There  was 
however  a  correlation  between  metabolic  insulin  sensitivity  and  endothelial  function  on 
combining  the  data  from  all  three  groups.  This  suggests  that  there  may  be  an  as  yet 
unidentified,  and  perhaps  unifying,  factor(s)  that  affects  both  metabolic  insulin  sensitivity 
and  endothelial  function  similarly,  irrespective  of  glycaemic  or  blood  pressure  status. 
1.10.3  Insulin-signalling  in  the  vasculature;  the  cellular  interface  between  metabolic 
and  vascular  insulin  resistance 
The  culture  of  human  endothelial  cells  has  led  to  a  greater  understanding  of  insulin  action 
in  vascular  cells,  and  has  highlighted  similarities  and  differences  between  vascular  and 
metabolic  insulin  action.  Zeng  et  al  (186)  demonstrated  a  dose  dependent  increase  in  NO 
release  from  cultured  human  umbilical  vein  endothelial  cells  (HUVECs)  treated  with 
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insulin,  and  found  that  this  action  shared  similar  properties  with  the  better-characterised 
insulin  signal  in  muscle  and  adipose  cells.  They  showed  that  inhibitors  of  tyrosine  Idnase, 
NOS  and  P13'-kinase  reduced  insulin-stimulated  release  of  NO  in  these  cells.  In  bovine 
aortic  endothelial  cells  (187),  physiological  insulin  concentrations  increased  endothelial 
NOS  mRNA,  protein  and  activity  over  a  2-8  hour  time  period,  an  effect  that  was  again 
sensitive  to  P13'-Idnase  inhibitors,  and  also  to  PKCO  overexpression.  Reinforcing  the 
importance  of  these  signalling  intermediates  in  vascular  insulin  responsiveness, 
overexpression  of  insulin  receptors  into  HUVECs  (188)  resulted  in  a  Mold  increase  in 
55 insulin  stimulated  NO  production.  In  cells  overexpressing  a  tyrosine  Idnase-deficient 
mutant  insulin  receptor,  this  effect  was  not  seen.  Similarly  overexpression  of  P13'-kinase  or 
PKB  mutants  inhibited  insulin  stimulated  NO  production. 
Extending  these  observations  to  models  of  insulin  resistance,  in  vascular  tissue  from  obese 
(insulin  resistant)  and  lean  (insulin  sensitive)  Zucker  rats  (189),  insulin  stimulated  tyrosine 
phosphorylation.  of  the  insulin  receptor,  IRS-1  and  -2  was  reduced  in  obese  compared  with 
lean  animals.  In  aortic  tissue  from  obese  animals,  association  of  p85  with  IRS-1,  IRS-I 
associated  P13'-Idnase  activity  and  insulin  stimulated  serine  phosphorylation  of  PKB  were 
all  reduced,  however  there  was  no  reduction  in  insulin-stimulated  activation  of  MAP 
kinase,  implying  selective  insulin  resistance.  The  insulin-stimulated  activation  of  PKB  in 
HUVECs  has  also  been  suggested  as  having  an  important  role  in  the  apoptotic  suppressive 
effect  of  insulin  (190). 
The  physiological  role  of  insulin  as  a  vasodilator,  and  the  influence  of  insulin-mediated 
vasodilation  in  determining  glucose  uptake,  remains  unclear.  Scientific  debate  continues 
surrounding  this  important  topic.  Some  groups  suggest  that  insulin  action  in  various  tissues 
may  be  influenced  by  similar  defects  given  the  commonality  of  the  insulin-signalling 
cascade  in  vascular,  muscle  and  adipose  tissues.  Data  from  endothelial  cell  culture  is 
discussed  below  that  seem  to  support  this  notion.  Other  groups  have  proposed  that  a 
reduction  in  insulin-mediated  glucose  uptake  may  be  at  least  partly  the  result  of  a  reduction 
in  the  sensitivity  of  vascular  tissue  to  insulin's  vasodilatory  stimulus  -  the  concept  of 
substrate  delivery  (reviewed  in  (191)),  though  the  strength  of  this  observation  may  be 
influenced  by  the  methodology  employed  (192). 
56 Having  discussed  the  definition,  associations  and  risk  associated  with  insulin  resistance, 
and  considered  the  normal  and  deranged  processes  of  insulin  action,  I  will  go  on  to 
examine  the  role  that  two  endocrine  systems  -  the  renin  angiotensin  system  (RAS)  and  the 
hypothalamo  pituitary  adrenal  (BPA)  axis  -  may  play  in  determining  endogenous  insulin 
sensitivity. 
57 1.11  The  renin  angiotensin  system  and  insulin  sensitivity 
1.11.1  Overview 
Circulating  angiotensinogen  (AGT)  is  synthesised  predominantly  in  the  liver,  though  in 
recent  years  it  has  become  apparent  that  an  increasing  number  of  alternative  tissues  also 
have  the  capacity  to  secrete  this  initial  substrate  in  the  formation  of  angiotensin  II  (AII). 
The  protease  renin,  which  is  secreted  by  the  juxtaglomerular  apparatus  in  the  kidney, 
converts  -  angiotensinogen  to  angiotensin  I.  Renin  is  released  in  response  to  hypovolaemia 
or  impaired  renal  blood  flow,  beta  adrenergic  stimulation  and  sodium  depletion. 
Angiotensin  I  is  then  converted  to  angiotensin  II  by  either  the  action  of  Angiotensin 
Converting  Enzyme  (ACE),  a  metalloprotease,  or  through  the  "non-ACE"  pathway, 
involving  the  chymostatin-sensitive  AII  generating  enzyme,  chymase,  cathepsin  G,  tissue 
plasminogen  activator  (tPA)  and  tonin  (193,194)  (figure  1.3).  The  relative  contribution  of 
each  pathway  varies  between  tissues  and  pathological  states,  however  it  has  been  suggested 
that  the  chymase  pathway  may  convert  up  to  60%  of  angiotensin  1  (195).  That  the  two 
pathways  are  distinct  is  confirmed  in  studies  demonstrating  an  additive  effect  of  chymase 
and  ACE  inhibitors.  In  addition,  the  relatively  non-specific  ACE  also  deactivates 
bradyldnin,  providing  an  important  difference  between  the  action  of  ACE  inhibitors  and 
angiotensin  II  type  1  (AT  1)  receptor  blockers. 
58 Figure  1.3:  The  classical  and  alternative  pathways  for  conversion  of  angiotensinogen 
to  angiotensin  11  in  humans. 
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59 1.11.2  Local  renin  angiotensin  system 
In  the  last  15  years  it  has  become  clear  that  certain  hormone  systems,  in  addition  to  their 
systemic  control  of  secretion  and  feedback  loops,  have  sufficient  levels  of  production  in 
local  tissues  to  support  the  notion  that  local,  self  regulating,  systems  exist.  These  may  have 
distinct  stimuli  and  inhibitors  of  synthesis,  and  may  behave  independently  of  the  systemic 
system.  One  such  hormonal  system  appears  to  be  the  renin  angiotensin  system;  indeed,  to 
date,  12  extrahepatic  tissues  have  been  identified  in  the  rat  that  have  detectable 
angiotensinogen  and  renin  mRNA,  including  the  Iddney,  heart,  adrenal  glands,  adipose 
tissue  and  the  gonads  (reviewed  in  (196,197). 
Locally  generated  AII  may  act  in  several  ways:  it  may  have  a  classical  endocrine  effect  at 
distant  receptors,  it  may  have  a  more  local  paracrine  or  even  autocrine  effect,  and  it  may  act 
intracellularly.  It  is  unlikely  that  the  circulating  levels  of  AII  are  influenced  to  a  great 
degree  by  these  local  systems,  however  they  allow  tissues  to  create  very  high,  or  low 
concentrations  of  ambient  AII,  which  may  be  important  in  determining  local  blood  flow 
and  metabolism. 
I  will  now  focus  on  the  evidence  for  the  presence  of  a  local  RAS  in  adipose  tissue,  the  role 
that  the  systemic  and  local  RAS  may  have  in  adipocytes,  and  the  potential  for  crosstalk 
between  the  All  and  insulin-signalling  cascade  that  may  exist  in  these  and  other  cells. 
60 1.11.3  The  renin  angiotensin  system  in  human  adipose  tissue 
1.11.3.1  Constituents  of  the  pathway 
The  first  groups  to  describe  adipose  tissue  as  a  site  expressing  elements  of  the  RAS  did  so 
while  studying  the  local  expression  of  the  AGT  gene  in  the  vasculature  and  its  supporting 
tissues.  AGT  mRNA  was  detected  in  rat  periatrial  and  periaortic  brown  adipose  tissue 
using  in  situ  hybridisation  and  Northern  blot  analysis(198).  The  local  expression  of  AGT 
was  found  to  be  under  the  influence  of  systemic  factors,  as  nephrectomy  increased  levels  in 
interscapular  and  periaortic  adipose  tissue,  while  ACE  inhibition  increased  only  the  levels 
in  interscapular  tissue. 
More  sensitive  molecular  biological  techniques,  such  as  polymerase  chain  reaction  (PCR) 
amplification  of  mRNA,  have  provided  evidence  of  widespread  expression  of  components 
of  the  RAS.  PCR  analysis  of  DNA  from  rat  interscapular  brown  adipose  tissue  confirmed 
AGT  gene  expression,  however  it  initially  proved  more  difficult  to  confirm  the  presence  of 
the  renin  gene,  despite  Western  blotting  of  adipose  tissue  demonstrating  the  presence  of 
two  isoforms  of  renin.  It  was  postulated  that  perhaps  the  sensitivity  of  the  PCR  was  not 
sufficient  to  detect  the  expression  of  the  renin  gene(199),  and  to  date  only  one  group  has 
identified  the  presence  of  renin  mRNA  in  adipose  tissue.  In  a  study  examining  adipose 
tissue  from  obese  subjects,  a  Swedish  group  demonstrated  the  presence  of  AGT  in  isolated 
adipocytes,  along  with  mRNA  for  both  renin  and  ACE.  Transcripts  for  cathepsin  D  and  G, 
components  of  the  non-RAS,  were  also  present  (200)  In  a  larger  study  (201),  expression  of 
AGT,  ACE  and  the  ATI  receptor  genes  was  again  confirmed  in  human  subcutaneous  and 
omental  adipose  tissue  samples  from  a  non-obese  population.  Though  no  mRNA  was 
found  for  the  renin  gene,  chymase  and  renin  binding  protein  genes  were  expressed. 
61 1.11.3.2  Angiotensin  II  receptors 
Although  adipose  tissue  may  be  able  to  generate  All  locally,  any  autocrine  or  paracrine 
effect  of  this  hormone  on  adipose  tissue  metabolism  requires  the  presence  of  specific 
receptors  that  bind  AIL  Crandall  et  al  (202)  confirmed  AH  binding  in  rodent  epididymal 
adipocytes,  and  went  on  to  show  that  this  was  displaced  by  a  specific  ATI  receptor 
antagonist,  suggesting  that  the  observed  binding  was  to  the  AT1  receptor  (203).  Using 
similar  binding  techniques  in  human  adipocytes,  the  presence  of  high  affinity  AH  binding, 
displaced  by  type  1  though  not  type  2  blockers,  was  subsequently  confirmed  (204). 
1.11.4  The  physiological  role  of  the  RAS  in  adipose  tissue 
1.11.4.1  Relationship  to  body  weight  and  obesity 
In  an  elegant  series  of  carefully  controlled  experiments,  Cassis  et  al(205)  found  that,  in  rats 
matched  for  caloric  intake,  low  dose  AII  infusion  over  a  14  day  period  resulted  in  an 
increase  in  systolic  blood  pressure  and  lack  of  weight  gain.  This  lack  of  weight  gain 
appeared  to'be  independent  of  AII's  effect  on  blood  pressure.  Explantation  of  organs  from 
AII  infused  rats  suggested  that  these  animals  had  a  reduction  in  the  relative  mass  of 
retroperitoneal  white  fat  and  diaphragmatic  muscle.  Other  groups  have  however  suggested 
that  AII's  effect  on  body  weight  may  be  partially  anorectic.  Rats  studied  after  14  days  of 
AII  infusion  at  pressor  doses  lost  18%  of  their  body  weight  after  seven  days  and 
maintained  this  weight  at  the  end  of  the  second  week,  whereas  sham  infused  rats  continued 
to  gain  weight  over  the  study  period.  This  weight  loss  was  prevented  by  co-administration 
of  losartan,  though  not  hydralazine,  suggesting  an  AT1  mediated  effect  that  was  not 
pressor  dependent.  Analysis  of  eating  patterns  in  the  studied  animals  showed  that  AII 
infused  rats'  food  intake  was  25%  of  those  receiving  a  sham  infusion.  After  matching  for 
62 food  intake,  74%  of  the  observed  weight  loss  was  accounted  for  by  differences  in  intake, 
while  the  remainder  seemed  secondary  to  an  alternative  property  of  All  (206). 
These  observations  suggest  that  the  RAS  has  a  potentially  important  role  in  the  regulation 
of  body  weight  and  fat  mass.  This  may  be  partially  mediated  by  a  central,  anorectic  effect 
via  the  ATI  receptor.  There  may  also  be  effects  in  adipose  tissue,  possibly  by  local 
potentiation  of  the  sympathetic  nervous  system. 
The  adipose  tissue  RAS  seems  also  to  be  influenced  by  nutritional  status.  In  mice  subjected 
to  two  days  of  fasting,  local  expression  of  AGT  mRNA  falls,  while  on  refeeding  this  is 
restored  then  rises  to  double  the  levels  seen  in  control  fed  animals.  Epididymal  fat  from 
ob/ob  and  db/db  mice  secretes  twice  as  much  AGT  per  cell  as  age  matched  controls.  Taken 
together,  these  findings  demonstrate  that  the  regulation  of  AGT  synthesis  in  adipose  tissue 
is  to  some  extent  dependent  on  nutritional  status,  and  suggest  that  in  genetically  obese 
animals,  thii  situation  may  be  exaggerated  (207).  It  may  be  that  local  AGT  secretion  has  a 
regulatory  role  in  adipose  tissue  perfusion,  modifying  the  release  of  fatty  acids  into  the 
systemic  circulation  depending  on  nutritional  status. 
1.11.4.2  Angiotensin  Il  and  prostaglandin  synthesis 
Prostaglandin  PGI2,  and  to  a  lesser  extent  PGE2  and  PGF2.  ',  are  produced  by  isolated 
adipocytes  in  response  to  noradrenaline-induced  lipolysis  (208).  This  effect  is  inhibited  by 
insulin  (209).  Arachidonic  acid,  the  substrate  for  prostaglandin  synthesis  in  adipocytes, 
may  be  derived  from  two  sources  -  cellular  phospholipids  and  triglycerides.  In  isolated  rat 
(210)  and  human  (211)  adipocytes,  AH,  bradykinin  and  vasopressin  all  stimulate  the 
production  of  PG12  from  adipocytes,  with  no  associated  rise  in  PGE2  or  glycerol  (210).  As 
63 PGI2  is  a  potent  vasodilator,  release  of  this  prostaglandin  in  response  to  AH  may  modify 
the  local  perfusion  of  adipose  tissue.  Similarly,  the  AII  regulated  release  of  PGI2  from 
perivascular  and  visceral  fat  in  other  tissues  or  organs  may  regulate  flow  to  various 
vascular  beds  (212).  These  in  vitro  findings  have  been  reproduced  in  vivo  using  in  situ 
microdialysis  of  rat  peri-epididymal  fat.  Through  an  indomethacin  sensitive  mechanism, 
AII  increased  local  production  of  6  keto-PGF  1.  a  stable  degradation  product  of  PG12,  with 
no  associated  effect  on  PGE2  or  glycerol(213).  This  suggests  that,  in  contrast  to 
isoproterenol  or  forskolin,  which  have  a  cAIV[P  mediated  lipolytic  effect  and  result  in 
glycerol  accumulation,  AII  mediates  its  effect  on  PGI2  production  through  an  alternative 
route,  perhaps  via  phospholipase  A2,  releasing  arachidonic  acid  from  cellular  lipids.  There 
is  some  evidence  that  this  is  indeed  the  case;  in  isolated  rat  adipocytes,  isoproterenol 
induced  prostaglandin  production  is  sensitive  to  insulin,  presumably  by  an  antagonistic 
effect  on  cAMP  production,  however  the  AH  induced  production  of  PG12  is  not  inhibited 
by  the  addition  of  insulin  (214). 
1.11.4.3  Adipocyte  differentiation 
In  co-culture  of  preadipose  and  adipose  cells,  the  addition  of  An  resulted  in  an  increase  in 
the  differentiation  of  the  preadipose  cells.  Addition  of  An  to  undifferentiated  cells  alone 
had  no  effect,  as  had  the  addition  of  AII  to  the  co-culture  experiments  in  the  presence  of  an 
AT2  blocker,  implying  that  this  effect  required  stimulation  of  differentiated  cells  at  the 
AT2  receptor.  Activity  of  the  enzyme  glycerol-3  -phosphate  dehydrogenase  (GPDH),  the 
rate  limiting  step  in  triglyceride  synthesis  (reviewed  in  (215))  and  an  indicator  of 
differentiation,  rose  fourfold  in  the  preadipose  cells.  This  process  was  again  sensitive  to 
cycclooxygenase  inhibition  and  to  the  addition  of  antibodies  directed  against  the  stable 
analogue  of  PG12.  Therefore,  An  stimulates  the  mature  adipocyte,  promoting  release  of 
64 PGI2,  which  then  stimulates  preadipocytes  at  the  AT2  receptor  and  promotes 
differentiation. 
Further  investigations,  using  the  murine  3T3  Ll  adipocyte  cell  line,  which  express  the  AT2 
receptor,  reinforce  AII's  role  as  an  adipogenic  hormone,  and  provide  some  insight  into  its 
intracellular  action(216).  48  hours  of  physiological  levels  of  AH  treatment  resulted  in 
increased  activity  of  both  GPDH,  and  fatty  acid  synthase  (FAS),  the  rate-limiting  step  in 
long  chain  saturated  fatty  acid  synthesis,  and  led  to  an  increase  in  intracellular  triglyceride 
stores.  This  process  was  abolished  by  the  addition  of  the  AT2  receptor  blocker  P-186. 
Parallel  experiments  in  human  adipocytes  also  demonstrated  that  72  hours  of  exposure  to 
AII  results  in  elevation  of  FAS,  and  to  a  lesser  extent  GPDH  activity. 
In  summary  therefore,  treatment  with  AII,  acting  at  the  AT2  receptor  in  differentiated 
adipocytes,  and  perhaps  at  the  ATI.  receptor  in  preadipocytes,  results  in  the  maturation  and 
differentiation  of  cells  into  adipocytes. 
In  addition  to  AII's  effect  on  adipocyte  differentiation  via  production  of  PGI2,  the  degree 
of  differentiation  of  adipose  tissue  is  an  important  determinant  of  the  expression  of  the 
RAS  in  adipose  tissue.  Cultured  adipocytes  express  AGT  mRNA  depending  on  the  method 
and  extent  of  cellular  differentiation;  the  amount  of  AGT  mRNA  in  3T3-F442A  adipocytes 
increases  with  the  degree  of  differentiation  into  adipocytes(217).  Glucocorticoids  also 
influence  expression  of  these  components;  in  cultured  ObI771  cells  exposed  to 
dexamethasone(218),  levels  of  AGT  mRNA  and  protein  synthesis  increased  12  fold. 
Similar  results  were  observed  in  explanted  rat  adipocytes  incubated  in  the  presence  or 
absence  of  dexamethasone.  Fatty  acids,  which  differentiate  adipocytes  via  the  PPARs, 
65 may  have  a  similar  role,  as  treatment  of  preadipocytes  with  fatty  acids  resulted  in  a  17.6 
fold  increase  in  cellular  AGT  mRNA  after  48  hours  (219). 
Thus  a  situation  exists  in  which  a  stimulus  to  adipocyte  AII  production,  such  as  feeding  or 
obesity,  may  increase  the  differentiation  of  adipose  tissue.  Once  fully  differentiated, 
adipocytes  are  then  more  able  to  produce  All  locally  by  the  increased  expression  of  AGT 
mRNA,  which  may  then  increase  differentiation  of  preadipocytes,  and  the  formation  of 
triglyceride  stores.  Once  able  to  produce  AII,  these  adipocytes  may  also  regulate  local 
blood  flow  and  nutrient  flux,  both  by  the  direct  effect  of  AH  on  the  vasculature,  and 
perhaps  also  by  secondary  production  of  other  vasoactive  hormones  such  as  the 
prostaglandins. 
1.11-4.4  Thermogenesis 
Mammals  have  a  highly  developed  adaptive  response  to  cold  exposure,  central  to  which  is 
the  sympatfietic  nervous  system,  involving  an  increase  in  metabolic  rate,  circulating 
catecholamines,  and  sensitivity  of  beta  adrenoceptors.  In  addition  to  an  increase  in  blood 
pressure,  changes  also  occur  at  the  tissue  level,  and  in  particular  an  increase  in  the 
thermogenic  interscapular  brown  adipose  tissue  (ISBAT),  is  seen.  These  adaptive  response 
are  prevented  by  captopril  therapy  (220).  In  cold  exposed  male  Sprague  Dawley  rats, 
plasma  AII  rises  acutely,  perhaps  secondary  to  an  increase  in  sympathetic  activity,  then 
falls  to  baseline  within  24  hours  before  rising  again  after  seven  days  (221).  ATI  receptor 
density  in  ISBAT  also  increases,  along  with  ISBAT  tissue  mass,  while  in  some  other 
tissues,  such  as  lung,  no  changes  in  ATI  receptor  density  occur,  implying  tissue  specificity 
The  elevation  of  plasma  All,  though  not  AT1  receptors,  depends  on  the  associated  increase 
in  food  intake  following  cold  exposure. 
66 These  data  demonstrate  that  the  adaptive  response  to  cold  in  rodents  involve  changes  in  the 
systemic  and  adipose  tissue  RAS.  These  changes  are  particularly  important  in  ISBAT, 
where  local  AH  may  enhance  the  thermogenic  response  to  sympathetic  stimulation. 
Furthermore,  in  models  of  defective  thermogenesis,  such  as  the  Zucker  rats,  this  process  is 
disrupted,  and  may  explain  in  part  the  development  of  obesity  by  defective  energy 
expenditure.  The  relevance  of  this  homeostatic  system  to  human  physiology  is 
questionable,  as  humans  have  no  brown  adipose  tissue,  however  it  does  provide  an 
example  of  the  physiological  regulation  and  role  of  the  adipose  tissue  RAS. 
67 1.11.5  The  renin  angiotensin  system  and  the  endothelium 
Cardiovascular  risk  factors  such  as  hypertension,  type  2  diabetes  and 
hypercholesterolaemia  are  associated  with  endothelial  dysfunction,  and  as  ACE  inhibitors 
may  have  an  effect  on  cardiovascular  mortality  in  high  risk  patients  (222),  possibly  outwith 
their  antihypertensive  action,  the  possibility  arises  that  they  may  act  by  improving  the 
function  of  the  endothelium. 
In  a  hypertensive  rat  model  of  endothelial  dysfunction,  Clozel  et  al  (223)  showed  that 
treatment  with  ACE  inhibition  improved  this  defect  in  isolated  aortic  rings.  Aortic 
vasodilation  in  response  to  acetylcholine  and  bradyIdnin  (224)  was  greater  in  ramipril 
treated  rats  than  those  receiving  hydralazine  or  placebo.  The  rarnipril  effect  was  negated  by 
the  co  administration  of  a  bradykinin  antagonist.  Thus  it  was  suggested  that  ACE  inhibition 
improves  endothelial  function,  most  likely  by  a  reduction  in  bradykinin  breakdown. 
Certainly,  bradyIdnin  is  a  potent  vasodilator  and  stimulates  the  production  of  NO,  PG12  and 
possibly  th6  endothelium  dependent  hyperpolarizing factor  (EDHF),  all  of  which  are 
vasodilators  (reviewed  in  (225)). 
Creager  et  al  ((226))  found  no  improvement  in  endothelial  function  in  association  with 
ACE  inhibition,  measured  by  recording  the  changes  in  forearm  blood  flow  in  response  to 
local  arterial  methacholine  infusion,  despite  a  significant  effect  of  ACE  inhibition  on 
systemic  blood  pressure.  In  a  randomised  cross  over  study  of  patients  with  CHD  (227)9 
comparing  eight  weeks  of  quinapril,  enalapril,  losartan  and  amlodipine,  only  quinapril  (an 
ACE  inhibitor  with  high  affinity)  was  associated  with  an  improvement  flow  mediated 
vasodilation.  In  hypercholesterolaemic  patients,  six  months  of  lisinopril  therapy  was 
associated  with  an  improvement  in  both  endothelium  dependent  and  independent 
68 vasodilation,  when  compared  with  placebo,  though  of  course  this  was  in  association  with  a 
fall  in  systemic  blood  pressure  (228). 
Most  of  the  actions  of  AII  in  the  endothelium  seem  to  be  mediated  by  the  AT1  receptor. 
Certainly  in  cultured  human  umbilical  vein  endothelial  cells,  the  AT1  receptor  is  expressed 
and  binds  AH  (229),  though  this  may  be  lost  at  higher  passages  (230).  Using  reverse 
transcriptase  (RT)  PCR,  however,  Zhang  et  al  ((23  1))  were  able  to  identify  the  presence  of 
both  the  AT  I  and  2  receptors  in  HUVECs. 
AII  may  have  a  direct  deleterious  effect  on  the  endothelium,  by  increasing  the  production 
of  superoxide  anions,  which  in  turn  reduce  levels  of  nitric  oxide  and  PG12  (232),  (233). 
The  main  source  of  vascular  superoxide  is  from  reduced  nicotinamide-adenine  dinucleotide 
(NADH)-dependent  oxidase.  In  HUVECs,  AH  exposure  for  one  hour  induced  a  dose- 
dependent  increase  in  superoxide  generation  that  was  inhibited  by  the  addition  of.  an  AT1 
receptor  bloýker,  and  to  a  lesser  extent  by  AT2  blockade  (23  1). 
AII  may  also  have  additional  effects  on  vascular  homeostasis,  by  acting  as  a  stimulant  to 
the  production  of  local  athero-  and  thrombogenic  factors,  such  as  PAM  (234),  PDGF 
(23  5),  Endothelin  -1  (23  6)  and  E-selectin  (23  7)  from  the  endothelium. 
An  additional  mechanism  through  which  AH's  effect  on  the  endotheliurn  may  be  harmful 
has  been  proposed  in  relation  to  the  atherogenic,  oxidised  form  of  LDL-cholesterol, 
receptors  for  which  are  present  in  the  endothelium.  (238).  Incubation  of  human  coronary 
artery  endothelial  cells  with  AII  increased  the  expression  of  these  receptors,  and  so  the 
cellular  uptake  of  LDL,  and  was  associated  with  cell  injury,  measured  by  lactate 
69 dehydrogenase  (LDH)  release.  This  effect  was  blocked  by  ATI  receptor  antagonism  in 
vitro,  while  in  internal  mammary  artery  biopsies  from  patients  treated  with  ACE  inhibitors 
prior  to  surgery,  there  was  a  reduction  in  the  mRNA  for  these  receptors  (239). 
While  the  focus  of  these  papers  has  been  on  the  effects  of  AII  on  endothelial  function,  the 
recently  reported  randomised  aldactone  evaluation  study,  which  identified  a  reduction  in 
mortality  in  patients  with  chronic  heart  failure  treated  with  spironolactone  in  addition  to 
their  conventional  therapy  (240),  has  prompted  investigation  into  the  role  of  aldosterone 
antagonism.  In  a  randomised,  double  blind,  placebo-controlled  crossover  study  in  patients 
with  chronic  heart  failure  (241),  one  month  of  spironolactone  therapy  improved 
endothelium  dependent  vasodilation  in  the  forearm,  possibly  by  increasing  NO 
bioavailability. 
Thus,  there  is  increasing  evidence  to  support  the  notion  that  AH,  and  perhaps  aldosterone 
may  have  deleterious  effects  on  the  vasculature,  possibly  mediated  at  the  level  of  the 
endothelium. 
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1.11.6.1  The  metabolic  effects  of  dietary  sodium  restriction;  an  overview 
There  is  now  a  wide  literature  concerning  the  metabolic  effects  of  a  low  sodium  diet. 
Despite  the  recommendations  by  guidance  bodies,  there  is  little  or  no  prospective  evidence 
to  support  the  notion  that  a  low  salt  diet  prolongs  life  (242).  This  is  despite  the  well- 
documented  reduction  in  blood  pressure  that  accompanies  dietary  sodium  restriction  (243), 
which  would  be  anticipated  to  be  associated  with  a  reduction  in  cardiovascular  mortality. 
As  such,  interest  has  focused  on  the  metabolic  effects  of  dietary  sodium  restriction  that  may 
be  deleterious;  possibilities  include  a  reduction  in  insulin  sensitivity,  adverse  effects  on 
lipid  profile  and  stimulation  of  counter  regulatory  hormones.  Of  particular  relevance  here  is 
the  effect  on  insulin  sensitivity,  as  this  may  be  a  direct  consequence  of  activation  of  the 
RAS,  and  as  such  these  data  are  reviewed  below. 
The  gold  standard  investigation  of  insulin  sensitivity,  as  outlined  earlier,  is  the  euglycaernic 
hyperinsulmaernic  clamp.  Similarly,  the  ideal  experimental  design  is  a  double  blinded, 
randomised,  placebo  controlled  trial  of  crossover  design  that  compares  low  and  high  salt 
phases.  Not  all  the  trials  have  used  either  of  these  techniques  or  designs,  and  so  the  relative 
merits  of  each  study  must  be  considered  individually. 
1.11.6.2  Low  sodium  diet  and  lipids 
Early  studies  were  designed  to  clarify  the  relationship  between  dietary  sodium  reduction 
and  plasma  lipid  profile.  To  observe  an  effect  on  insulin  sensitivity  was  not  the  primary 
goal,  and  as  such  simple  serum  insulin  was  used  as  a  marker  of  insulin  sensitivity.  In  a 
large  study  of  19-78  year  old  non-obese  normotensive  subjects  (244)  entered  into  a  single 
blind  crossover  study  comparing  seven  days  of  20mmol/day  and  300mmol/day  sodium 
71 intake,  total  and  LDL  cholesterol  were  greater  in  the  low  sodium  phase,  as  was  serum 
insulin  (245). 
Fliser  et  al  (246)  undertook  a  parallel  comparison  of  two  groups,  randomised  to  placebo  or 
the  alpha  1  receptor  blocker  doxazosin,  with  both  groups  undergoing  two  seven  day  periods 
of  low  sodium  diet  (20mmol/day)  supplemented  with  placebo  or  slow  sodium 
(200mmol/day).  No  washout  period  was  incorporated  into  the  design.  Low  sodium  diet  was 
associated  with  an  increase  in  total  cholesterol  and  LDL  cholesterol  after  two  and  seven 
days  of  diet,  though  more  marked  after  two  days.  Insulin  and  C-peptide  were  greater  on 
low  sodium  diet  after  two  days,  as  was  circulating  norepinephrine.  Doxazosin  therapy  was 
associated  with  blunting  of  the  lipid,  insulin  and  C-peptide  changes,  though  no  changes  in 
the  activation  the  sympathetic  nervous  system.  Goodfriend  et  al  (247)  included  a 
measurement  of  insulin  sensitivity  (ITT)  in  addition  to  an  oral  glucose  tolerance  test  after 
seven  days  of  low  (20mEq/day)  then  high  (200mEq/day)  sodium  intake  in  30  subjects.  A 
negative  correlation  was  observed  between  aldosterone  and  HDL  during  both  dietary 
phases.  A  weaker  relationship  was  also  seen  between  insulin  and  aldosterone,  and  between 
the  aldosterone-renin  ratio  and  insulin  during  the  high  sodium  phase. 
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As  early*  studies  examining  the  metabolic  effects  of  sodium  restriction  had  suggested 
metabolic  derangement,  further  studies  were  designed  to  examine  specifically  the 
relationship  between  insulin  sensitivity  and  sodium  intake.  Different  subject  groups  have 
been  studied: 
e  Normotensive  Subjects:  Fliser  et  al  (248)  investigated  the  hypothesis  that  the 
differing  results  seen  in  response  to  sodium  restriction  may  in  part  be  explained  by 
variation  in  the  duration  of  diet.  In  healthy  males,  insulin  sensitivity,  assessed  by  the 
clamp  technique,  was  measured  in  seven  males  after  one  week  of  randomly 
assigned  high  (200mmol/day)  and  low  (20mmol/day)  sodium,  and  in  seven  males 
after  three  days  of  the  same  dietary  protocol.  While  no  difference  in  M  value  was 
seen  after  seven  days,  clamps  after  three  days  showed  a  reduction  in  insulin 
sensitivity  associated  with  the  low  sodium  phase  (M  value  7.4  ±2  vs.  8.6  ±  1.1 
mg/kglmin) 
In  1996,  Grey  et  al  (249)  compared  more  modest  sodium  restriction  in  34  healthy 
normotensive  males,  ainiing  for  two  seven  day  periods  of  sodium  restriction  to  less 
than  80  mmol/day,  with  one  week  supplemented  with  placebo  and  the  other  by 
120mmol/day  of  slow  sodium  tablets.  The  study  had  a  randomised  double  blind 
crossover  design,  though  notably  there  was  no  washout  period  between  phases. 
Insulin  sensitivity  was  measured  using  fasting  plasma  insulin  (RIA)  and  CIGMA. 
Mean  urinary  sodium  after  the  low  sodium  phase  was  52  ±  25  mmol/day  compared 
with  185  ±  46  mmol/day  after  high  sodium.  No  change  in  blood  pressure,  insulin 
sensitivity  or  lipids  other  than  an  increase  in  HDL3  on  low  sodium  was  observed. 
73 Seven  subjects  were  salt  sensitive  (fall  in  "  ý3  mmHg  on  low  sodium),  though 
this  subgroup  did  not  behave  differently  to  that  in  the  main  analysis 
Not  all  studies  have  shown  a  fall  in  insulin  sensitivity  associated  with  dietary 
sodium  restriction.  Facchini  et  al  (250)  found  no  difference  in  steady  state  plasma 
glucose  (SSPG)  during  insulin  suppression  test  in  19  healthy  volunteers  undergoing 
five  day  dietary  periods  of  25  and  200mmol/day  sodium  intake,  despite  excellent 
compliance  (12  ý:  3mmol/24h  vs.  174A:  14  mmol/24h). 
o  Hypertensive  Subjects:  lwaoko  et  al  (251)  demonstrated  that  in  31  hypertensive 
subjects,  seven  days  of  low  sodium  intake  vs.  seven  days  of  high  sodium  intake  was 
associated  with  no  change  in  fasting  plasma  insulin  or  glucose  after  correction  for 
haematocrit.  However,  during  an  OGTT,  the  AUC  for  insulin  and  glucose  was  less 
in  the  high  sodium  phase,  suggesting  that  there  was  a  reduction  in  insulin  sensitivity 
asso6iated  with  dietary  sodium  restriction.  The  fall  in  AUC  glucose  on  a  low 
sodium  diet  correlated  with  the  absolute  value  of  AUC  glucose,  suggesting  that  the 
most  glucose  intolerant  subjects  were  most  susceptible  to  the  effects  of  dietary 
sodium  restriction.  The  group  in  fact  contained  seven  diabetics  and  18  subjects  with 
IGT  after  the  OGTT,  suggesting  that  the  group  was  heterogeneous.  There  was  no 
mention  of  blood  pressure  therapy.  Compliance  was  documented  by  the  urinary 
sodium  of  32mmol/24  hours  and  298mmol/24  hours  on  low  and  high  sodium  phases 
respectively,  and  despite  the  fact  that  MAP  rose  from  100  to  108  on  high  sodium, 
no  correlation  was  observed  between  salt  sensitivity  and  insulin  sensitivity. 
74 After  12  weeks  of  modest  sodium  restriction  in  34  hypertensive  patients  (20  male, 
mean  age  53),  (252)  C-peptide  rose  by  40%  and  glucose  rose  by  6%  (both  p<0.05) 
compared  with  baseline.  There  was  no  associated  evidence  of  sympathetic 
activation.  The  design,  and  lack  of  a  measure  of  insulin  sensitivity  limits  the  value 
of  this  study,  though  the  duration  of  diet  is  of  interest.  The  same  authors  published 
data  from  a  double  blind  cross  over  study  (253)  of  16  mild  to  moderate  hypertensive 
subjects  (mean  age  50,13  males)  randomly  assigned  to  a  period  of  modest  sodium 
restriction  for  two  periods  of  eight  weeks,  one  supplemented  with  placebo  and  the 
other  with  50mmol/day  of  sodium.  No  significant  difference  in  blood  pressure, 
glucose  or  insulin  was  found  between  phases. 
9  Type  2  diabetes:  Petrie  et  al  (254)  undertook  studies  of  dietary  sodium  restriction  in 
eight  diet  controlled  type  2  diabetics,  with  a  double  blind  randomised  placebo 
controlled  crossover  design,  measuring  M  values  after  four  days  of  sodium  replete 
(160'mmol/day)  and  deplete  (40mmol/day)  diet.  Insulin  sensitivity  was  12  %  lower 
(p=0.04)  on  low  sodium  intake. 
*  Other  cardiovascular  high  risk  groups:  To  determine  if  the  response  to  dietary 
sodium  restriction  was  related  to  the  cardiovascular  risk  profile,  Egan  et  al  (255) 
tested  the  effect  of  seven  days  of  dietary  sodium  restriction  (<20mmol)  and  seven 
days  of  normal  sodium  intake  (200mmol)  in  a  group  of  29  subjects  and  analysed  the 
responses  having  subdivided  the  cohort  into  groups  with  increasing  cardiovascular 
risk  factors.  In  those  with  the  highest  number  of  risk  factors,  the  response  of  the 
RAS  to  a  low  sodium  diet,  measured  by  plasma  renin  activity  and  aldosterone,  was 
greatest.  In  the  low  score  group,  low  sodium  was  associated  with  a  higher  insulin 
75 AUC,  fasting  total  cholesterol  and  LDL  cholesterol.  In  the  medium  score  group, 
similar  lipid  and  insulin  changes  were  observed,  and  in  the  high  score  group, 
elevations  in  TG,  total  cholesterol  and  insulin  (both  fasting  and  AUC)  were  seen. 
Only  in  the  high  risk  group  were  NEFA  greater  during  sodium  restriction.  Thus  in 
those  with  a  metabolic  profile  more  prone  to  cardiovascular  disease,  dietary  sodium 
restriction  was  associated  with  the  greatest  activation  of  the  RAS,  and  the  firmest 
evidence  of  a  reduction  in  insulin  sensitivity. 
1.11.6.4  Dietary  sodium  restriction  and  NEFA 
Circulating  free  fatty  acids  may  bind  directly  to  the  AII  receptor,  thus  reducing  AII  induced 
increases  in  plasma  aldosterone  (256).  Thus  studies  were  undertaken  to  determine  the  effect 
of  dietary  sodium  on  plasma  NEFA.  This  interaction  could  affect  not  only  the  RAS,  but 
would  also  have  repercussions  on  insulin  sensitivity  and  the  function  of  the  endothelium, 
both  of  which  are  reduced  by  plasma  NEFA.  Goodfriend  et  al  (257)  demonstrated  that 
saline  infusion  increased  plasma  NEFA.  High  sodium  diet  was  associated  with  borderline 
significant  increases  in  plasma  NEFA  when  compared  with  low  sodium  intake,  though 
these  data  were  the  sum  of  three  different  experimental  protocols.  Further  studies  revealed 
that  saline  infusion  was  accompanied  by  a  fall  in  plasma  insulin,  and  that  high  sodium  diet 
was  associated  with  a  reduction  in  plasma  insulin.  No  correlation  was  observed  between  the 
rises  in  NEFA  and  the  falls  in  plasma  insulin,  suggesting  a  lack  of  direct  causality.  In 
subjects  on  low,  though  not  high,  sodium  intake,  a  correlation  was  seen  between 
norepinephrine  and  NEFA.  These  interactions  may  provide  some  explanation  for  the 
observed  increase  in  the  aldosteronogenic  effect  of  AII  during  insulin  infusion;  insulin 
reduces  NEFA,  which  may  block  the  AII  receptor. 
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Rocchini  first  observed  a  relationship  between  the  metabolic  and  pressor  response  to 
dietary  sodium  restriction  (258).  In  comparison  of  obese  and  lean  volunteers  undergoing 
two  weeks  of  high  sodium  (>250mmol/day)  then  low  sodium  (<30mmol/day)  diet,  the  fall 
in  blood  pressure  in  the  obese  group  was  12  +1  mmHg  compared  with  an  increase  of  I± 
2mmHg  in  the  lean  group.  The  magnitude  of  this  sensitivity  (salt  sensitivity)  was  predicted 
by  fasting  insulin,  though  also  by  the  percentage  of  body  weight  made  up  by  fat,  which 
may  be  related.  In  keeping  with  these  observations,  the  obese  subjects  were  then  entered 
into  a  weight  loss  programme,  and  those  who  lost  more  than  lkg  of  weight  were  then  less 
salt  sensitive.  Those  who  lost  no  weight  remained  salt  sensitive  as  in  the  initial  phase. 
In  a  study  of  23  healthy  young  males  (259)  in  a  single  blind  randomised  crossover 
consisting  of  six  days  of  20mmol/day  and  six  days  of  260  mmol/day  sodium  intake, 
comparisons  were  made  between  salt  sensitive  (SS)  and  resistant  (SR)  subjects.  Response 
to  dietary  sodium  differed,  in  that  the  SS  group  showed  higher  plasma  glucose  during 
OGTT  than  the  SR  group  during  the  high,  but  not  low  sodium  phase.  In  the  SS  group, 
glucose  tolerance  improved  on  low  sodium,  though  in  the  SR  group  the  opposite  occurred 
on  low  sodium.  Thus  on  high  sodium  intake,  those  at  risk  of  later  developing  hypertension 
(SS)  were  more  insulin  resistant,  and  this  was  negated  on  low  sodium.  These  results  must 
be  interpreted  with  caution,  however,  as  a  surrogate  measure  of  insulin  sensitivity  was 
employed,  and  it  is  unclear  whether  dietary  sodium  intake  may  affect  the  absorption  of 
glucose  during  OGTT.  To  answer  some  of  these  criticisms  the  same  authors  (260) 
measured  insulin  sensitivity  by  insulin  suppression  test  in  18  healthy  male  volunteers  after 
two  weeks  of  20mmol/day  sodium  intake,  one  week  of  which  was  randomly  supplemented 
with  220mmol  sodium  daily.  In  the  seven  SS  subjects,  plasma  glucose  was  higher  than  in 
77 the  SR  subjects,  in  keeping  with  insulin  resistance,  though  no  difference  in  plasma  insulin 
was  observed. 
In  another  study  of  28  subjects  with  untreated  hypertension  (261)  who  underwent  one  week 
of  sodium  intake  of  220mmol/day,  then  one  week  of  30mmol/day,  MAY  was  measured  at 
the  end  of  both  phases,  and  salt  sensitivity  defined  as  a  fall  in  MAP  >10%.  Blood  pressures 
were  the  mean  of  25  readings  taken  every  five  minutes  after  a  30-minute  rest  period.  Ten 
subjects  were  salt  sensitive,  eight  salt  resistant  (<3%  fall  in  blood  pressure)  and  ten 
intermediate.  OGTT  with  plasma  insulin  was  performed  at  the  end  of  the  high  sodium 
period.  The  baseline  data  revealed  that  those  in  the  salt  sensitive  group  were,  on  retrospect, 
more  obese  and  had  higher  fasting  plasma  insulin  than  the  salt  resistant  group. 
Furthermore,  plasma  insulin  was  greater  during  the  OGTT  in  the  salt  sensitive  group.  A 
relationship  just  below  statistical  significance  was  seen  between  the  reduction  in  MAP  on 
the  low  sodium  phase  and  the  integration  of  the  area  of  insulin  and  glucose  curves  during 
OGTT  when  all  subjects  were  included.  Bigazzi  et  al  (262)  demonstrated  that  in 
hypertensive  patients,  comparison  of  the  29  SS  and  23  SR  subjects  (defined  after  one  week 
of  20mmol/day  sodium  then  one  week  of  250mmol/day  sodium)  revealed  no  difference  in 
baseline  plasma  glucose  and  insulin,  however  after  OGTT  AUC  glucose  and  insulin  was 
greater  in  the  SR  group.  More  recently,  a  study  of  16  non-obese  patients  with  mild 
hypertension  (263)  and  on  no  treatment  for  4  weeks,  examined  insulin  sensitivity  as 
measured  by  the  insulin  suppression  test  after  one  week  of  low  sodium  (40-60mEq/day) 
then  one  week  of  high  sodium  intake  (300mEq/day).  Salt  sensitivity  was  defined  as  an 
increase  in  MAP  >10%  in  response  to  high  sodium.  No  difference  in  fasting  insulin  or 
glucose  was  observed  between  the  groups,  however,  the  insulin  suppression  test  revealed 
78 that  glucose  disposal  was  less  and  steady  state  glucose  was  greater  in  SS  than  SR 
hypertensives.  This  difference  was  observed  during  both  low  and  high  sodium  phases. 
These  data  suggested  that  in  normotensive  individuals,  salt  sensitivity  is  associated  with 
insulin  resistance.  Not  all  groups  have  found  this  however,  as  in  a  study  of  27  normotensive 
males(264),  18  of  whom  were  salt  resistant  and  nine  of  whom  were  salt  sensitive,  there  was 
no  difference  in  the  mean  M  value  between  the  groups.  In  addition,  there  was  no  effect  of 
dietary  sodium  restriction  (60mmol  vs.  260mmol/day  for  seven  days)  on  insulin  sensitivity 
in  either  group.  In  fact,  in  untreated  hypertensive  patients,  greater  salt  sensitivity  was 
associated  with  greater  insulin  sensitivity  (265),  a  finding  similar  to  that  observed  in  21  SS 
males  (266)  whose  salt  sensitivity  correlated  significantly  and  positively  with  insulin 
sensitivity. 
An  additional  component  of  the  relationship  between  insulin  resistance  and  salt  sensitivity 
may  be  a  r6duction  in  the  normal  nocturnal  fall  in  blood  pressure  (267).  In  hypertensive 
subjects,  sodium  induced  increase  in  blood  pressure  between  phases  was  associated  with 
the  SSPG  during  an  insulin  sensitivity  test  while  on  the  high  sodium  phase.  SSPG  was 
negatively  correlated  with  the  fall  in  nocturnal  blood  on  high  sodium  intake,  while  sodium 
induced  increase  in  blood  pressure  was  negatively  correlated  with  nocturnal  fall  in  MAP, 
suggesting  that  the  lesser  the  nocturnal  blood  pressure  fall  the  greater  the  salt  sensitivity, 
the  greater  the  insulin  resistance. 
Thus  there  seems  to  be  a  relationship  between  salt  sensitivity  and  insulin  resistance, 
certainly  at  baseline,  though  the  metabolic  response  to  sodium  loading  and  restriction 
seems  less  clear,  and  may  differ  between  normotensives  and  hypertensives.  Similarly,  some 
79 of  the  variation  in  findings  may  be  accounted  for  by  variability  in  the  methods  used  to 
measure  insulin  sensitivity. 
If  salt  sensitivity  precedes  hypertension,  then  it  may  be  expected  to  be  common  in 
populations  with  a  high  prevalence  of  hypertension,  such  as  American  blacks  (268).  There 
is  some  evidence  to  suggest  that  this  might  be  the  case  (269),  however,  dietary  potassium 
plays  an  important  role  in  determining  the  sensitivity  of  MAP  to  sodium  restriction.  After 
sodium  loading  for  four  weeks,  American  blacks  receiving  potassium  supplementation 
suppressed  the  frequency  and  severity  of  salt  sensitivity  to  levels  seen  in  similarly  treated 
whites  (270).  However,  when  potassium  intake  was  limited  to  30mmol/day,  the  frequency 
of  SS  was  greater  in  blacks  than  whites 
1.11.6.6  Dietary  sodium,  insulin  sensitivity  and  the  vasculature 
In  addition  to  the  potentially  deleterious  effects  that  sodium  restriction  may  have  on  lipids 
and  metabofic  insulin  sensitivity,  activation  of  the  RAS  by  this  means  may  also  affect 
vascular  function.  This  may  be  mediated  by  All,  aldosterone  or  even  catecholamines  that 
are  produced  in  response  to  a  low  sodium  diet.  Alternatively,  if  dietary  sodium  is  associated 
with  a  fall  in  insulin  responsiveness  in  muscle  and  fat,  then  there  may  be  an  associated 
reduction  in  endothelial  insulin  sensitivity. 
In  18  obese  sub  .  ects,  no  difference  was  seen  in  plasma  insulin  or  glucose  between  SS  and  9 
SR  groups,  however  during  the  high  sodium  phase  insulin  increased  calf  blood  flow  only  in 
the  SR  subjects(271).  13  subjects,  eight  of  whom  had  borderline  hypertension,  were  entered 
into  a  double  blind  randomised  crossover  trial  (272)  consisting  of  one  week  on  low  sodium 
intake  (20mEg/day)  and  one  week  of  normal  intake  (240mEq/day),  with  vascular 
80 sensitivity  io  insulin  measured  in  dorsal  hand  veins  at  the  end  of  each  phase  (using  the 
linear  variable  differential  transformer  technique).  On  normal  sodium,  vascular  insulin 
sensitivity  was  lower  in  hypertensives  than  in  normotensives.  On  low  sodium,  vascular 
insulin  sensitivity  decreased  in  both  hypertensives  and  normotensives,  paralleled  by  an 
increase  in  norepinephrine.  Limb  blood  flow  in  18  healthy  male  volunteers  was  compared 
after  six  days  of  220mmol/day  and  40mmol/day  sodium  intake  (273).  No  change  in 
metabolic  insulin  sensitivity  dunng  two  stage  clamps  was  observed  between  'phases, 
however  leg  blood  flow  in  response  to  high  dose  insulin  was  significantly  greater  during 
high  than  low  sodium.  These  vascular  changes  were  dissociated  from  the  metabolic 
changes;  no  relationship  was  seen  between  the  metabolic  and  vascular  responses. 
In  WKY  rats,  no  difference  in  insulin  sensitivity  (M)  was  demonstrated  after  three  weeks  of 
low,  normal  and  high  sodium  diet,  however  insulin  enhanced  U-2  adrenergic  vasorelaxation 
in  aortic  rings  was  present  only  after  high  and  normal  sodium  intake,  again  suggesting  that 
low  sodiumýdiet  may  be  associated  with  endothelial  dysfunction  (274). 
1.11.7  ACE  inhibitors  and  insulin  sensitivity 
If  dietary  sodium  restriction  reduces  insulin  sensitivity,  possibly  through  a  direct  effect  of 
angiotensin  H  (see  section  1.11.10),  then  it  would  be  anticipated  that  inhibition  of  the 
generation  of  angiotensin  H  by  ACE  inhibition  would  have  an  insulin  sensitising  action. 
The  evidence  for  this  is  reviewed  below. 
The  first  study  to  demonstrate  an  improvement  in  insulin  sensitivity  in  association  with 
ACE  inhibition  was  reported  by  Pollare  et  al  (275)  in  1989.  They  found  that  in 
hypertensive  patients  there  was  an  11%  increase  in  insulin  sensitivity  (clamp  measured) 
after  four  weeks  of  captopril  therapy  compared  with  placebo.  Many  studies  followed  this, 
81 in  healthy  VOlunteers  (276),  patients  with  type  2  diabetes  (277),  (278))  and  patients  with 
hypertension  (276).  These  have  varied  in  design  (crossover,  parallel  group  and  before  and 
after),  duration  (1-12  weeks),  the  use  of  a  placebo  group  and  the  technique  employed  to 
measure  insulin  sensitivity  (clamp,  ivGTI).  As  such  the  literature  is  heterogeneous,  making 
it  difficult  to  reach  a  consensus.  Of  the  studies  demonstrating  a  positive  effect,  Paolisso 
1992  (279)  found  that  two  weeks  of  lisinopril  increased  insulin  sensitivity  (ivGTT)  by  18% 
in  a  double  blind  placebo  controlled  crossover  study  in  elderly  hypertensive  patients.  The 
same  authors  (280)  later  found  that  in  a  similar  patient  group,  8  weeks  of  lisinopril 
increased  insulin  sensitivity  by  33%  (M  value),  though  here  there  was  only  single  blinding. 
De  Mattia  (278)  reported  a  50%  increase  in  insulin  sensitivity  (clamp  generated)  in  patients 
with  type  2  diabetes  treated  for  ten  days  with  captopril  though  notably  changes  in  insulin 
sensitivity  were  not  a  primary  end-point  of  the  study.  If  changes  of  this  magnitude  are 
genuinely  the  case  in  diabetes,  then  this  is  difficult  to  reconcile  with  data  from  the  UKPDS 
treatment  groups  in  which  there  was  no  reduction  in  HbAlc  in  the  captopril  vs.  the  P 
blocker  groiip  (281).  In  a  recent  study,  using  double-blind,  placebo  controlled  crossover 
methodology  to  compare  four  weeks  of  trandolapril  therapy  with  placebo  in  hypertensive 
patients  with  type  2  diabetes(282),  no  effect  on  M  value  was  seen.  The  authors  took  this 
opportunity  to  review  the  published  data  in  this  area,  and  in  particular  consider  the 
methodologies  employed.  The  only  other  trial  identified  as  using  gold  standard 
methodology  was  undertaken  by  Wiggam  et  al  (283),  and  reported  no  effect  of  eight  weeks 
of  captopril  treatment  on  insulin  sensitivity  in  a  hypertensive  cohort. 
Less  scientifically  robust,  though  nonetheless  intriguing,  population-based  data  on  ACE 
inhibition  and  hypoglycaemia  have  been  reported  by  two  groups.  Herings  et  al  (284)  found, 
using  a  retrospective  nested  case  control  design,  that  hypoglycaemia  requiring 
82 hospitalisation  occurred  more  frequently  in  diabetic  patients  using  ACE  inhibitors  (OR 
2.8[95%  CI  1.4-5.7]),  irrespective  of  hypoglycaernic  therapy.  Using  similar  methodology, 
Morris  et  al  (285)  analysed  data  obtained  from  over  6,000  diabetic  patients  in  Tayside,  and 
again  identified  an  OR  of  4.3  [95%  CI  1.2-16.0]  for  the  risk  of  hypoglycaemia  in  subjects 
treated  with  ACE  inhibitors,  after  adjustment  was  made  for  other  factors.  No  other 
antihypertensive  agent  was  identified  as  having  a  similar  effect. 
Two  major  studies  have  reported  a  reduction  in  the  incidence  of  type  2  diabetes  in 
association  with  ACE  inhibition.  In  the  Heart  Outcomes  Prevention  Evaluation  (HOPE) 
study(222),  a  33%  reduction  in  new  cases  of  type  2  diabetes  was  reported  in  the  ACE 
inhibitor  group,  however  the  diagnosis  of  diabetes  was  based  only  on  patients  reporting  the 
diagnosis;  it  may  also  be  argued  that  as  the  patients  in  the  placebo  group  experienced  more 
events  requiring  hospitalisation,  they  would  most  likely  have  undergone  more  testing  of 
random  and  fasting  blood  glucose.  In  the  Captopril  Prevention  Project  (286),  a  reduction  in 
new  cases  of  diabetes  was  reported  in  hypertensive  patients  treated  with  captopril  compared 
with  those  treated  with  conventional  antihypertensive  medication  (predominantly  diuretics 
and  0  blockers).  Importantly,  there  was  no  placebo  group.  In  addition,  this  study  has  been 
subsequently  criticised  on  the  basis  of  the  randomisation  process,  raising  questions  about 
the  validity  of  the  findings. 
It  must  be  borne  in  mind  that  ACE  inhibition  not  only  reduces  circulating  AII,  so  reducing 
AII  stimulation  of  the  AT1  and  2  receptors,  but  also  increases  bradykinin  by  its  effect  on 
kininase.  In  contrast,  ATI  receptor  blockade  increases  AII,  and  so  increases  the  AII 
available  to  the  AT2  receptor.  There  is  no  associated  effect  on  Idnins.  Thus  the  effect  of 
83 blockade  must  be  examined  separately,  and  in  assessing  the  particular  role  of  the  AT1 
receptor  in  modifying  insulin  sensitivity,  these  agents  may  provide  a  "puree'  model. 
Analysis  of  this  literature  reveals  similar  methodological  and  design  heterogeneities  to 
those  encountered  when  considering  the  effects  of  ACE  inhibition.  In  a  randomised, 
double  blind  study  (287)  comparing  losartan  and  metoprol  ol  in  20  hypertensive  patients 
selected  also  because  they  were  hyperinsulinaemic,  there  was  no  change  in  insulin 
sensitivity  (M  value)  after  12  weeks  of  therapy  in  either  group.  In  keeping  with  this  finding, 
in  a  further  study  of  hypertensive  patients  treated  with  losartan  for  four  weeks  (288), 
though  on  this  occasion  with  a  crossover  design  and  placebo  control  group,  there  was  no 
effect  on  clamp  measured  insulin  sensitivity.  In  25  hypertensives,  comparing  losartan  to 
lisinopril,  no  effect  of  losartan  on  insulin  sensitivity  was  observed.  There  was  an 
improvement  in  insulin  sensitivity  associated  with  lisinopril  therapy,  however  the  absence 
of  a  placebo  limb  to  the  study  makes  interpretation  of  this  finding  difficult  (289).  In  a 
placebo  cofitrolled  crossover  study  of  normotensive  offspring  of  hypertensive,  parents, 
losartan  had  no  effect  on  insulin  sensitivity  after  14  days  of  therapy,  though  insulin 
sensitivity  was  measured  using  the  minimal  model  method  of  Bergman  (290). 
Some  studies  have  suggested  a  positive  effect  of  ATI,  receptor  blockade;  Paolisso  et  al 
(291)  demonstrated  an  improvement  in  insulin  sensitivity  following  four  weeks  of  losartan 
therapy  vs  placebo,  though  there  was  no  crossover  design  to  the  study,  while  two  weeks  of 
candesartan  therapy  (292)  was  reported  as  improving  insulin  sensitivity  in  an  uncontrolled 
"before  and  after"study  of  eight  patients. 
84 In  summary,  there  is  no  real  consensus  as  to  the  effects  of  ATI.  receptor  blockade  and  ACE 
inhibition  on  insulin  sensitivity,  as  the  heterogeneity  of  publications  makes  it  very  difficult 
to  compare  studies.  There  is  no  firm  evidence  to  suggest  that  either  class  of  drug  has  a 
positive  effect  in  this  regard. 
1.11.8  Infusion  of  AIE[  and  insulin  sensitivity 
The  results  of  the  above  studies,  which  suggest  a  fall  in  insulin  sensitivity  in  response  to 
dietary  sodium  restriction  and  a  potential  improvement  in  association  with  blockade  of  the 
RAS,  may  be  interpreted  as  inferring  that  AIII  has  a  direct  effect  to  reduce  insulin 
sensitivity.  As  such,  seveml  studies  have  tested  the  effect  of  AII  infusion  on  insulin 
sensitivity. 
A  series  of  studies  in  non-notensive  males  suggested  that  All  infusion  during  a  euglycaemic 
hyperinsulinaemic  clamp  improved  insulin  sensitivity.  The  doses  and  timing  of  AII 
administration  during  the  clamp  varied  between  groups,  as  did  the  magnitude  of 
improvement  in  insulin  sensitivity.  Fliser  et  al  (293)  demonstrated  a  significant  elevation  in 
M  value  during  the  last  hour  of  a  clamp  associated  with  an  infusion  of  AII  at  1.  Sng/kg/min 
compared  with  sham,  while  there  was  no  increase  in  blood  pressure.  In  a  study  of  39 
healthy  males,  Widgren  at  al  (294)  found  that  a  30-minute  infusion  of  AII  (O.  lng/kg/min) 
was  associated  with  increased  insulin  sensitivity  compared  with  the  preceding  period  of  the 
clamp.  Using  a  higher  dose  of  AII  (15ng/kghnin)  Townsend  et  al  (295)  showed  a  15% 
improvement  in  insulin  sensitivity  compared  with  placebo. 
These  studies  are  limited  by  the  lack  of  formal  blinding  and  randomisation.  Morris  and 
colleagues  undertook  a  double-blind,  randomised,  placebo-controlled  crossover  study  in  12 
85 healthy  volunteers  (296),  and  found  that  infusion  of  lng/kg/min  (subpressor)  and 
5ng/kg/min  (pressor)  AII  throughout  the  clamp  had  no  effect  on  insulin  sensitivity. 
Clearly  higher  doses  of  AII  may  have  confounding  pressor  effects  that  may  influence 
insulin  sensitivity.  In  the  Fliser  study,  there  was  no  increase  in  blood  pressure,  however  AII 
infusion  in  the  Townsend  and  Widgren  studies  was  accompanied  by  an  elevation  in  blood 
pressure.  Morris  documented  an  elevation  in  blood  pressure  in  response  to  Sng/kg/min, 
though  not  lng/kg/min. 
In  attempt  to  address  the  association  of  the  metabolic  and  pressor  effects  of  AII,  Buchanan 
(297)  devised  an  elegant  series  of  studies  in  healthy  males.  In  the  absence  of  insulin  during 
a  sham  clamp,  AII  had  no  effect  on  whole  body  glucose  turnover  or  leg  glucose  extraction, 
implying  no  direct  effect  of  AII  to  stimulate  glucose  uptake.  A  clamp  performed  at 
physiological  insulinaemia  demonstrated  that  AII  infusion  increased  blood  pressure,  whole 
body  glucose  clearance  and  plasma  insulin.  In  clamps  performed  at  insulin  levels 
sufficiently  high  to  remove  insulin  as  a  rate-limiting  step  in  glucose  uptake  (maximal 
insulin),  AII  increased  whole  body  glucose  clearance  with  no  effect  on  glucose  extraction 
across  the  leg.  In  combination  with  these  studies,  it  was  shown  that  AII  infusion 
redistributed  flow  from  the  insulin  insensitive  splanchnic  circulation  to  insulin  sensitive 
skeletal  muscle  beds.  These  observations  suggested  that  the  effect  of  AII  to  increase  insulin 
sensitivity  was  mediated  not  by  a  direct  stimulation  of  glucose  uptake  or  an  increase  in 
glucose  extraction,  but  by  a  redirecting  of  flow  to  insulin  sensitive  vascular  beds.  This 
explained  why  AII  only  augmented  insulin  sensitivity  in  the  presence  of  insulin.  In  keeping 
with  this,  Jamerson  et  al  (298)  infused  AII  into  the  brachial  artery  of  healthy  volunteers, 
86 and  found  no  direct  effect  on  insulin  stimulated  glucose  uptake  into  forearm  skeletal 
muscle. 
In  subjects  with  type  2  diabetes,  Morris  et  al  (299)  demonstrated  that  at  subpressor  and 
weakly  pressor  doses  of  AII,  insulin  sensitivity  increased.  The  AII  doses  were  calculated  as 
too  low  to  have  an  effect  of  renal  plasma  flow,  and  so  an  additional  action  of  AII  was 
suggested.  Both  of  these  sets  of  observations  may  be  explained  by  Buchanan's  postulate 
(297)  that  AII  may  increase  capillary  recruitment  in  insulin  sensitive  microcirculations, 
thus  increasing  the  delivery  of  substrate.  The  vascular  responsiveness  of  the 
microcirculation  may  therefore  be  important  in  determining  insulin  sensitivity,  and  as  such 
may  be  abnormal  in  insulin  resistant  states.  Certainly  in  type  1  diabetes,  the  vascular 
responsiveness  to  AII  is  abnormal  in  streptozotocin-induced  diabetes  animal  models  (300) 
and  humans  with  type  1  diabetes  (301).  In  a  double  blind  randomised  placebo  controlled 
study  of  15  volunteers  with  recent  onset  type  2  diabetes  (302),  AII  infusion  of  2ng/kg/min 
induced  no  increase  in  insulin  sensitivity  during  a  clamp,  whereas  in  a  matched  group  of 
healthy  volunteers,  insulin  sensitivity  increased  significantly.  AII  increased  MAP  by 
similar  absolute  values  in  both  groups,  however  the  AII  induced  increase  in  leg  blood  flow 
was  less  in  the  diabetic  group.  Interestingly,  the  change  in  insulin  sensitivity  and  leg  blood 
flow  were  correlated  in  both  groups,  suggesting  that  the  metabolic  effect  of  AII  was  related 
to  its  effect  on  redistribution  of  flow  to  insulin  sensitive,  though  not  insensitive,  local 
circulations. 
1.11.9  Effects  of  A]l  on  the  pancreas 
AII  may  also  modify  the  secretion  of  insulin,  providing  a  potential  confounder  in  some  of 
the  previously  discussed  studies.  Fliser  et  al  (303)  demonstrated  that,  in  a  double-blind, 
87 randomised,  placebo-controlled  study  of  healthy  volunteers,  pressor  doses  of  AH 
(5ng/kg/min)  reduced  basal  and  glucose  stimulated  insulin  secretion.  A  more  modest  effect 
was  seen  with  subpressor  doses.  The  pattern  and  spontaneous  pulsatility  of  insulin  secretion 
was  unaffected.  As  in  many  other  tissues,  the  pancreas  may  have  a  local  RAS.  In  dogs, 
(304)  AT2  receptors  were  identified  in  the  endocrine  and  exocrine  pancreas.  Thus  AII  may 
influence  pancreatic  insulin  secretion,  and  therefore  glucose  tolerance,  by  effects  either  on 
the  pancreatic  circulation  or  the  directly  on  the  islet. 
88 1.11.10  Intracellular  crosstalk  as  a  potential  cause  of  All  induced  reduction  in  insulin 
sensitivity 
1.11.10.1  Angiotensin  II  signalling 
Human  vascular  smooth  muscle  cells  have  two  well-characterised  angiotensin  II  receptors, 
the  ATI.  and  AT2  receptors,  which  were  cloned  in  1991  and  1992  respectively.  They  are 
members  of  the  G  protein  coupled,  seven  transmembrane  domain  receptor  superfamily. 
While  two  subtypes  of  the  type  1  receptor  are  present  in  rodent  tissue,  this  does  not  seem  to 
be  the  case  in  equivalent  human  cell  lines.  These  receptors  are  expressed  in  various  tissues, 
including  the  traditional  AII  target  tissues  such  as  vascular  smooth  muscle,  cardiac  muscle 
and  the  adrenal  gland,  but  more  recently  significant  numbers  of  receptors  have  been  shown 
to  be  present  in  tissues  such  as  adipose  tissue,  neural  tissue  and  skeletal  muscle  (see  section 
11.3).  It  has  been  suggested  that  the  effect  of  angiotensin  H  in  different  tissues  may  be 
explained  by  the  relative  amounts  of  the  type  1  and  2  receptor. 
Much  of  our  understanding  of  the  intracellular  events  that  follow  angiotensin  II  binding  is 
based  on  studies  in  cultured  vascular  smooth  muscle  cells,  with  assumptions  made  that 
similar  events  occur  in  other  tissues.  The  initial  post  receptor  events  of  the  ATI,  receptor 
are  typical  of  all  G  protein  coupled  receptors  (Figure  1.4).  While  inactive,  the  proteins  exist 
in  their  guanosine  diphosphate  (GDP)  bound  form,  as  a  heterotrimer  composed  of  an  c4  9, 
and  -y  subunit  associated  with  the  receptor.  Upon  ligand  binding,  conformational  changes 
occur  in  the  cz  subunit,  allowing  GDP  to  be  replaced  by  guanosine  triphosphate  (GTP).  The 
cz  and  fly  subunits  then  become  dissociated  from  the  receptor  (reviewed  in  (305). 
The  G  protein  coupled  receptors  are  classified  according  the  properties  of  the  cz  subunit, 
namely  G%,  Gc4,  and  Gcý.  The  AT1  receptor  is  an  example  of  a  Gcý  receptor.  The  released 
89 a,  P,  and  y  subunits  are  free  to  initiate  further  downstream  signalling  events.  In  response  to 
AII,  the  G%  GT?  activates  phospholipase  C  (PLC)  -fl,  which  in  turn  catalyses  the 
conversion  of  phosphatidylinositol-4,5  phosphate  into  inositol-1,4,5-  triphosphate  (IP3)  and 
diacylglycerol  (DAG).  Vascular  smooth  muscle  cells  have  very  little  PLC-fl,  though 
stimulation  of  the  ATI.  receptor  still  results  in  IP3  formation.  This  raises  the  possibility  that 
PLC-,  y  may  be  involved  with  this  process.  In  addition  to  PLC,  phospholipases  A2  and  D  are 
also  activated,  resulting  in  the  formation  of  the  prostaglandin  precursor  arachidonic  acid 
(306). 
The  result  of  DAG  accumulation  in  the  cell  is  activation  of  the  serine  threonine  kinase 
PKC.  It  is  not  clear  which  isoform  is  activated  in  response  to  AII,  though  it  is  suggested 
that  this  may  be  cell  type  specific;  in  cultured  vascular  smooth  muscle  cells  it  may  be  PKC- 
t  that  is  the  main  target. 
90 Figure  1.4:  G  protein  activation  and  subunit  dissociation 
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91 Again  in  vsmc,  AT1  receptor  activation  has  also  been  shown  to  activate  components  of  the 
Janus  Kinase  (JAK)  /  signal  transduction  and  activation  of  transcription  (STAT)  pathway. 
This  is  similar  in  nature  to  the  response  seen  in  cytoldne  receptors.  Activation  of  the  ATI, 
receptor  by  angiotensin  H  certainly  results  in  the  recruitment  of  JAK2  and  so  gives  the 
activated  receptor  the  capacity  for  tyrosine  residue  phosphorylation.  One  target  for  this 
Idnase  is  the  STAT  family  of  proteins,  which  then  bind  to  DNA  in  the  nucleus  following 
dimerization  (reviewed  in  (307,308). 
Using  rat  aortic  smooth  muscle,  Marrero  and  colleagues  (309)  investigated  the  role  that  AII 
activation  of  the  AT  l  receptor  has  on  the  STAT  family.  These  proteins  are  activated  by  the 
JAK  intracellular  kinases.  AH  stimulation  of  the  cell  resulted  in  association  of  JAK2  with 
the  AT1  receptor,  its  tyrosine  phosphorylation,  and  an  increase  in  its  Idnase  activity.  Tyk  2, 
another  member  of  this  family,  though  not  JAK1,  was  also  phosphorylated.  The  result  of 
this  activation  was  the  tyrosine  phosphorylation  of  STATs  1-3,  and  their  subsequent 
nuclear  translocation.  This  complete  process  was  prevented  by  addition  of  the  ATI  receptor 
blocker,  losartan.  Thus  AII,  acting  via  its  G-protein  coupled  receptor,  stimulates 
intracellular  Icinase  activity  in  smooth  muscle  cells.  This  has  relevance  to  the  later 
discussion  of  intracellular  crosstalk  between  signalling  systems. 
While  it  is  established  that  stimulation  of  the  ATI  receptor  leads  to  vasoconstriction, 
aldosterone  secretion  and  sympathetic  augmentation,  the  AT2  receptor  remains  less  well 
characterised;  a  role  in  the  regulation  of  apoptosis  (310)  and  stimulation  of  vasodilation 
(311)  has  been  suggested.  The  AT2  receptor  is  coupled  to  Gq,  (312)  and  inactivates  the 
extracellular  signal  regulated  kinase  (ERK). 
92 1.11.10.2  Intracellular  crosstalk  between  insulin  and  angiotensin  Il 
In  the  last  five  years,  a  novel  cellular  process  has  emerged  that  suggests  a  mechanism 
through  which  AII  may  reduce  insulin  responsiveness  at  the  level  of  individual  cells.  In  the 
investigation  of  it's  role  as  a  growth  factor,  AII,  acting  via  the  AT1  receptor,  was  found  to 
induce  tyrosine  phosphorylation  of  IRS-I  in  rat  cardiac  muscle  (313),  suggesting 
intracellular  crosstalk  between  the  second  messengers  activated  in  response  to  AII  and 
insulin.  Velloso  et  al  (314)  developed  this  theory  further  by  studying  the  tip  of  rats'  left 
ventricle  after  AH  and  insulin  had  been  injected  into  the  inferior  vena  cava.  Both  insulin 
and  AH  stimulated  the  phosphorylation  of  tyrosine  residues  on  IRS-1  and  2,  which  in  turn 
resulted  in  the  association  of  these  substrates  with  the  p85  subunit  of  PIY-kinase. 
Immunoprecipitation  experiments  confirmed  that,  in  response  to  AII,  JAK2  was  associated 
with  IRS-1  and  2,  as  well  as  the  ATI  receptor.  Despite  the  activation  of  these  early 
signalling  responses,  AII  induced  a  reduction  in  both  basal  and  insulin  stimulated  P13'- 
kinase  activity,  which  was  blocked  by  co-administration  of  a  specific  ATI  receptor  blocker. 
This  was  not  secondary  to  any  effect  on  the  insulin  receptor,  IRS-1/2  association  with  p85 
or  the  association  of  p85  with  the  catalytic  p1lo  subunit  of  PIY-kinase.  Further  studies 
were  undertaken  in  rat  aortic  smooth  muscle  (315),  with  similar,  though  subtly  different 
findings.  Importantly,  AH  pre-treatment  again  reduced  insulin  stimulated,  IRS-1  associated 
PIY-kinase  activity  by  60%.  However,  in  these  cells,  AII  reduced  insulin  stimulated 
tyrosine  phosphorylation  of  IRS-1,  and  its  subsequent  association  with  P13'-Idnase  by  30- 
50%.  The  non-specific  AII  receptor  blocker  saralasin  blocked  these  effects,  though  specific 
AT1  or  2  blockers  had  no  effect,  raising  the  possibility  that  a  third,  unchamcterised  AH 
receptor  is  important  in  this  process. 
93 A  mechanism  for  the  inhibition  of  P13'-Idnase  was  also  suggested;  AII  activates  protein 
Idnase  C,  a  serine  threonine  Icinase,  and  as  phosphorylation  of  serine  residues  on  the  beta 
subunit  of  the  insulin  receptor  or  IRS-I  inhibits  the  insulin-signalling  pathway,  this  was 
investigated  as  the.  site  of  crosstalk.  In  keeping  with  this,  phosphoserine  content  of  the 
insulin  receptor  and  IRS-1  was  increased  by  70%  and  75%  respectively  in  response  to  AH. 
The  observed  reduction  in  the  association  of  IRS-1  with  the  activated  insulin  receptor  also 
favoured  this  hypothesis. 
Thus,  these  two  related  papers  provided  a  novel  mechanism  through  which  AII  may  cause 
insulin  resistance  in  the  vasculature.  Importantly,  neither  study  measured  any  cellular 
endpoint  of  P13'-Idnase,  such  as  glucose  transport.  If  this  process  was  inhibited  by  AIL 
then  an  effect  of  AII  to  inhibit  insulin  signalling  in  skeletal  muscle  or  adipose  tissue  may 
translate  to  insulin  resistance  associated  with  activation  of  the  RAS  in  dietary  sodium 
restriction,  and  any  insulin  sensitising  effect  of  ACE  inhibitors.  This  hypothesis  is 
investigated  in  this  thesis. 
While  AII  may  crosstalk  with  insulin  and  modify  its  post  receptor  signalling,  it  is  important 
to  consider  a  potential  role  for  bradyIdnin  in  any  influence  that  activity  of  the  RAS  may 
have  on  insulin  sensitivity.  This  is  especially  relevant  in  the  context  of  ACE  inhibition,  as 
in  addition  to  inhibiting  the  ACE,  these  drugs  also  inhibit  the  kininase  enzyme,  and  as  such 
increase  local  and  circulating  Idnin  concentrations. 
1.11.10.3  Bradyidnin  and  insulin  stimulated  glucose  transport 
Henriksen  et  al  (316)  demonstrated  that  insulin  stimulated  glucose  uptake  into  the 
epitrochlearis  muscle  of  obese  Zucker  rats  was  greater  after  short  term  captopril  treatment, 
94 and  that  thi  s  effect  was  abolished  by  a  bradykinin  antagonist.  In  canine  adipocytes  (317), 
bradykinin,  in  the  presence  of  insulin,  increased  insulin  stimulated  2-deoxyglucose  uptake. 
Mechanistically,  bradyIdnin  increased  the  translocation  of  GLUT  4  to  the  cell  surface  in 
response  to  insulin,  possibly  by  increasing  insulin-stimulated  receptor  and  IRS-1 
phosphorylation.  20-month  old  rats  treated  acutely  with  captopril  (318)  showed  increased 
insulin-stimulated  receptor  and  IRS-I  phosphorylation  in  liver  and  muscle.  IRS-1 
association  with  P13'-kinase  also  rose.  Unlike  captopril,  losartan  had  no  effect  on  these 
early  events  in  the  insulin-signalling  cascade,  implying  that  the  captopril  effect  was  not  one 
of  a  reduction  in  AII.  In  fact,  administration  of  bradyIdnin  increased  insulin  receptor  and 
IRS-I  tyrosine  phosphorylation,  and  so  the  effect  of  ACE  inhibition  was  more  likely 
secondary  to  associated  inhibition  of  Icininase. 
Bradykinin  treated  obese  Zucker  rats  (319)  had  lower  fasting  insulin  and  free  fatty  acids,  as 
well  as  lower  insulin  and  glucose  response  to  an  OGTT,  than  saline  treated  controls.  Insulin 
stimulated  glucose  uptake  into  isolated  epitrochlearis  muscle  was  52%  greater  in  the 
bradykinin  treated  animals.  Interestingly,  contraction-stimulated  glucose  uptake  was  also 
improved,  suggesting  that  the  bradykinin  effect  may  not  be  exclusive  to  insulin-signalling 
pathways.  In  L6  myotubes  (320)  bradykinin-induced  translocation  of  GLUT4  to  the  plasma 
membrane  was  unaffected  by  pre-treatment  with  wortmannin,  as  is  the  case  in  exercise- 
induced  glucose  transport.  A  potential  link  between  the  vasodilatory  and  metabolic 
properties  of  bradykinin  was  proposed  after  Henriksen  (321)  demonstrated  that  the 
bradykinin-associated  increases  in  insulin  sensitivity  in  skeletal  muscle  of  the  obese  Zucker 
rat  were  inhibited  not  only  by  blockade  of  the  B2  receptor,  but  also  by  inhibition  of  NOS- 
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the  RAS  may  modify  insulin  sensitivity  in  humans,  no  studies  have  examined  the  effect  of 
AII  or  bradyIdnin  on  glucose  transport  in  human  tissue.  Baba  et  al  (322),  found  no  effect  of 
AII  or  bradykinin  on  insulin-stimulated  activation  of  the  insulin  receptor  tyrosine  kinase  in 
human  adipocytes,  though  no  measurement  of  glucose  transport  was  included  in  the 
communication. 
96 1.12  Glucocorticoids  and  insulin  sensitivity 
Glucoco'rticoid  excess,  seen  clinically  in  Cushing's  syndrome,  is  associated  with  obesity, 
hypertension  and  glucose  tolerance.  This  observation  has  led  some  to  hypothesise  that 
glucocorticoid  levels  may  underlie  the  development  of  the  metabolic  syndrome,  especially 
given  data  showing  that  rats  treated  with  glucocorticoids  in  utero  are  born  with  a  low 
birthweight,  while  later  developing  insulin  resistance  and  hypertension  (323).  In  addition, 
higher  0900  plasma  cortisol  concentrations  are  found  in  men  born  with  a  low  birthweight, 
and  are  associated  with  the  development  of  hypertension,  hypertriglyceridaemia  and 
glucose  intolerance  (324). 
1.12.1  Biology  of  cortisol 
Adrenocorticotrophic  hormone  (ACTH)  stimulates  the  secretion  of  cortisol  into  the 
circulation  from  the  adrenal  cortex.  Cortisol  circulates  either  unbound  (5-10%)  and 
therefore  active,  or  bound  to  cortisol  binding  globulin  (70-75%)  or  albumin  (20%).  At  high 
physiological  levels  of  cortisol,  these  binding  mechanisms  are  saturated,  and  so  large 
excursions  may  occur  in  free  cortisol. 
Cortisol  activates  either  GR  (corticosteroid  type  2)  or  MR  (corticosteroid  type  1)  receptors. 
GR  are  high  capacity,  low  affinity  receptors  that  are  widely  distributed,  in  contrast  to  the 
low  capacity  high  affinity  MR  receptors  that  bind  cortisol  depending  on  its  local 
availability  (determined  by  the  1  lp  hydroxysteroid  dehydrogenase  (1  Ifl  HSD)  enzymes). 
119  HSD-1  increases  availability  of  cortisol,  and  is  found  in  liver,  adipose  tissue  and 
skeletal  muscle.  Carbenoxolone,  which  inhibits  hepatic  IIP  HSD-  1,  increases  whole  body 
insulin  sensitivity,  with  no  effect  on  peripheral  insulin  sensitivity,  suggesting  that  a 
97 loWering  of  intra-hepatic  cortisol  may  be  the  mechanism  underlying  a  potential 
improvement  in  hepatic  insulin  responsiveness. 
1.12.2  Mechanism  of  glucocorticoid  induced  insulin  resistance 
That  glucocorticoids  reduce  insulin  sensitivity  is  not  a  novel  observation,  though  the 
underlying  mechanism  remains  unclear.  Early  observations  were  that  cortisol  excess 
reduced  hepatic  and  peripheral  insulin  sensitivity,  probably  by  a  post  receptor  mechanism 
(325).  Rooney  and  colleagues  (326)  investigated  the  effect  of  a  28  hour  cortisol  infusion 
on  insulin  sensitivity  and  found  an  increase  in  fasting  insulin,  a  reduction  in  peripheral 
insulin  sensitivity  (by  nearly  50%)  and  a  reduction  in  the  effect  of  infused  insulin  to  reduce 
hepatic  glucose  output.  It  was  suggested  that  the  increase  in  hepatic  glucose  output  was 
secondary  to  an  effect  on  phosphoenolpyruvate  carboxyldnase  (PEPCK),  the  rate-limiting 
step  in  gluconeogenesis.  In  addition  free  fatty  acids  increased,  which  may  contribute  to 
insulin  resistance  and  hyperglycaemia  by  substrate  competition  in  the  Randle  cycle.  A 
physiological  rise  in  glucocorticoid  concentration  may  also  increase  hepatic  glucose  output 
by  reducing  pancreatic  insulin  secretion  (seen  in  cultured  mouse  islet  cells  by  Lambillotte 
et  al  (327)  1997)  and  increasing  glucagon  secretion  (328).  It  was  suggested  that  cortisol 
reduced  peripheral  glucose  uptake,  as  demonstrated  by  a  reduction  in  muscle  glucose 
uptake  in  the  presence  rather  the  absence  of  a  physiological  nocturnal  cortisol  rise.  In 
keeping  with  this,  Paquot  et  al  (329),  observed  a  51.5%  reduction  in  glucose  uptake  in 
healthy  volunteers  during  a  hyperinsulinaemic  euglycaemic  clamp,  and  a  54%  reduction  in 
glucose  oxidation  after  2  days  of  dexamethasone  I  mg  bd. 
Several  authors  have  examined  the  nature  of  the  glucocorticoid-insulin  interaction  at  the 
cellular  level.  Montiel,  et  (330)  used  rat  glial  cells  to  demonstrate  a  reduction  in  insulin 
98 binding  at  the  plasma  membrane  in  association  with  dexamethasone  exposure,  an  effect 
that  was  sensitive  to  inhibition  of  protein  synthesis  by  cycloheximide.  Similarly,  Yasuda  et 
al  (331)  found  that  equivalent  doses  of  hydrocortisone  and  dexamethasone,  though  not 
prednisolone,  reduced  insulin  binding  in  erythrocytes.  It  seems  unlikely  that  this  is  the  sole 
explanation  for  corticosteroid  induced  insulin  resistance,  as  all  three  agents  reduce  insulin 
sensitivity.  In  addition,  these  findings  are  at  odds  with  the  observations  of  other  authors, 
who  found  that  in  patients  with  Cushing's  syndrome  there  was  an  increase  in  insulin 
binding  to  erythrocytes  (332)  and  monocytes  (333).  Lastly,  Watanabe  et  al  (334)  incubated 
isolated  rat  adipocytes  with  hydrocortisone  for  up  to  eight  hours  and  found  no  effect  on 
insulin  binding  site  number  or  affinity,  however  there  was  a  rightward  shift  in  the  uptake  of 
3-0-methylglucose  in  response  to  insulin,  favouring  a  post  receptor  mechanism  underlying 
insulin  resistance.  Giorgino  et  al  (335)  investigated  the  theory  that  the  defect  may  lie  at  the 
level  of  the  insulin  receptor  and  IRS-proteins  tyrosine  phosphorylation,  and  found  a 
reduction  in  tyrosine  phosphorylated,  insulin  receptors  and  in  skeletal  muscle  IRS-1. 
Interestingly,  these  changes  were  seen  when  the  animals  were  pre-treated  with 
streptozotocin,  suggesting  that  hyperinsulinaemia,  may  be  important  in  mediating  signalling 
disturbances. 
Additional  studies  in  rodents  suggested  that  a  defect  may  also  lie  at  the  level  of  GLUT  4's 
subcellular  distribution;  in  rat  adipocyte  membranes,  dexamethasone  resulted  in  a  relative 
redistribution  of  GLUT4  away  from  the  plasma  membrane  and  toward  the  LDM  fraction  in 
response  to  insulin  (336),  while  in  isolated  rat  soleus  muscle  from  animals  treated  with 
dexamethasone  for  5  days,  reduced  insulin-stimulated  glucose  transport,  glucose 
phosphorylation,  glucose  oxidation  and  glycogen  synthesis  was  observed,  in  association 
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insulin  (337). 
These  abnormalities  of  GLUT4  trafficking  may  display  tissue  specificity;  while  Coderre  et 
al  (338)  observed  a  decrease  in  adipocyte  GLUT4  expression  following  dexamethasone 
treatment,  an  increase  in  expression  was  seen  in  skeletal  muscle.  Again,  however,  GLUT4 
translocation  in  response  to  insulin  was  reduced. 
Thus,  glucocorticoids  induce  insulin  resistance  in  the  liver,  possibly  by  an  effect  on 
PEPCK,  and  in  skeletal  muscle  and  fat,  though  the  mechanism  in  these  tissues  is  not 
entirely  clear. 
100 1.13  Aims  of  this  thesis 
1.  To  develop  a  methods  of  determining  endogenous  insulin  sensitivity  in  human 
tissue 
2.  To  examine  the  relationship  with  the  insulin  resistant  phenotype  and  insulin 
response  in  isolated  tissue 
3.  To  determine  the  effect  of  dietary  sodium  restriction  on  insulin  sensitivity 
4.  To  explore  the  hypothesis  that  angiotensin  II  may  have  a  direct  effect  on  insulin 
action 
5.  To  examine  the  effect  of  glucocorticoid  exposure  on  insulin  sensitivity  in 
metabolic  and  vascular  tissue,  and  consider  the  coupling  of  these  effects. 
101 Chapter  2:  Materials  and  Methods 
2.1  Materials 
All  materials  used  in  the  course  of  this  thesis  were  of  good  quality  and  were  obtained  from 
the  following  sources: 
2.1.1  General  reagents 
Alpha  Laboratories,  Eastleigh,  Hampshire,  UK 
NEFA-C  assay,  Alpha  laboratories,  Eastleigh,  Hampshire,  UK 
Amersham  International  Plc,  Aylesbury,  Bucidnghamshire,  UK 
ECL  Western  Blotting  Detection  Kit 
Astra,  King's  Langley,  Herts.,  U.  K. 
1%  lignocaine  hydrochloride 
Bio-Rad  Laboratories  Ltd,  Hemel  Mempstead,  Hertfordshire,  UK 
Bio-Rad  protein  assay 
N,  N,  N',  N",  -tetramethylenediamine  (TEMED) 
Boehringer  Mannheim  GmbH,  Germany 
Complete  Tm  Protease  Inhibitor  Cocktail  Tablets 
Fisons,  Loughborough,  Leicestershire,  UK 
Acrylamide 
Ammonium  persulphate 
Diaminoethanetetra-acetic  acid,  disodium  salt  (EDTA) 
Glucose 
HEPES 
Magnesium  sulphate  heptahydrate 
N,  Nmethylene-bis-acrylamide 
102 Potassium  chloride 
Sodium  dodecyl  sulphate 
Sodium  chloride 
Sodium  dihydrogen  phosphate 
Sodium  hydrogen  carbonate 
Gibco  BRL,  Paisley,  UK 
Tris  base 
Kodak  Ltd,  Hemel  Mempstead,  Hertfordshire,  UK 
X-Omat  S  film 
Lorne  Laboratories,  Twyford,  Essex,  UK 
Collagenase,  Worthington  Type  1 
Merck  Ltd  (BDH),  Lutterworth,  Leicestershire,  UK 
Calcium  chloride  hexahydrate 
Dow  Coming  silicone  oil 
Magnesium  chloride  heptahydrate 
Potassium  dihydrogen  phosphate 
New  England  Biolabs,  Hitchin,  Hertfordshire,  UK 
Broad  range  pre-stained  protein  standards  (6-175kDa) 
NovoNordisk  A/S,  DK  2880,  Bagsvaerd,  Denmark 
Actrapid  human  insulin 
Packard  Instruments,  Groningen,  The  Netherlands 
Scintillation  fluid 
Premier  Brands  UIC,  Knighton  Adbaston,  Staffordshire,  UK 
Marvel  powdered  milk 
103 Schleider  &  Scheull,  Dassel,  Germany 
Nitrocellulose  membrane  (0.45Am) 
Sigma  Chemical  Company  Ltd,  Poole,  Dorset,  U.  K 
Acetylcholine 
Adenosine 
Bovine  Serum  Albumin 
Bromophenol  blue 
DL-dithiothreitol 
Human  angiotensin  II 
Isoproterenol 
L-lV'-monomethylarginine  (L-NMNIA) 
Norepinephrine 
Sucrose 
Triton  X-  100 
Seton  Healthcare  Group,  Tubiton  House,  Oldham,  UX 
Iodine 
2.1.2  Radioactive  materials 
NEN  Dupont  (UKý  Ltd,  Stevenage,  Hertfordshire,  UK 
2-deoxy-D-  [3  H]  gluco'se 
NEN  Life  Science  Products,  Boston,  NU 
1251  labelled  [Sar'Ile8]  Angiotensin  II 
104 2.1.3  Physiological  buffers 
KRH  buffer 
Fresh  KRH  buffer  (NaCI118mM,  NaHCO3  5mM,  KCI  4.7mM,  KH2  P04  1.2mM, 
MgS04.7H20  1.2niM,  HEPES  25mM,  pH  adjusted  to  7.4)  was  prepared  for  each  assay. 
Adenosine  IOOnM  and  CaC12  2.5mM  were  added  for  preparation  of  collection,  digestion 
and  wash  buffer. 
Wash  buffer 
To  400mls  of  KRH  buffer,  4g  of  Bovine  Serum  Albumin  (BSA)  were  added,  and  the  pH 
readjusted  to  7.4,  constituting  the  wash  buffer. 
Collection  buffer 
To  100mls  of  wash  buffer,  0.054g  of  glucose  was  added  (final  glucose  concentration  3mM) 
to  make  the  collection  buffer. 
Digestion  buffer 
For  digestion,  4ml  collection  buffer  with  2mg/mI  collagenase  was  added  to  each  gram  of 
fat. 
HES  buffer 
HEPES  20mM,  EDTA  lmM,  Sucrose  255mM,  pH  7.4 
Radioligand  binding  buffer 
MgCL2lOmM,  EDTA  lmM,  Tris-HCI  50mM,  pH  8.26  at  4'C 
Phosphate  buffered  saline  (PBS) 
NaCl I  SOmM,  NaH2PO4.2H20,  pH  7.4 
Physiological  salt  solution  (PSS) 
NaCl  118.4mM,  KCI  4.7mM,  MgS04.7H20  1.2mM,  NaHC03  24.9mM,  CaC12  2.5mM, 
glucose  11.  ImM,  EDTA  0.023mM 
105 2.1.4  SDS-PAGE  buffers 
Electrode  buffer 
Tris  base  25mM,  glycine  192mM,  0.1%  (w/v)  SDS 
Sample  buffer 
Tris.  HCI  93mM;  pH  6.8,  dithiothreitol  20mM  (added  immediately  before  use),  EDTA 
ImM,  10%  (w/v)  glycerol,  2%-  (w/v)  SDS,  0.002%  (w/v)  bromophenol  blue. 
2.1.5  Western  blot  buffers 
Blotting.  buffer 
NaH2PO4.2H20  25mM;  pH  6.5 
TBST-1 
2.42g  Tris.  HCI,  8.77g  NaCl,  0.2ml  Tween-20;  pH  7.4 
106 2.2  Methods 
2.2.1  Laboratory  methods 
2.2.1.1  Collection  of  subcutaneous  adipose  tissue 
All  patients  were  approached  the  day  prior  to  theatre  and  infonned  consent  obtained.  On 
the  day  of  theatre,  a  piece  of  adipose  tissue  was  removed  at  the  start  of  the  surgical 
procedure  by  the  operator;  tissue  weight  varied  between  1.5g  and  5g.  The  adipose  tissue 
was  placed  immediately  in  collection  buffer  (see  2.1.3),  prewarmed  to  37T,  and 
transported  to  the  laboratory. 
2.2.1.2  Digestion  of  adipose  tissue 
Once  in  the  laboratory,  any  attached  sIdn,  subcutaneous  connective  tissue  or  visible  blood 
vessels  were  dissected  from  the  adipose  sample  and  discarded.  The  tissue  was  then 
weighed,  and  washed  by  repeated  collection  buffer  changes  (section  2.1.3),  while  ensuring 
the  temperature  of  the  tissue's  immediate  environment  did  not  change.  For  tissue 
digestion,  4ml  of  a  2mg/ml  solution  of  collagenase  (section  2.1.3)  (374)  was  added  for 
each  gram  of  tissue  to  a  50ml  centrifuge  tube  containing  the  adipose  tissue  sample.  The 
tissue  was  then  chopped  into  smaller  pieces  using  scissors  and  agitated  in  a  shaldng  water 
bath  for  30  minutes.  At  the  end  of  this  period,  the  digestate  was  passed  through  a  filter  to 
leave  a  layer  of  adipocytes  floating  on  the  surface  above  buffer.  This  buffer  layer  was 
aspirated  and  replaced  with  fresh  wash  buffer  (section  2.1.3)  five  times. 
Finally  the  floating  adipocytes  were  suspended  at  90%  cytocrit  by  aspirating  the 
appropriate  volume  of  buffer  from  below  the  adipocyte  layer.  Aliquots  were  taken  and 
107 added  to  wash  buffer  to  achieve  a  final  adipocyte  concentration  of  10%,  1  00gl  of  cells  in 
900gl  of  buffer,  in  preparation  for  fin-ther  assay. 
2.2.1.3  Glucose  transport  assay 
Adipocytes  were  resuspended  at  10%  cytocrit  as  above.  The  cells  were  then  incubated  with 
agonist  /  antagonist.  All  insulin  stimulations  were  for  30  minutes,  and  with  five  minutes  of 
stimulation  remaining,  a  cocktail  of  3[H]  2-deoxy  D-glucose,  unlabelled  2-deoxy  D-glucose 
and  KRH  buffer  was  added,  achieving  a  final  concentration  of  1011M  2-deoxyglucose  / 
2.  SgCi  /ml  (described  in  (351)).  Angiotensin  II  was  added  with,  or  15  minutes  prior  to, 
insulin.  Each  assay  condition  was  matched  with  an  equivalent  preparation  containing 
cytochalasin  B  (IOpM).  Cytochalasin  B,  a  fungal  metabolite,  is  an  effective  inhibitor  of 
insulin-stimulated  glucose  transport.  Following  the  completion  of  the  incubation  times, 
SOgI  aliquots  of  cells  were  removed  from  each  assay  condition  and  then  centrifuged  at 
3500g  through  an  oil  layer.  The  overlying  cells  were  then  aspirated,  solubilised  in  triton-X 
100,  and  3[H]  counts  determined  in  triplicate  using  a  Beckman  scintillation  counter.  The 
cytochalasin  B  counts  were  then  subtracted  from  each  assay  result  in  order  to  account  for 
non-specific  glucose  transport.  Results  were  expressed  as  fold  increase  in  uptake  relative  to 
the  basal  counts. 
2.2.1.4  Assay  of  non-esterified  (free)  fatty  acids 
Adipocytes  were  prepared  as  described  in  section  2.2.1.1.  Into  900gl  of  wash  buffer,  1000 
of  adipocytes  (from  suspension  at  90%  cytocrit)  were  added,  and  left  to  quiesce  for  15 
minutes.  Agents  were  added  at  time  (t)  =0  minutes.  For  the  basic  analysis  of  insulin- 
mediated  suppression  of  isoproterenol-induced  lipolysis,  insulin  (0.01-loOnM)  and 
isoproterenol  (200nND  were  added  to  adipocyte  suspensions.  In  any  given  experiment,  one 
108 assay  vial  contained  adipocytes  in  buffer  alone  for  analysis  of  basal  NEFA  release,  one  vial 
contained  adipocytes  and  isoproterenol  (200nK,  and  the  other  five  vials  contained 
isoproterenol  (2OOnK  and  increasing  concentrations  of  insulin  (0.01-100nND.  For  the 
assessment  of  the  effect  of  angiotensin  II  on  insulin  action,  angiotensin  II  was  added  either 
with,  or  15  minutes  prior  to,  insulin  and  isoproterenol.  For  wortmannin  assays,  wortmannin 
was  added  30  minutes  prior  to  insulin.  Once  agonist/antagonists  were  added,  the  adipocyte 
suspension  was  left  for  45  minutes  shalcing  at  370C  in  a  water  bath.  After  45  minutes,  50gl 
aliquots  of  buffer  were  removed  from  each  individual  reaction  condition  and  placed  in 
plastic  tubes,  still  at  370C.  The  amount  of  liberated  fatty  acid  in  the  reaction  was  then 
assayed  using  a  commercially  available  Idt  (NEFA  C,  Alpha  Laboratories).  To  each  50[d 
aliquot,  lml  of  reagent  A,  then  after  ten  minutes,  2ml  of  reagent  B  were  added.  Five 
minutes  later  lml  of  the  resulting  mixture  was  decanted  into  a  cuvette  for 
spectrophotometric  analysis  at  a  wavelength  of  550nm.  Each  assay  was  conducted  with  a 
standard  at  lmmol/l  of  free  fatty  acid  (supplied  with  the  assay  kit),  allowing 
standardisation,  and  the  absorbance  of  the  media  alone  taken  as  the  zero  value.  The  basis  of 
the  NEFA  assay  is  a  two-step  enzymatic  reaction,  involving  the  activity  of  acyl  CoA 
synthetase,  acyl  CoA  oxidase  and  peroxidase. 
The  recovery  of  the  different  free  fatty  acids  (stated  in  the  accompanying  data  sheet),  as  a 
reflection  of  the  assay  accuracy,  is  detailed  in  table  2.1. 
109 Table  2.1:  Recovery  of  non-esterified  fatty  acids,  using  the  NEFA-C  WAKO  assay 
Free  fatty  acid  Recovery  Accuracy 
Acetic  Acid  0  0 
Propionic  Acid  0 
.0 
Butyric  Acid  0  0 
Valeric  Acid  14  9 
Caproic  Acid  98  99 
Caprylic  Acid  97  94 
Capric  Acid  89  86 
Lauric  Acid  98  97 
Myristic  Acid  103  93 
Palmitic  Acid  97  94 
Stearic  Acid  90 
Arachidic  Acid  94  - 
Palmitoleic  Acid  100  103 
Oleic  Acid  100  102 
Linoleic  Acid  102  100 
Arachidonic  Acid  89  85 
Citric  Acid  0  0 
Oxalic  Acid  0  0 
110 2.2.1.5  Preparation  of  human  adipocyte  membrane  fractions 
Adipocytes  were  digested  as  above,  and  re-suspended  at  35%  cytocrit.  After  two  washes  in 
iCe-cold  phosphate  buffered  saline  the  cells  were  resuspended  at  66%  cytocrit  in  HES 
buffer  containing  protease  inhibitors.  The  remaining  steps  were  carried  out  at  4*C.  The 
cells  were  homogenised  by  20  up  and  down  strokes  of  a  Dounce  homogeniser.  They  were 
then  centrifuged  at  30OOg  at  4`C  for  5  minutes.  The  resulting  fat  cake  and  pellet  were 
discarded,  while  the  supernatant  was  centrifuged  at  100,000g  at  4*C  for  60  minutes.  The 
membrane  pellet  was  washed  then  resuspended  in  binding  buffer  with  protease  inhibitor 
cocktail  tablets  and  protein  concentration  assayed  as  described  in  section  2.2.1.7. 
2.2.1.6  Radioligand  binding  studies 
Membranes  were  prepared  from  either  adipocytes  or  vascular  smooth  muscle  cells 
(positive  control,  provided  by  Dr  Jill  Wakefield,  Institute  of  Biomedical  and  Life  Sciences, 
University  of  Glasgow)  and  resuspended  in  radioligand  binding  buffer.  Duplicate  150AI 
aliquots  of  the  resuspended  membranes  were  then  added  to  glass  tubes  containing  5OgL 
125,  labelled  [SarIle8]  Angiotensin  H  and  either  50jiL  of  H20  or  losartan  (provided  by  Dr  J 
Brosnan,  University  of  Glasgow)  (10ýM  final  concentration)  to  define  non-specific 
binding.  Equilibrium  binding  was  achieved  by  incubation  at  37T  for  45  minutes,  and 
reaction  terminated  by  vacuum  filtration  over  0.3%  (v/v)  polyethylenimine-soaked  GF/B 
filters  and  washing  with  ice-cold  radioligand  binding  buffer  supplemented  with  0.01% 
(w/v)  CHAPS  using  a  Brandel  cell  harvester.  Receptor  bound  ligand  was  quantified  using 
a  gamma  counter. 
III 2.2.1.7  Determination  of  sample  protein  concentration 
This  method  was  used  to  determine  the  protein  concentration  in  membrane  preparations 
obtained  from  human  adipocytes.  A  101.  Ll  aliquot  of  each  sample  was  added  to  200111  of 
Bio-Rad  protein  assay  reagent  and  790  jil  of  water.  After  mixing  and  equilibration,  the 
absorbance  was  read  in  a  spectrophotometer  at  a  wavelength  of  595rim.  The  concentration 
of  the  sample  was  determined  from  a  standard  curve  constructed  from  bovine  serum 
albumin  standards  (0.125mg/ml-2mg/ml)  treated  in  the  same  manner. 
2.2.1.8  SDS/Polyacrylamide  gel  electrophoresis 
Sodium  dodecyl  sulphate  (SDS)/  Polyacrylamide  gel  electrophoresis  (PAGE)  was 
undertaken  using  the  Bio-Rad  mini-Protean  H  gel  apparatus.  4cm  of  resolving  gel  (10% 
acrylamide  /  0.28%  bisacrylamide  in  0.383mM  Tris.  HCI,  pH  8.8;  0.1%  SDS,  polymerised 
with  0.1%  ammonium  persulphate  and  0.019%  NNN,  N',  -tetramethylenediamine 
(TEMED))  underlay  2cm.  of  stacking  gel  (5%  acrylamide  /  0.136%  bisacrylamide  in 
125mM  Tris.  HCI,  pH  6.8;  0.1%  SDS,  polymerised  with  0.1%  ammonium  persulphate  and 
0.05%  TEMED). 
After  separation  of  the  proteins,  the  gels  were  removed  and  equilibrated  in  blotting  buffer 
(see  2.1.5)  for  30  minutes.  Each  gel  was  then  placed  on  nitrocellulose  paper  and 
sandwiched  between  two  layers  of  filter  paper.  This  was  placed  in  a  cassette  and  the 
proteins  transferred  onto  the  nitrocellulose  in  a  transfer  tank.  After  3  hours,  the 
nitrocellulose  was  removed  and  placed  in  blocking  buffer  (TBST-1  with  5%  (w/v)  non-fat 
milk)  overnight.  The  membrane  was  then  placed  in  1%  (w/v)  non-fat  milk/TBST-1 
containing  primary  antibody  and  shaken  at  37*C  for  one  hour.  Following  five  washes  with 
TBST-1  over  the  next  hour,  the  membrane  was  incubated  for  one  hour  at  room  temperature 
112 in  1%  non-fat  milk/TBST-1  containing  species-specific  HRP-linked  anti-IgG.  Following 
this,  the  nitrocellulose  membrane  was  washed  then  submerged  in  solution  one  and  two 
(Amersham  ECL  Western  Blotting  detection  kit)  for  one  minute.  The  nitrocellulose  was 
then  placed  in  a  X-ray  film  cassette  and  exposed  to  Kodak  X-Omat  S  film  prior  to 
developing. 
113 2.2.2  Clinical  methods 
2.2.2.1  Recruitment  of  patients  and  volunteers 
The  Ethics  Committee  of  the  West  Glasgow  Hospitals  University  NHS  Trust  approved  all 
clinical  and  experimental  protocols.  After  full  explanation  of  experimental  procedures, 
informed  consent  was  obtained.  Each  volunteer  was  issued  with  details  of  the  study  as  well 
as  investigators'  contact  telephone  numbers. 
Healthy  volunteers  for  clinical  studies  were  recruited  in  the  Clinical  Investigation  and 
Research  Unit  (CIRU),  Department  of  Medicine  and  Ilerapeutics,  Western  Infirmary, 
Glasgow.  Medical  and  nursing  students  were  excluded.  All  volunteers  were  aged  1840 
years. 
Volunteers  for  clinical  studies  were  screened  by  health  questionnaire  and  physical 
examination.  Venous  blood  was  obtained  for  haematology,  biochemistry  and  virology  to 
assess  suitability  for  studies  prior  to  recruitment.  Volunteers  with  elevated  fasting  plasma 
glucose,  hypertension  and  intercurrent  acute  or  chronic  illness  were  excluded.  In  addition, 
volunteers  underwent  routine  electrocardiography  and  were  excluded  if  a  resting  ECG  was 
abnormal.  Female  volunteers  were  not  recruited  into  clinical  studies.  Volunteers  were 
instructed  to  fast  overnight  prior  to  clinical  procedures  and  assessments.  Taxis  were 
available  to  transfer  volunteers  to  and  from  the  CIRU. 
For  laboratory  studies  requiring  human  tissue,  gynaecology  patients  suitable  for  donation 
of  subcutaneous  adipose  tissue  during  routine  laparotomy  were  approached  24  hours  prior 
to  theatre,  and  their  consent  obtained  for  tissue  extraction  as  well  as  peripheral  venous 
114 blood  sampling.  All  patients  were  undergoing  surgery  for  benign  disease.  Patients  with 
non-gynaecological  illness,  including  hypertension  and  diabetes,  were  not  approached. 
Any  abnormalities  of  peripheral  blood  subsequently  found  were  relayed  to  the  appropriate 
General  Practitioner. 
2.2.2.2  Clinical  and  morphometric  measurements 
2.2.2.2.1  Body  mass  index 
Body  weight  and  height  were  measured  with  subjects  in  light  clothes  without  shoes  to  the 
nearest  0.5  kg  of  weight  and  to  the  nearest  O.  Scm  height.  The  weighing  scales  were 
calibrated  regularly  (CIRU  and  ward  G9  scales,  Westem  Infirmary,  Glasgow). 
Body  mass  index  (BNfl,  kglrný)  was  calculated  from  the  formula 
Body  Mass  Index  =  Body  weight  (kg)  /  (height  (m))  2 
2.2.2.2.2  Blood  pressure  and  heart  rate 
I 
All  blood  pressure  and  pulse  measurements  were  recorded  using  a  Dinamap  Critikon 
(Johnson  and  Johnson  Professional  Products  Ltd  UK).  At  volunteer  screening,  and  in  the 
assessment  of  gynaecological  patients,  readings  were  taken  supine  after  ten  minutes  rest. 
Blood  pressure  readings  prior  to  and  during  the  euglycaernic  hyperinsulinaemic  clamp  were 
taken  with  the  volunteer  lying  supine. 
2.2.2.3  Clinical  procedures 
2.2.2.3.1  Hyperinsulinaemic  euglycaemic  clamp 
Insulin  sensitivity  was  assessed  using  a  modification  (180  rather  than  120  minutes)  of  the 
hyperinsulinaemic  euglycaemic  clamp  (10).  Volunteers  were  asked  to  attend  the  CIRU 
having  fasted  from  midnight  the  preceding  evening.  With  the  volunteer  lying  at  450  on  a 
115 bed,  two  18-gauge  intravenous  cannulae  were  inserted;  the  first  was  placed  anterogradely 
into  the  left  antecubital  fossa  for  administration  of  glucose  and  insulin  infusions,  and  the 
second  retrogradely  into  the  right  hand  for  the  sampling  of  venous  blood.  The  right  hand 
was  then  placed  in  a  heated  box  for  the  remainder  of  the  morning,  with  the  temperature 
inside  the  box  kept  at  55'C  to  arterialise  sampled  venous  blood. 
Intravenous  soluble  insulin  was  infused  in  0.9%  saline  with  a  10%  v/v  dilution  of  the 
volunteer's  own  venous  blood  to  minimise  adsorption  of  insulin  to  the  plastic  syringe  or 
infusion  device.  This  was  infused  into  the  left  antecubital  fossa  cannula  using  a  Braun 
Perfusor  pump  at  a  constant  rate  for  180  minutes  after  a  brief  initial  period  of  priming.  The 
aim  was  to  achieve  steady  state  circulating  insulin  at  approximately  1201X/ml  above  the 
basal  fasting  level. 
The  insulin  infusion  regime  was  as  follows 
0-4  minutes  4.5mU/kglmin 
4-7  minutes  3.  OmU/kglmin 
7-180  minutes  1.5mU/kg/min 
Prior  to  the  commencement  of  the  infusions,  the  volunteer  lay  rested  for  30  minutes  after 
insertion  of  the  cannulae  to  allow  for  acclimatisation.  During  this  period,  basal  blood 
samples  were  taken.  Blood  pressure  and  heart  rate  were  recorded  at  baseline,  and  every  15 
minutes  thereafter  during  the  clamp.  20%  glucose  (Baxter  Healthcare,  Norfolk,  U-K)  was 
infused  into  the  left  antecubital  cannula  at  a  variable  rate  via  an  IMED  infusion  device 
(MED,  Abingdon,  U.  K). 
116 Insulin  was  commenced  at  time  (t)  =  zero  minutes  and  adjusted  according  to  the  above 
i  regimen,  while  glucose  infusion  commenced  at  t=  two  minutes  and  was  altered 
accordingly  thereafter.  While  the  insulin  infusion  was  held  at  a  constant  rate  following  the 
priming  period,  the  glucose  infusion  rate  was  adjusted  throughout  the  clamp  to  maintain 
serum  glucose  at  5.2mmol/l.  Arterialised  venous  blood  was  drawn  from  the  warmed  hand 
cannula  every  five  minutes,  centrifuged  for  ten  seconds  at  1000  revolutions  per  minute 
(rpm),  and  serum  glucose  determined  by  the  glucose  oxidase  method  using  a  Beclanan  2 
glucose  analyser  (Beclanan  Instruments,  Fullerton,  CA,  USA).  The  glucose  infusion  was 
altered  at  increments  of  lmg  glucose/kg  body  weight/min  (mg/kg/min).  The  retrograde 
cannula  in  the  warmed  hand  was  kept  patent  by  the  infusion  of  0.9%  saline  (<100ml  total 
volume  infused  per  clamp)  and  frequent  saline  bolus  flushes. 
2.2.2.3.2  Calculation  of  insulin  sensitivity 
During  the  euglycaemic  hyperinsulinaemic  clamp,  steady  state  was  achieved  once  the 
serum  glucose  was  stable  at  around  5.2mmol/I  at  a  constant  glucose  infusion  rate.  Once 
reached,  this  was  maintained  until  the  last  40  minutes  of  the  clamp,  when  the  glucose 
infusion  was  held  constant  and  the  serum  glucose  documented  every  five  minutes.  Central 
to  the  calculation  of  insulin  sensitivity  (M)  is  the  assumption  that  at  this  dose  of  insulin 
infusion,  there  is  total  suppression  of  hepatic  glucose  output,  and  so  the  glucose  infusion 
rate  equates  to  the  disappearance  of  glucose  into  insulin  sensitive  tissues  i.  e.  insulin 
sensitivity. 
In  the  calculation  of  M,  corrections  are  made  for  urinary  glucose  loss  (UC)  and  for  any 
difference  between  the  desired  serum  glucose  of  5.2mmol/I  and  the  actual  average  serum 
glucose  value  during  steady  state. 
117 Thus,  to  calculate  insulin  sensitivity  (No 
I-UC+SC 
I.  =  average  glucose  infusion  rate  during  steady  state 
UC  correction  for  urinary  loss  (negligible  during  hyperinsulinaemic 
euglycaemic  clamp) 
SC  space  correction  (mg/kgImin) 
SC  (5.2-G)  x  17.86  x  0.095 
G=  mean  glucose  during  steady  state 
17.86  unit  conversion  factor  (mmol/l  to  mg/dl) 
0.095=  glucose  space  constant 
Morris  et  al  calculated  the  between  day  intra  individual  coefficient  of  variation  for  insulin 
sensitivity  to  be  6%  using  this  technique  (2  1). 
2.2.2.3.3  Buffock  biopsy 
Subjects  were  invited  to  attend  the  CIRU  at  0830,  having  fasted  from  midnight.  With  the 
I 
subject  lying  prone,  one  buttock  was  exposed  and  the  area  sterilised  with  10%  Iodine.  1% 
lignocaine  hydrochloride  was  then  instilled  subcutaneously  to  cover  an  area  of  6cm  x  4cm. 
Once  the  area  was  anaesthetised,  an  elliptical  incision  no  greater  than  3cm  x  0.75  cm  was 
made  and  a  diamond  shaped  segment  of  adipose  tissue  was  removed.  Four  skin  stitches 
were  then  inserted  to  close  the  wound.  The  volunteer  was  then  given  a  light  meal  and 
asked  to  refrain  from  exertion  for  five  days  while  keeping  the  wound  clean.  Ten  days  later 
the  stitches  were  removed. 
118 2.2.2.4  Assay  methodology  for  analysis  of  venous  blood 
2.2.2.4.1  Analysis  of  routine  blood  samples  in  Gartnavel  General  Hospital 
Samples  for  urea,  creatinine,  electrolytes,  total  cholesterol,  triglycerides,  HDL-cholesterol, 
LDL-cholesterol,  glucose,  cortisol  and  growth  hormone  were  collected  and  placed 
immediately  into  the  appropriate  containers.  They  were  then  analysed  as  routine  samples 
in  the  Biochemistry  Department,  Gartnavel  General  Hospital. 
2.2.2.4.2  Assay  of  non-routine  blood  samples 
Samples  for  measurement  of  renin,  angiotensin  H,  aldosterone  and  catecholamines  were 
undertaken  in  the  laboratory  of  Dr  JJ  Morton,  Blood  Pressure  Unit,  Western  Infirmary, 
Glasgow.  Total  plasma  renin  concentration  was  measured  using  a  micro  assay  based  on 
antibody  trapping  as  described  by  JA  Millar  et  al  (339).  Plasma  AII  was  measured  using  a 
kit  from  Diagnostic  Products  Ltd,  Glyn  Rhonwy,  Gwynedd,  M  Plasma  aldosterone  was 
measured  using  a  commercially  available  mdioimmunoassay  (RIA)  Icit  (Biodata,  Milan), 
using  the  method  of  Mackenzie  and  Clements  (340).  Catecholamines  were  measured  by 
high  pressure  liquid  chromatography  (HPLC)  with  electrochemical  detection  (341). 
Samples  for  insulin  and  C-peptide  were  analysed  by  commercially  available 
mdioimmunoassay  (DiaSorin,  UK).  The  fasting  insulin  resistance  index  was  calculated  as 
described  by  Duncan  (18); 
FIRI  =  (fasting  glucose  x  fasting  insulin)  /  25 
Plasma  levels  of  tissue  plasminogen  activator  were  measured  with  a  commercially 
available  enzyme  linked  immunosorbent  assay  (ELISA)  from  Biopool  AB,  Umea,  Sweden. 
119 Plasma  von  Willebrand  factor  (vW"F)  antigen  levels  were  measured  using  an  in-house 
(Professor  GDO  Lowe,  Dr  A  Rumley,  Glasgow  Royal  Infirmary)  ELISA,  employing  rabbit 
anti-human  polyclonal  antibodies  obtained  from  DAKO  p1c,  High  Wycombe,  UK 
2.2.2.4.3  Assay  of  urinary  biochemistry 
Urine  was  collected  in  plain  containers  over  a  24-hour  period  for  assay  of  urinary  sodium 
and  cortisol.  Samples  were  assayed  in  the  Biochemistry  Department,  Gartnavel  General 
Hospital. 
2.2.2.5  Myography  protocol 
2.2.2.5.1  Preparation  of  arteries 
Resistance  arteries  were  dissected  as  described  in  section  2.2.2.3.3.  Where  possible,  four 
segments  of  artery  (approx.  200-400ýLm  average  diameter  and  2mm,  in  length)  were 
mounted  as  ring  preparations  on  two  40gm  stainless  steel  wires  in  a  four-channel  small 
vessel  myograph  (Danish  MyoTechnology,  Aarhus,  Denmark),  as  initially  described  by 
Mulvany  and  Halpem  (342). 
One  wire  was  attached  to  an  isometric  force  transducer  and  the  other  to  a  movable 
micrometer.  The  vessels  were  bathed  in  a  physiological  salt  solution  (PSS).  The 
temperature  was  maintained  at  37  OC,  and  pH  maintained  at  7.4,  with  a  gas  mixture  of 
S%C02  and 
95%02  being  bubbled  throughout  the  experiment. 
2.2.2.5.2  Normalisation  of  vessels 
Following  a  rest  period  of  30  minutes,  each  artery  was  stretched  at  one-minute  intervals  to 
determine  the  resting  tension-internal  circumference  (L)  relationship.  The  LaPlace 
120 equation,  Pý=T/r  (P  is  the  effective  pressure,  T  is  the  wall  tension  and  r  is  the  internal 
radius),  'was  used  to  determine  L100.  This  is  the  calculated  intemal  diameter  the  vessel 
would  have  in  vivo  when  relaxed  and  subjected  to  a  transmural  pressure  of  100mmHg 
(13.3Kpa).  To  achieve  optimal  contraction,  each  vessel  was  then  set  to  the  normalised 
intemal  dimneter  Ll  =  0.9LIoo 
2.2.2.5.3  Myography  protocol 
A  trained  technician,  blinded  to  study  randomisation  phases,  undertook  all  myography 
studies.  Following  the  normalisation  procedure  described  above,  the  vessels  were 
maintained  in  physiological  salt  solution  (PSS)  at  370C  for  a  further  60  minutes.  The 
vessels  were  then  exposed  twice  to  KPSS  (PSS  solution  with  KCI  substituted  for  NaCl  on 
an  equimolar  basis).  Vessels  were  then  incubated  for  30  minutes  in  PSS  before  a 
cumulative  concentration  response  curve  (CRC)  to  norepinephrine  (NE)  from  InM  to 
301M  After  a  further  30-minute  incubation,  a  plateau  contraction  was  obtained  with  lOgM 
NE  before  i  concentration  response  curve  to  acetylcholine  (ACh)  fromInM  to  30AM  was 
performed.  If  vessels  were  either  unable  to  contract  to  KPSS  or  NE,  or  showed  no 
relaxation  to  ACh,  they  were  excluded  from  the  study. 
Vessels  were  then  pre-incubated  for  30  minutes  in  PSS  alone  (control)  or  insulin  (lnM), 
insulin  (100pM),  or  insulin  (lOpNI)  before  a  NE  concentration  response  curve.  Finally, 
vessels  were  pre-incubated  with  insulin  as  before  with  the  addition  of  L-NG-monomethyl- 
arginine  (L-NMMA)  (1[LND  to  all  vessels.  A  final  concentration  response  curve  to  NE  was 
then  obtained. 
121 2.2.2.6  Statistical  techniques  employed  in  this  thesis 
All  statistical  analysis  was  undertaken  using  the  Minitab  statistical  package  (Minitab  Inc., 
Pennsylvania,  USA).  The  level  of  statistical  significance  was  taken  to  be  ap  value  of 
<0.05.  Data  are  expressed  as  mean  and  standard  errors  unless  stated  otherwise.  The 
Anderson-Darling  test  was  used  to  assess  the  distribution  of  a  dataset,  and  if  not  normally 
distributed,  data  were  log  transformed. 
2.2.2.6.1  Metabolic  studies 
For  the  studies  comparing  metabolic  variables  during  active  and  placebo  phases,  statistical 
analysis  was  undertaken  using  the  paired  Student's  t-test.  In  the  comparison  of  unpaired 
groups  with  normally  distributed  variables,  an  unpaired  West  was  used. 
2.2.2.6.2  Studies  in  human  adipocytes 
For  comparison  of  the  effect  of  angiotensin  H  on  insulin  action  in  isolated  adipocytes,  the 
unpaired  Mist  was  used.  Where  appropriate,  area  under  the  curve  was  calculated  as  a 
summary  measure  of  serial  observations  (343).  Simple  correlations  were  tested  using 
Pearson's  correlation,  after  logarithmic  transformation  where  appropriate. 
2.2.2.6.3  Myography  studies 
In  this  thesis,  two  parameters  were  used  to  compare  myography  data  between  phases. 
Response  was  first  expressed  as  the  pD2,,  which  is  the  negative  log  of  the  concentration  of 
agonist  (norepinephrine)  required  to  produce  50%  of  the  maximal  contractile  response 
(l,  uM  norepinephrine).  This  is  referred  to  as  the  sensitivity.  In  addition,  using  the  Law  of 
LaPlace,  the  maximum  active  effective  pressure  (mN/mm2)  was  calculated  from  wall 
tension  and  internal  radius,  and  expressed  as  an  absolute  number.  This  second  parameter 
122 allowed  comparison  of  the  maximum  effect  of  agonist,  in  the  presence  and  absence  of 
insulin. 
123 Chapter  3:  Insulin-mediated  suppression  of  lipolysis;  development  and  application  of 
an  assay  of  insulin  sensitivity 
3.1  Introduction 
Insulin  sensitivity  is  considered  by  convention  to  be  sensitivity  to  the  glucose  lowering 
action  of  insulin,  measured  systemically  using  the  techniques  described  in  chapter  1.  It 
remains  difficult,  however,  to  measure  insulin  action  in  isolated  human  tissue.  Furthermore, 
it  cannot  be  assumed  that  whole  body  and  cellular  insulin  sensitivity  are  closely  correlated 
in  an  individual;  whole  body  insulin  sensitivity  (M)  values  generated  from  the  euglycaemic 
hyperinsulinaemic  clamp  are  the  result  of  integrated  insulin  responses  in  various  tissues, 
and  may  also  be  influenced  by  properties  of  the  vascular  beds  supplying  these  tissues.  In 
this  chapter  the  development  of  an  assay  of  adipocyte  insulin  sensitivity  is  described, 
however  rather  than  examining  the  glucose  lowering  effects  of  insulin,  the  action  of  insulin 
to  attenuate  the  process  of  lipolysis  and  release  of  non-esterified  fatty  acids  (NEFA)  is 
measured.  Having  developed  this  technique,  associations  of  insulin  action  in  isolated 
adipocytes  with  the  phenotypic  characteristics  of  the  insulin  resistance  syndrome  are 
described.  While  intuition  would  suggest  that  insulin  resistance  in  isolated  tissue  is 
associated  with  type  2  diabetes,  hypertension,  dyslipidaemia  and  obesity,  the  literature  that 
supports  this  is  limited  largely  to  the  study  of  populations  with  severe  syndromes  of  insulin 
resistance,  such  as  pathological  obesity  (153)  and  type  2  diabetes  (15  1). 
124 Two  hypotheses  are  investigated: 
x  That  insulin  will  attenuate  the  process  of  isoproterenol-induced  lipolysis  in  isolated 
human  adipocytes. 
n  That  the  application  of  this  assay  to  healthy  females  will  show  a  relationship 
between  insulin  action  in  isolated  tissues  and  characteristics  of  the  insulin  resistant 
phenotype. 
125 3.2  Methods 
3.2.1  Identification  and  recruitment  of  subjects 
Women  were  recruited  from  the  gynaecology  wards  of  the  Western  Infirmary,  Glasgow. 
All  subjects  were  undergoing  laparotomy  for  non-malignant  gynaecological  disease. 
Exclusion  criteria  were  as  follows 
m  Treated  or  untreated  hypertension  (BP  >  160/90  mmHg) 
a  Type  1  or  2  diabetes 
m  Family  history  of  diabetes  in  first  degree  relative 
0  Intercurrent  drug  therapy 
a  Malignant  disease 
a  Post  menopausal  or  <6  periods  in  last  twelve  months 
The  protocol  was  approved  by  the  Ethics  Committee  of  the  Western  Infirmary,  and  all 
subjects  gave  informed  consent.  Peri-umbilical  subcutaneous  adipose  tissue  was  obtained 
and  prepared  as  described  in  Chapter  2.2.1.1 
126 3.2.2  Preliminary  studies  of  NEFA  release 
Preliminary  experiments  were  undertaken  to  develop  the  assay  of  insulin-mediated 
attenuation  of  isoproterenol-induced  lipolysis.  In  all  experiments,  adipocytes  were  obtained 
as  described  in  section  2.2.1.1  and  assays  undertaken  to  determine; 
1.  The  time  course  of  isoproterenol-induced  lipolysis  ±  adenosine.  Cells  were 
incubated  with  isoproterenol  200nM  for  20,40  and  60  minutes,  having  been 
digested  and  suspended  in  the  presence  or  absence  of  adenosine  (100nW. 
2.  The  concentration-response  relationship  of  isoproterenol-induced  lipolysis  ± 
adenosine.  Cells  were  incubated  with  increasing  concentrations  of  isoproterenol, 
from  2nM  to  51iM,  for  45  minutes  and  NEFA  release  assayed.  Cells  were  digested 
either  in  the  presence  or  absence  of  adenosine  lOOnM. 
3.  The  time  course  of  insulin-mediated  suppression  of  isoproterenol-induced  lipolysis. 
The  temporal  nature  of  insulin's  suppression  of  isoproterenol-induced  lipolysis  was 
examined  using  two  insulin  concentrations  (O.  lnM,  lOnM)  incubated  for  15,30,45 
and  60  minutes  with  adipocytes  treated  for  45  minutes  with  isoproterenol  200nM. 
Adenosine  100nM  was  present  in  the  buffer. 
4.  The  effect  of  wortmannin  on  basal  and  insulin-attenuated  lipolysis.  Adipocytes 
were  incubated  in  the  presence  and  absence  of  wortmannin  100nM  for  30  minutes, 
then  the  release  of  NEFA  in  either  the  unstimulated  state  or  the  insulin-mediated 
suppression  of  isoproterenol-induced  lipolysis  measured.  Assays  were  undertaken 
in  the  presence  of  adenosine  1  OOnM. 
127 3.2.3  Studies  of  insulin  action  and  subject  phenotype 
Adipose  tissue  was  obtained  at  laparotomy  from  20  females.  Results  were  analysed  in  two 
ways;  the  subjects  were  divided  into  two  discrete  groups  defined  on  the  basis  of  BMI, 
providing  a  lean  (BMI  :. -525kg/m  2)  and  obese  (BMI; 
->30kg/m2)  group  (as  defined  by  the 
WHO  (344)),  and  also  by  examining  data  from  all  20  volunteers  and  testing  for  a 
continuous  relationship  between  insulin  action  and.  characteristics  of  the  insulin  resistant 
phenotype.  The  index  of  insulin  sensitivity  was  expressed  as  the  area  under  the  curve 
(AUC)  of  insulin-mediated  attenuation  of  isoproterenol-induced  lipolysis  between 
concentrations  of  O.  OlnM  and  lOnM  insulin  -  the  greater  the  area  under  the  curve,  the 
lesser  the  sensitivity  to 
-insulin. 
As  the  response  to  insulin  at  I  nM-  I  OnM  was  maximal,  and 
falling  at  lOOnM  concentrations,  analysis  of  the  AUC  was  not  extended  to  include  that  seen 
at  I  OOnM  insulin. 
3.2.4  Measurement  of  BMI  and  blood  pressure 
BMI  and  blood  pressure  were  measured  as  described  in  Chapter  2. 
3.2.5  Serum  insulin  and  fasting  insulin  resistance  Index  (FIRI) 
Samples  for  fasting  insulin  and  glucose  were  obtained  on  the  day  of  theatre  when  possible, 
and  assayed  as  described  in  Chapter  2.  FIRI  was  calculated  as  described  by  Duncan  et  al 
(18). 
3.2.6  Serum  lipid  analysis 
Samples  for  fasting  lipid  profile  were  obtained  on  the  day  of  theatre  when  possible  and 
processed  as  described  in  materials  and  methods. 
128 3.2.7  Statistical  analysis 
In  all  assays,  each  expressed  value  was  determined  from  the  mean  of  two  values  assayed  in 
exactly  the  same  manner.  Comparison  of  groups  was  undertaken  using  an  unpaired  West. 
For  the  correlation  analyses,  variables  were  tested  for  normality  using  the  Anderson- 
Darling  normality  test  and  logarithmically  transformed  as  appropriate.  In  all  cases,  p<0.05 
was  taken  as  signifying  conventional  levels  of  statistical  significance. 
129 3.3  Results 
3.3.1  Preliminary  assays  of  NEFA  release  and  insulin  suppression 
Preliminary  assays  were  undertaken  to  demonstrate  and  confirm  several  basic  tenets  of  the 
assay  technique. 
3.3.1.1  Time  course  of  isoproterenol-induced  lipolysis 
A  time  course  of  isoproterenol  incubation  and  NEFA  release  was  undertaken  in  isolated 
human  adipocytes  (figure  3.1),  demonstrating  increasing  release  of  NEFA  in  response  to  a 
single  concentration  of  isoproterenol  (200nM)  for  up  to  one  hour. 
3.3.1.2  Concentration-response  of  isoproterenol-induced  lipolysis 
Figure  3.2  demonstrates  a  concentration  response  curve  of  isoproterenol-induced  lipolysis 
in  isolated  human  adipocytes.  Notably,  incubation  with  200nM  isoproterenol  (subsequently 
used  as  the  standard  concentration  in  the  final  assay)  induced  a  sub-maximal  release  of 
NEFA  into  the  media.  In  addition,  figure  3.2  shows  the  anticipated  anti-lipolytic  action  of 
pre-incubation  with  adenosine  (lOOnNl)  on  isoproterenol-induced  lipolysis. 
3.3.1.3  Time  course  of  insulin  action 
Insulin's  attenuation  of  lipolysis  was  confirmed  in  this  preliminary  experiment  and  its 
action  was  shown  to  be  time-dependent  across  the  limited  range  of  incubation  periods 
studied  (figure  3.3). 
3.3.1.4  Wortmannin  and  insulin-mediated  attenuation  of  lipolysis 
Isolated  cells  were  incubated  with  100nM  wortmannin  for  30  minutes,  then  the  basal 
release  of  NEFA  assayed  and  this  value  compared  with  cells  untreated  with  wortmannin 
130 M. 
kFigure  3.4.1).  A  significant  increase  in  the  basal  release  of  NEFA  was  demonstrated  in  the 
presence  of  wortmannin  (p=0.026  comparing  wortmannin  present  and  absent,  n--4).  No 
effect  of  wortmannin  per  se  was  seen  on  the  assay  standard  with  a  predetermined  NEFA 
concentration  of  lmmol/l,  confirming  that  there  was  no  confounding  effect  of  wortmannin 
on  the  readings  obtained  from  light  spectrophotometry. 
Cells  were  preincubated  with  lOOnM  wortmannin  for  30  minutes  and  insulin-mediated 
attenuation  of  isoproterenol-induced  lipolysis  assayed  (figure  3.4.2).  Wortmannin 
abrogated  the  effect  of  insulin  to  suppress  NEFA  release  (p<0.01  comparing  AUC  ± 
wortmannin  lOOnM,  n--4).  These  assays  confirmed  the  dependence  on  P13  Idnase  of 
insulin's  attenuation  of  lipolysis,  and  in  addition  suggested  a  role  for  P13  Idnase  in  the 
detennination  of  the  basal  rate  of  lipolysis. 
3.3.2  The  relationship  between  adipocytes  ex  vivo  and  the  clinical  phenotype 
3.3.2.1  Baseline  characteristics 
Table  3.1  details  the  mean  baseline  characteristics  of  all  20  subjects  recruited,  while  in 
table  3.2  the  characteristics  of  the  lean  (n--9)  and  obese  (n--9)  groups  are  shown. 
Importantly,  while  BMI,  fasting  insulin  and  LDL-cholesterol  were  lower  in  the  lean 
subjects,  there  was  no  difference  in  blood  pressure,  age  or  fasting  glucose. 
3.3.2.2  Basal  release  of  NEFA  and  phenotypic  characteristics 
The  relationship  between  the  basal  release  of  NEFA  (i.  e.  the  amount  of  NEFA  in  media 
after  45  minutes  incubation  of  adipocytes  in  buffer  alone)  and  phenotypic  characteristics 
was  examined.  Given  the  non-parametric  distribution  of  the  values  of  the  basal  NEFA 
release,  data  were  logariflunically  transformed.  Significant  relationships  were  observed 
131 between  BMI  (figure  3.5.1),  serum  total/HDL-cholesterol  ratio  (figure  3.5.2),  and  age 
(figure  3.5.4). 
3.3.2.3  Insulin-mediated  suppression  of  isoproterenol-induced  lipolysis  and 
phenotypic  characteristics 
Insulin-mediated  suppression  of  isoproterenol-induced  lipolysis  was  significantly  less  in 
obese  subjects  compared  with  their  lean  counterparts  (expressed  as  the  AUC  of  the  insulin 
(lOpM-IOnM)  concentration  response  curve,  figure  3.6,  p<0.01  comparing  lean  and  obese 
groups).  Indeed,  in  correlation  analyses,  the  AUC  of  insulin  concentration  response  curve 
was  shown  to  correlate  significantly  with  BMI  and  total/HDL-cholesterol  ratio,  though  not 
FERI  or  age  (figure  3.7.1-4).  There  was  no  correlation  between  the  release  of  NEFA  in 
response  to  isoproterenol  alone  and  BMI  (figure  3.8). 
132 Table  3.1:  Baseline  characteristics  of  all  20  subjects  studied 
Mean:  h  S.  D. 
Number  20 
Age  (years)  3  8.7  :h7.3 
Mean  Arterial  Pressure  91.8  ±  9.1 
BMI  (kgtm2)  1  29.1  ±5.5 
Fasting  Insulin  Resistance  Index.  3.1  *  1.3 
Total  cholesterol  (mmol/1)  4.0±  0.7 
Total:  11DL  cholesterol  3.6+-1.4 
Triglycerides  (mmol/1)  1.14  ±  0.7 
Smokers  6 
Table  3.2:  Characteristics  of  the  lean  and  obese  subgroups 
Lean 
(mean+-SD) 
Obese 
(mean+-SD) 
West 
(unpaired) 
Number  91  9 
Age  (years)  40  ±  5.1  37.66+-11  1  0.79 
Mean  Arterial  Pressure 
(mmHg)  I 
87.66  ±  7.2  95.2  ±  9.9  I  0.09 
BMI  (kg/m)  24.2  ±  1.4  34.22  ±  3.2  <0.001  I 
Fasting  Insulin  Resistance 
Index 
2.4  ±  0.6  3.9:  h  1.5  0.014 
Total  cholesterol  (mmol/1)  3.64±  0.5  4.31±  0.8  0.06 
Total:  HDL  cholesterol  3.0  ±  0.5  3.8  ±  1.5  0.13 
LDL  cholesterol  (mmol/1)  2.0  ±  0.4  2.5+-0.5  10.034 
Triglycerides  (mmol/1)  0.9  :h0.23  1.3  :h0.9  0.25 
Smokers  3  3 
133 Figure  3.1:  Time  course  of  isoproterenol-induced  lipolysis 
Cells  were  incubated  with  isoproterenol  200n.  M  for  20,40  and  60  minutes,  both  in  the 
presence  and  absence  of  adenosine  (I  OOnM). 
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Isoproterenol  200  nM  (ninutes) Figure  3.2:  Concentration-response  relationship  of  isoproterenol-induced  lipolysis 
Cells  were  incubated  with  increasing  concentrations  of  isoproterenol,  from  2nM  to  2jiM, 
for  45  minutes  and  NEFA  release  assayed.  This  was  performed  in  the  presence  of 
adenosine  100riM. 
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0  -9  -8  .7  .6 Figure  3.3:  Time  course  of  insulin-mediated  suppression  of  isoproterenol-induced 
lipolysis. 
The  temporal  nature  of  insulin's  suppression  of  isoproterenol-induced  lipolysis  was 
examined  using  two  insulin  concentrations  (100pM,  10nM)  incubated  for  15,30,45  and  60 
minutes  with  adipocytes  treated  for  45  minutes  with  isoproterenol  200nM.  Adenosine 
I  OOnM  was  present  in  the  buffer. 
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l5rTin  30rrin  45nin  Main  15ryin  30nin  45nin  60rTin Figure  3.4:  Effect  of  wortmannin  on  basal  and  insulin-attenuated  lipolysis. 
Adipocytes  were  incubated  in  the  presence  and  absence  of  wortmannin  I  OOnM  for  30  minutes,  then 
either  the  release  of  NEFA  in  the  unstimulated  state  (Figure  3.4.1  (p<0.05  for  companson  of  basal 
NEFA  release  ±  wortmannin)  or  the  insulin-mediated  suppression  of  isoproterenol-induced  lipolysis 
(Figure  3.4.2)  (p<0.05  for  comparison  of  AUC  of  insulin-mediated  attenuation  of  isoproterenol- 
induced  lipolysis  ±  wortmannin)  measured.  Assays  were  undertaken  in  the  presence  of  adenosine 
lOOnM.  Error  bars  denote  standard  errors. 
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Insulin-mediated  attenuation  (lOpM-IOnW  of  isoproterenol-induced  (200n.  M)  lipolysis  in 
subcutaneous  adipocytes  obtained  from  nine  lean  (BMI:  525  kghn2)  and  nine  obese 
(BMI>-30kg/m2)  females  (p=0.001  for  comparison  of  AUC  between  lean  and  obese  groups). 
Error  bars  denote  standard  errors. 
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0  10  20  30  40  50 3.4  Discussion 
In  this  chapter,  the  development  of  an  assay  of  insulin  responsiveness  in  human  adipose 
tissue  is  described,  based  on  the  insulin-mediated  suppression  of  isoproterenol-induced 
lipolysis.  This  assay  was  then  used  to  measure  insulin  sensitivity  in  adipose  tissue  from 
well-characterised,  otherwise  healthy  females  undergoing  laparotomy,  and  showed  a 
relationship  between  the  clinical  phenotype  and  insulin  action  in  isolated  tissue. 
The  central  tenet  of  this  assay  is  the  inhibitory  effect  of  insulin  on  cellular  release  of 
NEFAs.  Isoproterenol,  acting  via  its  cell  surface  fl  adrenoceptors,  stimulates  adenylate 
cyclase  activity,  generating  cAMP.  This  then  stimulates  activation  of  the  cAMP  dependent 
protein  Icinase  A  (PKA),  which  phosphorylates  and  activates  hormone  sensitive  lipase;  this 
enzyme  is  the  rate-limiting  step  in  the  hydrolysis  of  stored  triglyceride  to  glycerol  and 
NEFA  (reviewed  in  (345)).  Released  NEFAs  then  activate  the  colorimetric  reaction  used  in 
the  assay  -  NEFAs  in  the  presence  of  added  acyl-CoA  synthetase  form  acyl  CoA.  This  is 
then  oxidised  by  added  acyl-CoA  oxidase  to  produce  hydrogen  peroxide  which,  in  the 
presence  of  added  peroxidase,  allows  the  oxidative  condensation  of  3-methyl-N-ethyl-N-(O- 
hydroxy-ethyl)-aniline  and  forms  a  purple  adduct  with  an  absorption  maximum  of  550nm. 
The  precise  mechanism  through  which  insulin  attenuates  lipolysis  is  as  yet 
uncharacterised,  though  it  appears  that  insulin  acts  via  the  tyrosine  phosphorylation  of  the 
insulin  receptor  and  IRS  proteins  leading  to  the  activation  of  P13'-Idnase.  That  this  step  is 
necessary  for  the  suppression  of  lipolysis  is  demonstrated  by  my  results  that  show  pre- 
treatment  with  the  P13'-kinase  inhibitor  wortmannin  blocking  this  effect  (figure  3.4).  It  is 
suggested  that,  through  further  second  messenger  events,  insulin  also  reduces  activation  of 
142 PKA,  perhaps  involving  phosphodiesterase  E3  (346),  thus  reducing  activation  of  hormone 
sensifive  lipase. 
Important  preliminary  assays  were  undertaken  to  characterise  the  cellular  response  to 
isoproterenol.  Isoproterenol  is  a  non-specific  agonist  of  the  adipocyte  fl-adrenoceptor. 
Alternative  stimuli  used  by  other  groups  in  similar  systems  include  forskolin  (stimulates 
adenylate  cyclase),  8-bromo  cyclic  ANT  (cyclic  AMP  analogue)  and  individual  9- 
adrenoceptor  agonists  (dobutamine  and  terbutaline).  It  is  proposed  that  the  sensitivity  to 
catecholamine-induced  lipolysis  is  reduced  in  obesity,  possibly  mediated  by  impaired 
expression  of  hormone  sensitive  lipase  (347). 
In  the  present  assay,  neither  the  time  courses  employed  (figure  3.1,  figure  3.3),  nor  the 
concentration  of  isoproterenol  (figure  3.2)  saw  isoproterenol's  or  insulin's  maximal 
lipolytic  stimulus.  In  addition,  there  was  no  suggestion  that  obese  subjects  released  more 
NEFA  in  response  to  isoproterenol  (figure  3.8).  These  observations  in  combination  suggest 
that  the  release  of  NEFA  observed,  both  basally  and  after  insulin  suppression,  was  not 
simply  a  function  of  cell  size  and  triglyceride  capacity.  This  is  of  particular  importance  as 
the  cell  size  was  not  measured,  and  so  the  results  are  not  expressed  with  a  correction  for 
cell  size.  Despite  this,  however,  and  again  to  avoid  generating  results  that  were  more  due  to 
sensitivity  to  lipolysis  than  insulin  sensitivity,  results  were  expressed  in  terms  of  insulin 
action  relative  to  the  effect  of  isoproterenol  alone,  rather  than  as  absolute  numbers. 
While  these  studies  were  not  designed  to  define  formally  the  role  of  adenosine  in  the 
regulation  of  lipolysis,  adenosine  does  have  anti-lipolytic  activity,  mediated  via  the  Al 
receptor,  which  modifies  the  activity  of  adenylate  cyclase  (348).  The  net  anti-lipolytic 
143 activity  of  adenosine  is  likely  to  be  at  least  partly  dependent  on  the  ratio  of  Al:  A2  receptors 
in  a  given  tissue.  The  content  of  adenosine  is  higher  and  the  response  to  it  less  in  omental 
than  subcutaneous  adipocytes  (349).  It  has  been  demonstrated  that  in  adipocytes  from  obese 
animal  models,  there  is  increased  sensitivity  to  adenosine-mediated  inhibition  of  lipolysis 
(350).  Given  the  confounding  effects  of  adenosine,  assays  were  undertaken  at  a  "clamped" 
supraphysiological,  though  not  maximally  effective,  concentration  of  adenosine  (100nM). 
Other  groups  have  addressed  this  problem  in  a  similar  manner,  though  some  have  added 
adenosine  deaminase  to  the  buffer  to  reduce  endogenous  adenosine  levels,  and  then  added 
exogenous  adenosine  (3  5  1). 
Having  developed  this  assay,  the  technique  was  employed  to  measure  cellular  insulin 
sensitivity  in  humans  and  to  consider  this  in  the  setting  of  the  clinical  phenotype. 
Phenotype  characterisation  consisted  of  measurement  of  BMI,  blood  pressure,  fasting 
glucose,  total,  LDL-  and  HDL-  cholesterol  and  triglycerides.  In  addition,  age,  family 
history,  smoking  and  menopausal  status  were  recorded.  Insulin  sensitivity  in  human 
adipose  tissue  has  been  assessed  previously,  mainly  using  measurements  of  glucose  uptake. 
Here,  the  suppression  of  lipolysis  was  used,  mainly  because  personal  experience  of  glucose 
transport  assays  in  human  tissue  had  shown  that  use  of  this  parameter  was  confounded  by 
the  effects  of  the  basal  rate  of  glucose  transport,  and  limited  by  the  larger  volume  of  tissue 
required  to  construct  a  dose  response  curve  of  insulin-stimulated  glucose  uptake.  The 
additional advantage  of  the  present  assay  is  that  there  is  no  need  for  the  use  of 
radioisotopes.  Other  groups  have  used  microdialysis  techniques  to  analyse  in  vivo  adipose 
tissue  lipolysis,  though  it  cannot  be  assumed  that  this  reflects  only  the  action  of  insulin  at 
the  cell;  these  measurements  may  be  confounded  by  the  effects  of  local  blood  flow.  In 
keeping  with  this,  in  a  study  of  family  members  of  patients  with  obesity  or  type  2  diabetes, 
144 insulin-mediated  attenuation  of  lipolysis  was  reduced  using  in  vivo  microdialysis 
measurements,  though  not  in  an  in  vitro  assay  undertaken  in  parallel  (15  8). 
While  there  is  a  literature  that  demonstrates  a  reduction  in  insulin  action  in  isolated  tissue 
from  subjects  with  type  2  diabetes,  there  are  fewer  published  data  exploring  insulin 
sensitivity  in  isolated  adipose  tissue  from  patients  without  diabetes.  Bogardus  et  al  ((352) 
found  that  there  was  no  correlation  between  obesity  and  maximal  glucose  uptake  in  isolated 
adipocytes  from  non-diabetic  Pima  Indians,  and  concluded  that  obesity  had  only  a  minor 
role  in  determining  in  vivo  and  in  vitro  glucose  uptake.  Kashiwagi  et  al  (152),  however,  did 
find  that  the  EC50  of  insulin's  antilipolytic  action  (measured  by  glycerol  release)  was 
greater  in  mildly  obese  Pima  Indians  (mean  BMI  33  kg/m2)  than  lean  volunteers  (mean 
BMI  22  kglm2). 
In  the  present  study,  a  close  relationship  was  observed  between  the  basal  release  of  NEFA 
and  BMI,  independent  of  blood  pressure,  FIRI  and  lipid  profile.  This  may  represent  an 
effect  of  total  cell  volume  or  number  in  the  obese  subjects;  the  effect  of  wortmannin  to 
increase  this  value  (figure  3.4.1)  also  suggests  however  that  the  basal  NEFA  value  is  to 
some  extent  influenced  by  P13'-Idnase  activity,  and  so  insulin.  Obese  patients,  who  have  an 
increased  risk  of  developing  further  characteristics  of  the  insulin  resistance  syndrome,  were 
shown  to  be  insulin  resistant  even  when  normoglycaemic  and  normotensive,  implying  that 
cellular  insulin  resistance  is  an  early  feature.  The  data  were  analysed  not  only  by  comparing 
Ican  and  obese  groups  (figure  3.6),  but  also  by  examining  the  cohort  as  a  whole  (figure  3.7) 
to  demonstrate  a  continuous  relationship  between  cellular  insulin  resistance  and  obesity, 
independent  of  age  and  blood  pressure.  It  must  be  borne  in  mind  that  these  relationships 
between  isolated  tissue  and  the  whole  body  phenotype  are  evident  after  the  adipocytes  have 
145 been  extracted,  digested  and  maintained  ex  vivo  for  at  least  90-minutes  prior  to  analysis, 
reinforcing  the  strength  of  the  observations.  This  is  of  fundamental  importance;  while  there 
is little  doubt  that  there  is  a  circulating  influence  of  agents  such  as  glucose  and  TNF-ci  in 
vivo,  it  seems  unlikely  that  the  findings  in  isolated  tissue  reflect  these  influences  after 
digestion  etc.  It  is  possible  that  the  cells  continue  to  secrete  agents,  such  as  resistin  (141) 
that  may  have  a  paracrine  effect  once  in  vitro,  however  it  is  most  likely  that  the  observation 
of  a  relationship  between  clinical  and  cellular  features  of  insulin  resistance  reflects  an 
intrinsic  cellular  defect. 
The  role  of  adipose  tissue  in  the  development  of  insulin  resistance,  type  2  diabetes  and 
vascular  disease  is  an  area  of  great  current  scientific  interest.  More  than  thirty  years  ago, 
however,  Randle  hypothesised  that  the  release  of  NEFA  from  adipose  tissue,  secondary  to 
resistance  to  insulin,  may,  by  substrate  competition,  result  in  hyperglycaernia.  While  there 
have  been  subsequent  advances  in  this  particular  field,  mainly  at  the  molecular  level,  the 
central  tenet  behind  Randle's  hypothesis  still  holds  true,  while  further  work  has  also 
suggested  there  may  be  a  role  for  NEFA  in  mediating  the  endothelial  dysfunction  that  is 
associated  with  insulin  resistance.  Recent  publications  propose  that  adipose  tissue  releases 
other  factors,  such  as  TNF-q,  EL-6,  resistin  and  angiotensin  II  that  may  all  have  a  role  in 
modifying  insulin  action  in  a  variety  of  target  organs,  and  may  even  couple  the  metabolic 
and  vascular  manifestations  of  insulin  resistance.  Intriguingly,  endothelial  NOS  message 
and  protein  have  recently  been  isolated  in  human  adipocytes  (353).  Given  these 
observations,  it  may  become  more  appropriate  to  consider  adipose  tissue  as  an  endocrine 
organ. 
146 In  summary,  I  have  developed  an  assay  of  insulin  action  in  isolated  human  adipose  tissue, 
using  insulin's  well-described  role  in  the  suppression  of  lipolysis.  I  have  also  shown  that 
the  insulin  sensitivity  of  isolated  tissue  reflects  the  host  phenotype.  I  have  gone  on  to  use 
this  assay  in  chapter  5  to  investigate  the  effect  of  angiotensin  H  on  insulin  action  in  adipose 
tissue. 
147 Chapter  4:  Dietary  sodium  restriction  and  insulin  sensitivity 
4.1  Introduction 
The  relationship  between  the  RAS  and  insulin  sensitivity  remains  unclear.  While 
angiotensin  Il  infusion  has  been  reported  to  increase  insulin.  sensitivity(293,299),  activation 
of  the  RAS  by  dietary  sodium  restriction  may  have  the  opposite  effect  (248,254)  .  Using  the 
euglycaemic  hyperinsulinaemic  clamp,  some,  though  not  all,  groups  have  found  that  low 
sodium  diet  is  associated  with  a  reduction  in  insulin  sensitivity  (reviewed  in  Chapter  1).  As 
moderate  dietary  sodium  restriction  is  now  a  major  part  of  the  non-pharmacological 
management  of  hypertension,  potentially  adverse  metabolic  consequences  need  to  be 
thoroughly  explored. 
Analysis  of  the  current  literature  gives  no  clear  message;  differences  in  the  degree  and 
duration  of  sodium  restriction,  the  populations  under  study,  and  the  method  of  measuring 
insulin  sensitivity  make  it  difficult  to  reach  a  consensus.  Therefore,  a  double-blind, 
randomised,  placebo-controlled  crossover  study  was  designed  to  test  the  effect  of  modest 
dietary  sodium  restriction  on  insulin  sensitivity.  Only  modest  sodium  restriction  was  used 
in  an  attempt  to  maintain  clinical  relevance  to  the  result;  the  use  of  a  simple  diet  sheet  and 
the  avoidance  of  pre-prepared  meals  mean  that  similar  results  may  be  anticipated  were 
these  conditions  applied  to  the  general  population.  Additionally,  the  euglycaernic 
hyperinsulinaemic  clamp  was  used  as  the  gold  standard  method  for  the  assessment  of 
insulin  sensitivity.  The  metabolic  effects  of  sodium  restriction  may  be  linked  to  its  pressor 
effects  (354),  and  as  such  detailed  blood  pressure  measurements  were  obtained  at  the  end  of 
each  dietary  phase. 
148 There  isalso  variability  in  published  studies  with  regard  to  the  assessment  of  neurohumoral 
activation  in  response  to  sodium  restriction.  In  addition  to  measuring  renin,  aldosterone  and 
angiotensin  II  (AII),  serum  cortisol,  noradrenaline,  and  growth  hormone  were  also 
measured.  Lastly,  as  the  endothelium  expresses  AT1  receptors,  and  may  have  a  role  in 
determining  insulin  sensitivity,  markers  of  endothelial  function  during  both  normal  and 
restricted  sodium  intake  were  also  measured. 
0 
149 4.2  Methods 
The  study  was  designed  as  double-blind,  randomised,  placebo-controlled  crossover  trial 
comparing  low  and  normal  sodium  intake  for  five  days,  with  a  washout  period  of  seven 
days  between  phases. 
4.2.1  Volunteers 
15  healthy  males  (mean  age  26.5  ±  3.66  (SD)  years,  mean  BMI  23.33  ±  2.4  (SD)  kg/m), 
were  recruited  to  the  study  by  advertisement.  Subjects  with  any  intercurrent  medical 
condition,  including  hypertension  and  diabetes  mellitus,  were  excluded.  Volunteers 
underwent  a  standard  physical  assessment  prior  to  enrolment  into  the  study,  and  all  gave 
written  informed  consent.  All  aspects  of  the  study  protocol  were  approved  by  the  Ethics 
Committee  of  the  West  Glasgow  Hospitals  University  NHS  Trust. 
4.2.2  Low  sodium  diet 
Volunteers  were  asked  to  limit  oral  sodium  intake  for  two  periods  of  five  days,  separated  by 
at  least  one  week.  During  these  periods,  ten  tablets  were  taken  daily,  either  Slow  Sodium 
(100mmol/day)  (Ciba-Geigy,  Horsham,  UK)  or  matched  placebo,  in  random  order. 
A  diet  sheet  was  given  to  each  volunteer  at  the  screening  visit  (figure  4.1),  detailing  low 
sodium  foodstuffs  and  a  sample  daily  diet.  Dietary  advice  was  reinforced  by  the  study  nurse 
and  investigator.  Volunteers  were  asked  not  to  smoke,  or  drink  alcohol  during  the  study. 
4.23  Urinary  electrolytes 
Urine  was  collected  into  preservative  for  the  24  hours  preceding  the  euglycaemic  clamp. 
On  the  fifth  morning  of  each  phase,  volunteers  attended  the  Clinical  Investigation  and 
150 Research  Unit,  having  fasted  overnight.  To  measure  salt  sensitivity,  blood  pressure  was 
recorded  lying  recumbent  in  a  quiet  room  every  two  minutes  for  one  hour,  using  a  semi- 
automated  sphygmomanometer  (Dinamap  Critikon,  Johnson  and  Johnson  Professional 
Products  Ltd.,  U.  K.  ). 
4.2.4  The  euglycaemic  hyperinsulinaemic  clamp 
The  euglycaernic  hyperinsulinaernic  clamp  protocol  was  derived  from  that  described  by 
DeFronzo  et  al  1979  (10)  and  is  detailed  in  Chapter  2. 
4.2.5  Analysis  of  serum  biochemistry 
At  baseline,  60,120,150  and  180  minutes,  blood  was  taken  for  insulin  and  electrolytes. 
Samples  for  C-peptide,  plasma  renin,  aldosterone,  angiotensin  11  and  cortisol  were  collected 
at  the  start  and  end  of  the  clamp.  Baseline  samples  were  also  obtained  for  total  cholesterol 
and  triglycerides,  markers  of  endothelial  function,  noradrenaline,  growth  hormone  and 
glucose.  The  methods  for  all  of  these  assays  are  detailed  in  Chapter  2. 
4.2.6  Statistical  analysis 
Analysis  was  performed  using  the  Minitab  statistical  package.  All  means  are  expressed  ± 
the  standard  error  of  the  mean,  except  where  stated  otherwise.  Equivalent  values  from  each 
study  phase  were  compared  using  paired  t-tests.  For  studies  of  correlation,  non-normally 
distributed  variables  were  first  expressed  as  their  natural  logarithm. 
151 4.3  Results 
All  15  recruits  completed  both  phases  of  the  protocol,  and  experienced  no  adverse  events. 
4.3.1  Body  weight 
There  was  no  significant  difference  in  body  weight  between  phases  (table  4.1). 
4.3.2  Urinary  sodium  excretion 
Urinary  excretion  of  sodium  for  the  24  hours  prior  to  the  clamp  was  measured  to  estimate 
compliance  with  diet  and  medication.  Mean  urinary  sodium  during  the  24  hours  prior  to  the 
clamp  after  the  placebo  phase  was  70.6  J:  45.1  mmol/24  hours,  compared  with  175  ::  L  72.1 
mmol/24  hours  (p<0.01)  (table  4.1)  after  sodium  supplementation. 
4.3.3  Serum  sodium 
Serum  sodium  at  the  commencement  of  the  clamps  was  lower  after  the  period  of  sodium 
depletion  in  comparison  with  the  sodium  replete  phase  (table  4.1). 
4.3.4  Activation  of  other  counter-regulatory  endocrine  systems 
There  were  no  differences  in  baseline  or  post  clamp  noradrenaline,  cortisol  or  growth 
hormone  between  phases  (table  4.1) 
4.3.5  Lipids 
There  were  no  significant  differences  in  total  cholesterol  or  triglycerides  between  phases 
(table  4.1). 
152 4.3.6  Blood  pressure 
No  significant  changes  in  systolic  or  diastolic  blood  pressure  were  observed  between 
phases  (table  4.1)  when  group  means  were  compared.  However,  eight  of  the  fifteen 
volunteers  were  salt  sensitive  (SS),  defined  as  a  fall  in  mean  arterial  pressure  (MAP)  of  at 
least  3mmHg  in  response  to  sodium  restriction.  When  salt  sensitivity  was  considered  as  a 
continuous  variable,  no  statistically  significant  correlation  was  seen  between  the  degree  of 
salt  sensitivity  and  the  change  in  insulin  sensitivity  (figure  4.4). 
4.3.7  Activation  of  the  renin  angiotensin  system 
Before  each  clamp,  plasma  renin  activity,  aldosterone  and  angiotensin  II  were  measured 
after  20  minutes  supine  rest  to  document  the  degree  of  activation  of  the  RAS  (table  4.2).  All 
three  parameters  were  significantly  greater  at  the  start  and  end  of  the  euglycaemic  clamp 
during  sodium  restriction. 
4.3.8  Insulin'sensitivity 
Fasting  insulin,  C-peptide  and  glucose  were  not  significantly  different  between  phases 
(table  4.3).  Despite  this,  insulin  sensitivity,  measured  as  the  M  value  derived  from  a 
euglycaemic  hyperinsulinaemic  clamp,  was  reduced  during  sodium  depletion  compared 
with  the  sodium-replete  phase  (M--1  1.0±2.4  (SD)  mg/kgImin  vs  12.4±3.5  (SD)  mgfkglmin) 
(table  4.3  and  figure  4.3).  There  was  no  difference  in  the  mean  insulin  during  the  180- 
minute  clamp,  or  during  the  final  40  minutes  of  the  clamp,  between  phases  (table  4.3  and 
figure  4.2).  However,  even  after  correcting  for  potential  confounding  effects  of  differences 
in  serum  insulin  during  steady  state,  there  was  a  significant  difference  in  the  insulin 
sensitivity  index  between  phases  (WI  during  sodium  deplete  phase  0.08  +-  0.03  (SD)  vs  0.1 
0.05  (SD)  during  sodium  replete  phase  p=0.043).  The  mean  effect  was  a  fall  in  insulin 
153 sensitivity  of  1.4  mg/kg/min  (95%  CI  0.2-2.6),  which  equates  to  a  mean  11%  reduction 
(95%Cf2%-21%). 
While  data  from  all  volunteers  who  underwent  randomisation  were  included  in  the  main 
analysis,  a  subgroup  of  subjects  with  arbitrarily  defined  "gooX'  compliance  with  dietary 
sodium  restriction  (table  4.4)  (urinary  sodium  on  low  sodium  diet  <80mmol/24  hours)  was 
analysed.  In  this  group  (n7--11),  dietary  sodium  restriction  was  similarly  associated  with  a 
fall  in  insulin  sensitivity  (M  value  during  sodium  deplete  phase  11.45  ±  2.7  (SD) 
mg/kg/min  vs  13.1  d:  3.8  (SD)  mg/kgImin  during  sodium  replete  phase  p=0.045). 
4.3.9  Parameters  of  RAS  activation  and  insulin  sensitivity 
After  logarithmic  transformation,  baseline  values  of  renin,  angiotensin  II  and  aldosterone 
following  sodium  restriction  were  expressed  as  a  percentage  of  the  sodium  replete 
equivalent  values,  and  plotted  against  the  change  in  insulin  sensitivity  (the  M  value  during 
sodium  restriction  as  a  percentage  of  the  M  value  when  sodium  replete).  No  statistically 
significant  correlation  was  observed  between  any  of  these  variables  and  the  percentage 
change  in  insulin  sensitivity  (figure  4.5). 
4.3.10  Markers  of  endothelial  function 
Markers  of  endothelial.  function  (von  Willebrand  factor,  tissue  plasminogen  activator)  were 
measured  at  the  end  of  each  study  phase  to  determine  whether  sodium  restriction  has  an 
effect  on  the  endothelium.  There  was  no  statistically  significant  difference  in  any  of  these 
markers  between  phases  (table  4.1). 
154 Figure  4.1:  Sample  diet  sheet,  issued  to  volunteers  at  commencement  of  sodium 
restricted  diet. 
Food  Group  Salty  Foods  to  Avoid  Suitable  Alternatives 
Breakfast  All  others  Weetabix,  Shredded  Wheat 
Cereals 
Bread,  Cakes  All  others  Bread  (Wholemeal/white  max  4 
and  Biscuits  slices/day),  sweet  cakes  or 
sweet  biscuits  only. 
Starchy  All  others  Potatoes,  rice,  pasta. 
Carbohydrates 
Eggs  Scotch  Eggs  Boiled,  poached,  scrambled  or 
fried 
Milk  Salted  Lassi  Y2pint  semi-skimmed  milk 
daily 
Cheese  Cottage/cream  cheese, 
maximum  of  50g  daily 
Meats  and  Bacon,  ham,  gammon.  All  smoked  All  fresh  and  frozen  meats  e.  g. 
Poultry  meats.  Salami,  sausages,  beefburgers.  beef,  lamb,  pork,  turkey, 
Tinned  meats,  e.  g.  comed  beef,  luncheon  chicken  etc. 
meat.  Meat  pies  and  manufactured  meat 
dishes.  Dehydrated  packed  meals.  Meat 
paste  and  pate. 
Fish  All  smoked,  cured,  salted,  tinned  or  All  fresh  or  frozen  fish.  Fish  in 
pickled  fish.  Fish  paste  and  pate,  batter  or  breadcrumbs. 
taramasalata.  Shellfish  e.  g.  prawns, 
shri  s.  Manufactured  fish  dishes. 
Soups  Packet  and  tinned.  Home  made  soup  with  no  added 
salt  or  stock 
Drinks  Fruit  juice,  reduced  sugar  fruit 
squash,  diet  fizzy  drinks, 
mineral  water,  tea,  coffee,  tonic 
water. 
Fruit  Olives,  salted  nuts.  Fresh,  frozen  or  tinned  in 
natural  juice.  Unsalted  nuts. 
Vegetables  Tinned  unless  labelled  "no  added  salt".  Fresh,  frozen  or  tinned  in 
Baked  beans.  naturaIjuice. 
Spreads  All  others.  Polyunsaturated  margarine. 
Miscellaneous  Meat  or  yeast  extract  e.  g.  Bovril,  Use  black  pepper,  herbs  and 
Marmite,  Oxo.  Gravy  granules,  stock  spices  to  flavour  food.  Use 
cubes,  garlic  salt.  Pickles,  chutneys,  unsalted  snacks  or  fresh  or 
tomato  ketchup,  Worcester  sauce,  tomato  dried  fruit  as  snacks 
I  juice,  chilli  sauce.  I 
155 Table  4.1:  Comparison  of  body  weight,  blood  pressure  and  serum  biochemistry  after 
five  days  of  sodium  restricted  and  supplemented  diet. 
All  values  are  quoted  as  mean  ±  one  standard  deviation 
Parameter  Sodium  deplete  Sodium  replete  p  value 
Weight  (kg)  73  ±  9.1  74  ±  7.8  0.19 
Urinary  sodium  (mmol/24  hours)  70  ±45  175  ±  72.1  <0.001 
Baseline  serum  sodium  (mmol/1)  139.4  ±  1.72  141.2  ±  1.82  0.015 
Systolic  blood  pressure  (mmHg)  115±  12  115  ±  9.6  0.97 
Diastolic  blood  pressure  (mmHg)  58  ±  10.7  60  ±  8.2  0.33 
Fasting  total  cholesterol  (mmol/1)  4.0  ±  0.83  3.9  ±  0.81  0.14 
Fasting  triglycerides  (mmol/1)  0.8  ±  0.34  0.7  ±  0.45  0.8 
Growth  hormone  (mUII  0900  hrs))  1.5  ±  3.12  0.51±  0.69  0.3 
Noradrenaline  (nmol/1)  1.7  ±  0.86  1.7  ±  0.8  0.25 
Cortisol  (nmol/1'0900  hrs)  342  ±  135.0  286  ±  91.7  0.14 
von  Willebrand  factor  (%)  90  ±  0.4  85  ±  10.2  0.4 
Tissue  plasminogen  activator  (ng/ml)  6.3  ±  0.61  5.3+0.52  0.12 
156 Table  4.2:  Comparison  of  the  components  of  the  circulating  renin  angiotensin  system 
after  sodium  deplete  and  supplemented  diet. 
All  values  are  quoted  as  mean  ±  one  standard  deviation 
Parameter  Sodium  deplete  Sodium  replete  p  value 
Plasma  renin  activitv  (uU/ml) 
Time  0 
Time  180 
25.0+10.43 
24.9  11.16 
13.4  ±  7.28 
12.3  ±  6.58 
<0.001 
<0.001 
Plasma  a1dosterone  (ng/100ml) 
Time  0 
Time  180 
15.8  9.91 
11.6  9.18 
8.4  J:  5.77 
6.1  ±  3.89 
<0.05 
<0.05 
Plasma  angiotensin  II  A)F-/ml) 
Time  0 
Time  180 
28.5:  L  17.27 
28.3  ±  22.03 
11.0  d:  6.89 
12.3  :h6.85 
<0.001 
<0.005 
157 Table  4.3:  Comparison  of  euglycaemic  hyperinsulinaemic  clamp  results  on  day  flve 
after  sodium  deplete  and  supplemented  diet. 
All  values  are  quoted  as  mean  ±  one  standard  deviation 
Parameter  Sodium  deplete  Sodium  replete  p  value 
Fasting  insulin  (pU/ml)  11.6  ±  3.24  11.4  ±  3.02  0.83 
Fasting  C-peptide  1.7  ±  0.51  1.6  ±  0.53  0.21 
(ng/ml) 
Fasting  glucose  4.5  ±  0.33  4.5  ±  0.45  0.43 
(mmol/1) 
M  (mg/kg/min)  11.0  ±2.4  12.4  ±3.5  0.027 
Insulin  sensitivity  index  0.08  ±  0.03  0.1  ±  0.05  0.043 
(MM 
Mean  plasma  insulin 
180  minutes  142.1  ±  60.34  136.9  ±  70.24  0.37 
final  40  minutes  147.2  ±  68.16  138.1±  67.52  0.1 
158 Table  4.4:  Dietary  sodium  restriction  and  insulin  sensitivity;  subgroup  analysis  of 
"good"compliers  (n--Il) 
All  values  are  quoted  as  mean±  one  standard  deviation 
Parameter  Sodium  deplete  Sodium  replete  p  value 
M  (mgtkglmin)  11.4±  2.7  13.1±  3.8  <0.001 
Urinary  sodium 
(mmol/24  hours) 
47±  23  152±  62  0.045 
159 Figure  4.2:  Serum  insulin  during  euglycaemic  hyperinsulinaemic  clamp 
Serum  insulin  was  measured  throughout  the  euglycaemic  hyperinsulinaemic  clamps  during 
both  phases.  At  no  individual  time  point,  nor  as  a  mean  value  throughout  the  procedure, 
was  there  any  difference  in  serum  insulin  between  phases.  Error  bars  denote  the  standard 
error  of  the  mean. 
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Insulin  sensitivity,  measured  by  the  euglycaemic  hyperinsulinaemic  clamp,  was  measured 
after  the  sodium  deplete  and  replete  phases.  Insulin  sensitivity  was  significantly  reduced 
during  dietary  sodium  depletion  (M  value  12.4  ±  3.5  (SD)  mglkg/min  sodium  replete 
vs.  11.0  ±  2.4  (SD)  mg/kgImin  sodium  deplete,  p=0.027).  Values  shown  illustrate  the  mean 
ý--)  and  95%  confidence  intervals(-)for  each  phase. 
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161 Figure  4.4:  Salt  sensitivity  and  the  change  in  insulin  sensitivity  between  sodium 
replete  and  deplete  phases. 
Salt  sensitivity  (MAP  during  sodium  replete  minus  NIAP  during  sodium  deplete)  was 
plotted  against  the  absolute  change  in  insulin  sensitivity  (M  during  sodium  replete  minus  M 
during  sodium  deplete).  A  trend  was  observed  though  no  statistically  significant  correlation 
was  observed  (p>0.05  for  correlation). 
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162 Figure  4.5:  The  relationship  between  the  degree  of  activation  of  the  renin  anglotensin 
system  and  the  change  in  insulin  sensitivity. 
To  determine  whether  there  was  a  relationship  between  the  degree  of  change  (delta)  in  an  individual 
component  of  the  renin  angiotensin  and  the  change  in  insulin  sensitivity  between  phases,  these  values  were 
plotted,  after  log  transformation  of  the  values  for  percentage  change  (delta)  in  renin  /  angiotensin  II 
/aldosterone,  in  figures  4.5.1  (delta  renin  vs  delta  M,  p>0.05)  figure  4.5.2  delta  angiotensin  II  vs  delta  M, 
p>0.05)  and  figure  4.5.3  (delta  aldosterone  vs  delta  M  p>0.05). 
Figure  4.5.1 
4 
W-0.006 
log 
deplete 
2- 
renin  / 
replete  renin 
I- 
011 
0  50  100 
deplete  Wreplete  M  (%) 
Figure  4.5.2 
4- 
R2  =  0.0238 
3- 
log 
deplete  All  2- 
replete  All 
150 
0iI 
0  50  100  150 
deplete  MI  replete  M 
Figure  4.53 
4- 
log 
3- 
R2  =  0.012 
deplete 
2- 
aldolreplete 
aldo 
0 
0  50  100  150 
deplete  Wreplete  M  (%) 
163 4.4  Discussion 
This  is  the  first  study  to  show  that  a  modest  reduction  in  dietary  sodium  is  associated  with  a 
fall  in  insulin  sensitivity  measured  by  the  euglycaemic  hyperinsulinaernic  clamp  in  normal 
volunteers. 
Although  other  groups  have  demonstrated  that  sodium  restriction  may  be  associated  with 
insulin  resistance,  most  have  used  severe  dietary  restriction.  In  contrast,  the  present  study 
aimed  to  examine  the  effect  of  modest  sodium  restriction  to  between  60  and  80  mmol/day. 
Rather  than  supplying  volunteers  with  prepared  food,  they  were  simply  asked  to  follow  a 
diet  sheet  during  the  study.  Thus,  the  measures  used  to  reduce  dietary  sodium  were  simple, 
and  as  such  the  sodium  restriction  in  this  study  is  similar  to  the  strategies  recommended  to 
the  general  population  in  advice  on  low  sodium  diet.  It  is  therefore  possible  that  a  similar 
metabolic  outcome  may  be  anticipated,  were  dietary  sodium  restriction  to  be  applied  to  a 
larger  population. 
Despite  the  relatively  large  number  of  studies  that  have  investigated  the  effect  of  sodium 
restriction  on  insulin  sensitivity,  there  is  no  clear  consensus  of  opinion.  Several  potential 
explanations  for  the  heterogeneity  of  results  are  proposed.  Different  methods  used  to 
measure  insulin  sensitivity  may  explain  some  of  these  findings;  studies  have  measured 
fasting  and  post-load  insulin  (259),  the  insulin  tolerance  test(255),  the  CIGMA  (249),  the 
insulin  suppression  test  (260)  and  the  euglycaernic  hyperinsulinaernic  clamp(248).  The 
clamp  technique  is  the  accepted  gold  standard  in  the  measurement  of  insulin  sensitivity  and 
has  a  high  level  of  reproducibility  (see  table  1.1).  As  such,  the  change  in  insulin  sensitivity 
demonstrated  in  this  study  is  likely  to  reflect  a  definite  biological  change,  though  the 
magnitude  of  the  difference  may  have  been  beyond  the  resolution  of  detection  using 
164 alternative  techniques.  The  populations  studied  also  vary  between  studies,  as  in  addition  to 
normal  volunteers,  some  groups  have  considered  effects  on  hypertensives  ((251)  (252)  and 
subjects  with  type  2  diabetes  (254).  Not  all  studies  have  been  of  a  double-blind  crossover 
design  with  randomis  ed  phases  of  dietary  intervention,  incorporating  a  washout  period. 
Lastly,  and  perhaps  most  importantly,  the  degree  of  sodium  restriction  varies  from  a 
comparison  of  <Ommol/day  with  >200mmol/day,  to  the  more  modest  range  used  in  this 
study. 
In  a  randomised,  placebo-controlled  crossover  trial  in  34  normotensive  males,  Grey  et  al 
(249)  compared  insulin  sensitivity,  measured  by  continuous  infusion  of  glucose  and 
modelling  assessment  (CIGMA),  after  seven  days  of  dietary  sodium  intake  of 
<80mmol/day  plus  placebo  with  one  week  of  the  same  diet  though  supplemented  with 
120mmol  oral  sodium  daily.  Thus,  the  trial  design  was  similar  the  present  study  but  insulin 
sensitivity  was  measured  using  CIGMA,  which  makes  certain  physiological  assumptions 
(table  1.1).  Urinary  sodium  results  were  similar  to  those  described  in  the  present  study  (low 
sodium  52±25mmol/day,  high  sodium  186±46  mmol/day),  though  there  was  no  change  in 
insulin  sensitivity  between  phases.  It  is  unclear  why  I  have  found  a  difference  in  insulin 
sensitivity  using  a  similar  protocol.  As  discussed,  the  use  of  the  euglycaemic  clamp 
technique  may  have  enabled  me  to  detect  more  subtle  changes  in  insulin  sensitivity.  It  must 
also  be  noted  that  the  Grey  study  (249)  had  no  washout  period  between  phases.  Lastly,  the 
duration  of  diet  may  be  important.  In  type  2  diabetes,  Petrie  et  al  (254)  reported  a  reduction 
in  insulin  sensitivity  associated  with  dietary  sodium  restriction  for  five  days,  while  Fliser  et 
al  (248)  demonstrated  that  three  days  of  severe  sodium  restriction  was  associated  with  a 
reduction  in  insulin  sensitivity,  however  seven  days  of  the  same  diet  had  no  effect. 
165 By  measuring  renin,  aldosterone  and  angiotensin  II  after  both  phases  of  the  protocol,  I  have 
characterised  the  activity  of  the  RAS  in  response  to  our  dietary  intervention.  This  has 
shown  that  even  modest  sodium  restriction  is  associated  with  significant  elevations  of  all 
three  of  these  components,  and  therefore  overall  activation  of  the  system.  In  a  meta. 
analysis  of  trials  involving  low  sodium  diets,  analysis  of  20  populations  with  sodium 
excretion  reduced  to  between  40  and  100mmol  sodium/24  hours  demonstrated  that  this 
degree  of  dietary  sodium  restriction  resulted  in  a  twofold  increase  in  renin  and  aldosterone 
(355).  My  own  data  are  in  keeping  with  these  figures;  in  this  study  a  mean  sodium 
excretion  of  70.6  mmol/24  hours  was  associated  with  a  doubling  of  renin  and  aldosterone. 
To  put  these  in  some  context,  more  severe  sodium  restriction,  resulting  in  levels  of  urinary 
sodium  excretion  less  than  20mmol/24  hours,  was  associated  with  a  five-  to  six  fold 
increase  in  renin  and  aldosterone  (355).  Thus,  studies  using  more  severe  sodium  restriction 
than  my  own  have  resulted  in  more  dramatic  activation  of  the  RAS.  However,  using  a  less 
severe  sodium  restriction  I  was  still  able  to  elevate  renin,  aldosterone  and  AII.  As  the 
increase  in  the  activity  of  the  system  in  my  study  was  almost  exactly  to  the  level  seen  in 
similar  studies  of  sodium  restriction,  it  seems  unlikely  that  the  reason  for  demonstrating  an 
effect  on  insulin  sensitivity  was  due  to  unusually  high  activity  in  response  to  the  diet. 
Overall,  there  was  no  change  in  systolic  or  diastolic  blood  pressure  between  phases.  While 
severe  sodium  restriction  is  associated  with  a  reduction  in  blood  pressure  (354)  more 
modest  reductions  have  previously  been  reported  as  having  no  effect  (249).  Salt  sensitivity, 
considered  as  a  continuous  variable  or  defined  as  a  fall  in  MAP  Z!:  3mmHg,  may  be 
involved  in  the  subsequent  development  of  hypertension  (356)  and  may  also  be  related  to 
the  metabolic  response  to  sodium  restriction.  Melander  et  al  (354)  demonstrated  recently 
that  in  males  with  hypertensive  first-degree  relatives,  the  improvement  in  insulin  sensitivity 
166 associated  . with  high  (240mmol/24  hours)  vs  low  (10mmol/24  hours)  sodium  intake 
correlated  with  salt  sensitivity.  In  the  present  study,  a  similar,  though  weaker,  relationship 
was  observed  (figure  4.4).  1  did  not  observe  a  relationship  between  the  degree  of  salt 
sensitivity  and  the  activation  of  the  RAS.  This  may  reflect  the  more  modest  sodium 
restriction  and  more  physiological,  though  still  biologically  significant,  activation  of  the 
RAS  than  seen  in  other  studies. 
The  analyses  in  the  present  study  were  performed  on  all  15  patients  recruited.  Four 
volunteers  failed  to  reduce  urinary  sodium  excretion  to  less  than  100mmol  sodium/24  hours 
during  sodium  restriction,  however  it  was  felt  inappropriate  to  exclude  volunteers  on  this 
basis.  Three  of  these  volunteers  demonstrated  a  100%  increase  in  two  of  renin,  aldosterone 
and  All  between  high  and  low  sodium,  while  the  remaining  volunteer  increased  aldosterone 
by  >100%  between  phases.  Nonetheless,  after  exclusion  of  these  four  volunteers  from  the 
analysis,  insulin  sensitivity  continued  to  remain  lower  during  the  low  sodium  phase  (table 
4.4). 
No  difference  in  total  cholesterol  or  triglycerides  was  seen  between  phases.  Fliser  et  al 
(246)  demonstrated  that  total  cholesterol  rose  in  association  with  severe  sodium  restriction, 
however  using  a  less  severe  regime,  Grey  et  al  (249)  found  no  effect  on  total  cholesterol, 
though  noted  a  rise  in  HDL3  during  sodium  restriction.  In  addition,  sodium  restriction  was 
not  associated  with  any  change  in  the  concentrations  of  circulating  markers  of  endothelial 
function.  It  has  been  demonstrated  that  3  weeks  of  severe  sodium  restriction  in  WKY  rats 
(274)  has  a  deleterious  effect  on  the  endothelium;  these  results  would  not  support  that 
observation,  however  this  was  not  the  primary  question  that  the  present  study  was  designed 
to  answer,  and  the  strength  of  the  relationship  between  circulating  markers  and  more  direct 
167 functional  measurements  (the  WKY  studies  were  undertaken  in  aortic  ring  preparations)  of 
endothelial  integrity  is not  clear. 
The  mechanism  through  which  sodium  restriction  has  reduced  insulin  sensitivity  in  this 
study  is  unclear.  The  lack  of  a  significant  difference  in  noradrenaline,  cortisol  and  growth 
hormone  between  phases  suggests  that  these  hormones  are  not  responsible,  though  it  is 
acknowledged  that,  for  example,  measurement  of  plasma  noradrenaline  is  not  an  ideal 
marker  of  activity  of  the  sympathetic  nervous  system.  In  addition,  there  are  other  hormones 
that  may  be  involved  which  were  not  measured,  such  as  antidiuretic  hormone  and  atrial 
natriuretic  hormone.  The  most  obvious  candidate  hormones  that  may  underlie  a  direct 
effect  are  the  activated  components  of  the  RAS,  in  particular  aldosterone  and  angiotensin 
II.  In  two  recent  studies,  aldosterone  was  found  to  correlate  positively  with  insulin 
resistance  (357)  and  negatively  with  insulin  sensitivity  (358).  A  potential  molecular 
explanation  for  this  has  been  proposed  from  work  in  cultured  human  promonocytes,  where 
aldosterone  treatment  reduced  insulin  receptor  mRNA  in  a  dose  and  time  dependent  manner 
(359).  Interestingly,  aldosterone  has  also  been  shown  to  correlate  negatively  with  plasma 
levels  of  HDL-cholesterol,  another  component  of  the  metabolic  syndrome  (247).  In  50 
untreated  hypertensive  patients,  however,  Lind  et  al  (360)  observed  no  correlation  between 
aldosterone  and  insulin  sensitivity,  though  did  find  a  relationship  between  insulin  resistance 
and  plasma  renin  activity.  In  my  study,  there  was  no  strong  relationship  between  these  two 
variables  and  insulin  sensitivity. 
It  has  also  been  demonstrated  in  rodent  cardiac  and  aortic  smooth  muscle  that  AII  may  have 
an  effect  of  cellular  insulin  responsiveness  by  intracellular  crosstalk  between  signalling 
168 intermediates  (314).  This  potential  mechanism  through  which  activation  of  the  RAS  may 
reduce  insulin  sensitivity  is  explored  further  in  chapter  5. 
The  lack  of  prospective  studies  of  insulin  sensitivity  and  cardiovascular  end-points  makes  it 
difficult  to  quantify  the  risk  associated  with  an  11%  fall  (as  seen  here  in  response  to  sodium 
restriction)  in  insulin  sensitivity.  Cross  sectional  data  from  the  IRAS  study  (361) 
demonstrate  a  continuous  relationship  between  insulin  sensitivity  (measured  using  the 
frequently  sampled  intravenous  glucose  tolerance  test)  and  the  intimal.  media  thickness  of 
the  internal  carotid  artery.  Furthermore,  longitudinal  follow  up  of  cohorts  of  healthy  males 
from  Paris  and  HelsinId  suggest  that  fasting  hyperinsulinaemia,  as  a  surrogate  for  insulin 
resistance,  is  associated  with  an  adverse  cardiovascular  outcome.  To  put  this  reduction  in 
insulin  sensitivity  in  some  context,  several  authors  have  considered  a  negative  effect  on 
insulin  sensitivity  as  a  potential  mechanism  to  explain  the  disappointing  effects  on 
cardiovascular  mortality  of  beta-blockers  in  the  treatment  of  hypertension.  Atenolol  was 
shown  to  reduce  insulin  sensitivity  (measured  by  the  euglycaernic  hyperinsulinaemic 
clamp)  by  12%  after  4-6  weeks  of  treatment  (362),  leading  the  authors  to  speculate  that  this 
metabolically  adverse  action  may  reduce  the  overall  gain  otherwise  associated  with  a 
reduction  in  blood  pressure. 
In  summary,  I  have  demonstrated  that  modest  sodium  restriction  is  associated  with  a 
reduction  in  insulin  sensitivity.  While  this  has  been  demonstrated  previously  using  strict 
dietary  regimes  that  are  difficult  to  adhere  to  over  prolonged  periods,  the  present  study  used 
a  more  modest,  and  therefore  palatable,  diet.  Despite  this,  activation  of  the  RAS  was 
achieved  in  all  volunteers,  with  no  significant  increase  in  the  activity  of  other  neurohumoral 
systems.  I  suggest  that  this  modest  reduction  in  insulin  sensitivity  may  be  of  clinical 
169 importance,  perhaps  contributing  to  the  disappointing  effects  of  sodium  restriction  on 
mortality  in  the  general  population  (242). 
170 Chapter  5:  Angiotensin  11  and  insulin  sensitivity  in  human  adipocytes 
5.1  Introduction 
In  the  previous  chapter  modest  dietary  sodium  restriction  was  shown  to  be  associated  with  a 
significant  reduction  in  whole  body  insulin  sensitivity.  The  underlying  mechanism  is 
unclear,  however  it  has  been  suggested  tha.  t  this  effect  may  secondary  to  activation  of  the 
RAS,  possibly  mediated  by  a  direct  effect  of  angiotensin  II  on  insulin  action.  In  support  of 
this,  some  groups  have  found  an  improvement  in  insulin  sensitivity  in  association  with 
ACE  inhibition  (279)  (278),  while  others  have  observed  increased  frequency  of 
hypoglycaemia  in  patients  with  type  I  diabetes  treated  with  ACE  inhibition  (285,363)  (see 
section  1.11.7  . 
Data  from  rodent  cardiac  myocytes  and  aortic  smooth  muscle  cells  have  highlighted  a 
potential  mechanism  through  which  angiotensin  H  may  reduce  insulin  sensitivity  at  the 
cellular  level.  Angiotensin  H  was  found  to  reduce  the  insulin  stimulated  activation  of 
Insulin  Receptor  Substrate  1  (IRS-1)  -  associated  phosphatidylinositol  3'  Idnase  (P13'- 
Idnase)  in  both  of  these  cell  lines,  possibly  via  ATJ  receptor  mediated  phosphorylation  of 
serine/threonine  residues  on  the  regulatory  subunit  of  this  key  signalling  intermediate 
(314,315).  Downstream  effects  of  insulin  stimulation  are  mediated  predominantly  by  IRS-1 
and  -2  associated  P13'-Idnase.  This  step  plays  a  pivotal  role  in  the  translocation  of  the 
insulin  responsive  glucose  transporter  GLUT4  to  the  cell  surface  and  in  the  regulation  of 
hormone  sensitive  lipase;  as  such,  any  reduction  in  the  activity  of  this  enzyme  may  be 
anticipated  to  reduce  insulin-stimulated  glucose  transport  and  insulin-mediated  suppression 
171 of  lipolysis.  These  important  metabolic  end-points  were  not  measured  in  the  initial  reports 
of  intracellular  crosstalk  between  insulin  and  angiotensin  II  signalling. 
This  chapter  tests  the  hypothesis  that  angiotensin  I[[  will  reduce  insulin-stimulated  glucose 
uptake  and  insulin-mediated  suppression  of  lipolysis  in  human  adipose  tissue.  While  this 
intracellular  crosstalk  has  thus  far  only  been  demonstrated  in  rodent  muscle  cells,  I  have 
studied  this  relationship  in  human  adipocytes.  As  well  as  being  more  accessible  than  human 
muscle  cells,  adipocytes  are  a  well-characterised  insulin  responsive  tissue.  In  addition,  over 
the  last  ten  years  it  has  become  evident  that  adipose  tissue  is  one  of  the  many  sites  that 
possess  a  local  RAS  (200,201),  and  as  such  any  interaction  between  AII  and  insulin  may  be 
of  physiological  importance  in  determining  local  and  systemic  insulin  sensitivity. 
172 5.2  Methods 
5.2.1  Recruitment  of  subjects 
Subjects  were  recruited  as  outlined  in  materials  and  methods.  All  subjects  were  female  in- 
patients  undergoing  gynaecological  surgery  for  non-malignant  disease,  and  were  excluded 
if  they  were  hypertensive,  aged  over  60  years,  had  a  BMI  >  33  kg/m  2  or  were  using 
intercurrent  drug  therapy.  Between  one  and  five  grams  of  peri-umbilical  subcutaneous 
adipose  tissue  was  dissected  from  each  subject. 
5.2.2  Laboratory  methods 
A  detailed  description  of  the  methods  of  adipocyte  isolation,  preparation  of  membrane 
fractions,  radioligand  binding,  Western  Blotting,  glucose  transport  and  NEFA  assays  is 
found  in  Chapter  2. 
5.2.2.1  Radioligand  binding  studies 
f 
Adipocyte  membranes  were  incubated  in  the  presence  of  InM  125  I-labelled  (Sar',  Ile8) 
angiotensin  H  with  or  without  10liM  losartan  (a  specific  ATI  receptor  antagonist).  The 
losartan  displaced  binding  was  taken  to  be  the  amount  of  AII  bound  to  the  ATI  receptor,  as 
is  fully  described  in  Chapter  2.2.1.6. 
5.2.2.2  Western  blotting  of  human  adipocyte  membranes  for  the  AT1  receptor 
Human  adipocyte  membranes  were  prepared  as  described,  and  electrophoresed  on  a  iO% 
polyacrylamide  gel.  Protein  was  then  transferred  onto  nitrocellulose,  and  probed  with  anti- 
angiotensin  II  type  I  receptor  antibody  (Autogen  Bioclear  UK  Ltd),  then  anti-rabbit  HRP 
173 labelled  secondary  antibody.  Membranes  prepared  from  rodent  vascular  smooth  muscle 
cells  were  included  as  a  positive  control. 
5.2.2.3  Glucose  transport  assays 
A  full  description  of  the  glucose  transport  assay  is  included  in  the  materials  and  methods 
section.  Cells  were  incubated  with  angiotensin  II  for  30  minutes  to  examine  whether  AII 
has  an  effect  on  glucose  transport  in  the  absence  of  insulin.  To  assess  the  effect  of 
angiotensin  H  on  insulin-stimulated  glucose  transport,  increasing  concentrations  of  AR 
were  added  to  a  single  concentration  of  insulin,  and  increasing  concentrations  of  insulin 
were  added  to  a  single  concentration  of  AII. 
5.2.2.4  Angiotensin  H  and  lipolysis 
Equivalent  experiments  were  undertaken  for  the  analysis  of  the  effect  of  All  on  lipolysis, 
both  in  the  presence  and  absence  of  insulin,  using  the  previously  described  methods. 
5.2.3  Statistical  analysis 
For  binding  assays,  mean  values  of  specific  AR  binding  were  compared  with  non-specific 
binding  using  a  paired  t-test.  The  area  under  the  curve  (AUC)  for  glucose  uptake  and 
suppression  of  lipolysis  was  calculated  for  each  assay  using  the  method  described  by 
Matthews  for  the  analysis  of  serial  measurements  (343).  Comparisons  of  these  parameters 
with  and  without  AIII  were  made  using  a  paired  t-test.  Glucose  uptake  and  lipolysis  were 
compared  for  each  concentration  of  AII  with  basal  levels  using  paired  t-tests.  Data  are 
expressed  as  mean  and  standard  error. 
174 5.3  Results 
5.3.1  The  angiotensin  11  receptor  and  human  adipose  tissue 
Immunoblotting  unstimulated  adipose  tissue  membranes  with  a  specific  antibody  (figure 
5.1)  confirmed  the  presence  of  the  Angiotensin  Il  Type  1  (ATI)  receptor,  as  evidenced  by  a 
cross-reacting  species  at  the  expected  molecular  weight  and  at  a  similar  position  to  the  ATI, 
receptor  expressed  in  vascular  smooth  muscle  cells. 
Radioligand  binding,  using  vascular  smooth  muscle  cells  as  a  positive  control  and  losartan 
to  displace  specific  binding  at  the  AT1  receptor,  demonstrated  the  presence  of  binding  to 
the  ATI  receptor  in  human  adipocyte  membranes  (figure  5.2)  with  a  mean  value  of  22  ±3 
finol  AH  bound  per  mg  membrane  protein  (n--4).  As  anticipated,  binding  to  the  AT1 
receptor  in  vascular  smooth  muscle  cell  membranes  was  of  far  greater  magnitude  (706 
147  finol  AH  bound  per  mg  membrane  protein,  n---4)  (figure  5.3). 
5.3.2  Angiotensin  H  and  glucose  transport 
5.3.2.1  Angiotensin  H  alone 
Human  adipocytes  were  incubated  with  increasing  doses  of  AH  and  glucose  uptake  assayed 
as  described  in  materials  and  methods.  As  shown  in  figure  5.4,  no  effect  of  physiological  or 
pharmacological  concentrations  of  AII  was  observed  on  adipocyte  glucose  transport  in  the 
absence  of  insulin  (p=ns  for  comparison  of  glucose  transport  between  any  single  AII 
concentration  and  basal  glucose  uptake). 
175 5.3.2.2  Angiotensin  11  and  insulin 
Co-incubation  of  increasing  doses  of  angiotensin  II  with  lOnM  insulin  (figure  5.5)  had  no 
effect  on  insulin-stimulated  glucose  uptake  into  adipocytes  (p=ns  for  comparison  of  glucose 
transport  at  lOnM  insulin  ±  AII  at  all  concentrations). 
Preliminary  experiments,  limited  by  tissue  availability,  showed  no  effect  of  lOOnM  AH 
(figure  5.6.1)  or  IAM  AII  (figure  5.6.2)  on  glucose  transport  (pýs  for  comparison  of 
insulin-stimulated  glucose  transport  ±AII).  More  complete  concentration  response  curves 
comparing  insulin-stimulated  glucose  transport  with  and  without  AH  incubation  again 
demonstrated  no  effect  of  AH  (figure  5.7,5.8)  (p=ns  for  comparison  of  AUC  of  insulin- 
stimulated  glucose  transport  AAII). 
5.3.3  Angiotensin  H  and  insulin-mediated  suppression  of  lipolysis 
AH  concentration  response  curves  showed  no  significant  effect  on  NEFA  release  over  the 
concentratioýs  tested  (p=ns  for  NEFA  release  at  any  concentration  of  AII,  compared  with 
basal  NEFA  release  (figure  5.9.1).  As  adenosine  has  an  anti-lipolytic  action,  I  considered 
the  possibility  that  a  weak  lipolytic  action  of  angiotensin  11  may  be  overwhelmed  by 
adenosine;  however,  in  adenosine-free  buffer,  again  no  effect  of  increasing  concentrations 
of  AR  was  observed  on  adipocyte  release  of  NEFA  (figure  5.9.2). 
As  shown  in  chapter  3,  preliminary  studies  using  the  P13'-Idnase  inhibitor  wortmannin 
confirmed  that  insulin-mediated  suppression  of  isoproterenol-induced  lipolysis  is  indeed 
P13'-Idnase  dependent.  As  such,  any  negative  effect  of  angiotensin  II  on  insulin  -  mediated 
activation  of  P13'-Idnase  would  be  anticipated  to  translate  to  a  reduction  in  insulin- 
mediated  suppression  of  lipolysis;  however,  co-incubation  of  angiotensin  II  with  insulin 
176 and  isoproterenol  had  no  effect  on  the  liberation  of  NEFA  from  adipocytes  (p=ns  for 
companson  of  AUC  of  insulin-mediated  attenuation  of  isoproterenol-induced  lipolysis 
AII)  (figure  5.10). 
177 Figure  5.1:  Western  blot  of  human  adipocyte  membrane  fraction  for  angiotensin  11 
type  I  receptor. 
Human  adipocyte  membrane  fraction  (20ýtg)  (far  right  lane),  with  vascular  smooth  muscle 
membranes  (50ýtg)  (far  left  lane)  as  a  positive  control,  probed  with  anti  -anglotens  In  11  type 
I  receptor  antibody.  The  middle  three  lanes  represent  subcellular  fractionation  of  murme 
3T3  Ll  adipocytes.  (HDM=  high-density  microsomes,  LDW  low-density  microsomes, 
PM=  plasma  membrane)  and,  for  the  purposes  of  this  thesis,  should  be  disregarded.  The 
result  shown  is  representative  of  three  similar  experiments. 
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178 Figure  5.2:  Angiotensin  11  binding  to  human  adipocyte  membranes. 
The  results  shown  represent  the  mean  (±  sem)  of  four  experiments,  each  of  which  was 
analysed  in  duplicate.  A  significant  difference  was  demonstrated  between  the  total  binding 
of  radiolabelled  angiotensin  11  and  non-specific  binding  (binding  of  radiolabelled 
anglotensin  II  in  the  presence  of  the  ATI  receptor  blocker  losartan)  (p=0.008)  which 
represented  specific  binding  to  the  ATI  receptor.  Mean  binding  to  the  ATI  receptor  in 
human  adipocyte  membranes  was  22±3  finol  All  bound  per  mg membrane  protein. 
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179 Figure  5.3:  Angiotensin  11  binding  to  human  vascular  smooth  muscle  membranes. 
The  results  shown  represent  the  mean  (±  sem)  of  four  expenments,  each  of  which  was 
analysed  in  duplicate.  A  significant  difference  was  demonstrated  between  total  binding  and 
non-specific  binding,  representing  specific  binding  to  the  AT  I  receptor  (p<0.00  1). 
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180 Figure  5.4:  Angiotensin  11  and  glucose  uptake  in  human  adipocytes. 
Adipocytes  were  incubated  with  increasing  concentrations  of  angiotensin  11  (1  nM-  I  pM)  for 
30  minutes  and  glucose  uptake  assayed.  Adipocyte  glucose  uptake  was  considered  the 
amount  of  3H  2-deoxyglucose  associated  with  adipocytes  after  incubation  with  angiotensin 
II  for  30  minutes  and  expressed  as  a  fold  change  relative  to  the  amount  of'  3H  2- 
deoxyglucose  taken  up  into  adipocytes  in  the  basal  state.  No  difference  in  glucose  uptake 
was  evident  at  the  concentrations  of  angiotensin  11  tested  (p=ns  for  comparison  Of  gILICOSe 
uptake  at  all  All  concentrations  vs.  glucose  uptake  basally).  The  results  shown  represent  the 
mean  (±  sem)  of  five  experiments,  in  which  each  individual  sample  was  analysed  in 
tnplicate. 
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-09  -08  -07  -ob Figure  5.5:  Insulin-stimulated  glucose  uptake  and  coincubation  with  increasing 
concentrations  of  angiotensin  Il 
Insulin-  stimulated  glucose  transport  in  human  adipose  tissue  in  response  to  insulinlOnM 
alone  was  compared  with  coincubation  with  increasing  doses  of  All  +  insulin  lOnM. 
Adipocyte  glucose  uptake  was  considered  the  amount  of  3H  2-deoxyglucose  associated 
with  adipocytes  after  incubation  with  insulin  (doses  shown)  ±  angiotensin  11  (doses  shown) 
for  30  minutes  and  expressed  as  a  fold  change  relative  to  the  amount  of  3H  2-deoxyglucose 
taken  up  into  adipocytes  in  the  basal  state  (having  excluded  the  3H  2-deoxyglucose  uptake 
in  the  presence  of  cytochalasin  B,  considered  non-facilitative).  The  values  are  generated 
from  the  means  of  four  identical  experiments,  ±  sem.  All  individual  samples  were  measured 
in  triplicate.  There  was  no  significant  effect  of  angiotensin  11  on  insulin-stimulated  glucose 
uptake  (p>0.05  for  all  comparisons). 
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182 Figure  5.6:  Angiotensin  H  and  insulin-stimulated  glucose  uptake  in  human  adipocytes. 
The  effect  of  15  minutes  pre-incubation  with  AII  1  OOnM  (figure  5.6.1)  and  AII  I  AM  (figure 
5.6.2)  on  insulin-stimulatcd  glucose  uptake  in  human  adipose  tissue  was  examined.  The 
values  shown  represent  the  means  ±  s.  e.  m.  of  three  sets  of  experiments  for  both  datasets, 
with  all  individual  samples  analysed  in  triplicate.  Adipocyte  glucose  uptake  was  considered 
to  be  the  amount  of  3H  2-deoxyglucose  associated  with  adipocytcs  after  incubation  with 
insulin  (doses  shown)  ±  angiotensin  II  (doses  shown)  for  30  minutes  and  expressed  as  a 
fold  change  relative  to  the  amount  of  3H  2-deoxyglucose  taken  up  into  adipocytes  in  the 
basal  state  (having  excluded  the  3H  2-deoxyglucose,  uptake  in  the  presence  of  cytochalasin 
B,  considered  non-facilitative).  These  assays  were  limited  by  tissue  availability,  hence  the 
limited  concentrations  of  AIII  used.  There  was  no  significant  effect  of  angiotensin  II  on 
insulin-stimulated  glucose  transport. 
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183 Figure  5.7:  Angiotensin  11  pre-incubation  and  insulin-stimulated  glucose  uptake  in 
human  adipose  tissue. 
The  effect  of  angiotensin  II  (100nM)  pre-treatment  (15  minutes)  on  insulin-stimulated 
glucose  transport  in  human  adipose  tissue  was  examined.  Adipocyte  glucose  uptake  was 
considered  the  amount  of  3H  2-deoxyglucose  associated  with  adipocytes  after  incubation 
with  insulin  (doses  shown)  ±  angiotensin  II  (doses  shown)  for  30  minutes  and  expressed  as 
a  fold  change  relative  to  the  amount  of  3H  2-deoxyglucose  taken  up  into  adipocytes  in  the 
basal  state  (having  excluded  the  3H  2-deoxyglucose  uptake  in  the  presence  of  cytochalasin 
B,  considered  non-facilitative).  The  results  shown  represent  the  mean  (d:  sem)  of  four 
experiments,  each  sample  of  which  was  analysed  in  triplicate.  There  was  no  effect  of 
angiotensin  II  on  insulin  stimulated  glucose  uptake  (p>0.05  for  comparison  of  AUC  insulin 
alone  vs  angiotensin  II  +  insulin). 
4.5 
4 
3.5 
3 
increase  in 
glucose  uptake 
2.5 
2 
1.5 
1 
0.5 
0 
All  lOOnM 
pretreatment 
0  -11  -10  -09  -08  -07 
insulin  logM 
184 Figure  5.8:  lnsulin-stimulated  glucose  uptake  and  coincubation  with  angiotensin  II. 
The  effect  of  angiotensin  H  (IOOnM)  coincubation  on  insulin-stimulated  glucose  transport 
was  examined  in  human  adipose  tissue.  Adipocyte  glucose  uptake  was  considered  the 
amount  of  3H  2-deoxyglucose  associated  with  adipocytes  after  incubation  with  insulin 
(doses  shown)  ±  angiotensin  III  IOOnM  for  30  minutes  and  expressed  as  a  fold  change 
relative  to  the  amount  of  3H  2-deoxyglucose  taken  up  into  adipocytes  in  the  basal  state 
(having  excluded  the  3H  2-deoxyglucose  uptake  in  the  presence  of  cytochalasin.  B, 
considered  non-facilitative).  The  results  shown  represent  the  mean  (+-sem)  of  four 
experiments,  each  sample  of  which  was  analysed  in  triplicate.  There  was  no  effect  of 
angiotensin  II  on  insulin  stimulated  glucose  uptake  (p>0.05  for  comparison  of  AUC  insulin 
alone  vs  angiotensin  H+  insulin). 
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incubation Figure  5.9:  Angiotensin  11  and  release  of  NEFA  from  adipocytes. 
The  effect  of  45  minutes  of  coincubation  with  angiotensin  III  on  NEFA  release  from  isolated 
human  adipocytes  in  ihe  presence  (figure  5.9.1)  and  absence  (figure  5.9.2)  of  adenosine 
(lOOnM)  and  isoproterenol  (2OOnM).  The  NEFA  release  in  response  to  isoproterenol  alone 
is  taken  as  the  100%  value  in  5.9.1,  while  the  basal  value  in  5.9.2  is  the  NEFA  release  from 
unstimulated  adipocytes,  with  all  other  values  expressed  as  a  percentage  of  this.  For  both 
graphs,  the  results  shown  represent  the  means  (±sem)  of  four  experiments,  with  the 
individual  samples  analysed  in  duplicate.  There  was  no  effect  of  angiotensin  II  on  NEFA 
release,  either  in  the  presence  or  absence  of  adenosine  and  isoprenaline  (p>0.05  comparing 
angiotensin  H  NEFA  release  with  no  angiotensin  II). 
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basal  -9  -8  -7  -6  -8  -6 Figure  5.10:  Angiotensin  11  and  insulin-mediated  suppression  of  lipolysis 
The  effect  of  angiotensin  H  (ljLM)  co-incubation  on  insulin-mediated  suppression  of 
lipolysis  was  examined  in  human  adipocytes.  The  NEFA  release  in  response  to 
isoproterenol  alone  is  taken  as  the  100%  value,  with  all  other  values  expressed  as  a 
percentage  of  this.  The  results  shown  represent  the  mean  (±sern)  of  four  experiments,  each 
sample  of  which  was  analysed  in  duplicate.  There  was  no  effect  of  angiotensin  II  on 
insulin-mediated  suppression  NEFA  release  (p>0.05  comparing  AUC  insulin  alone  with 
insulin  +angiotensin  II) 
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187 5.4  Discussion 
I  have  demonstrated  that  human  adipose  tissue  expresses  the  ATI  receptor,  and  that  AH 
binds  to  this  receptor  after  digestion  and  isolation  of  cells  according  to  my  protocol. 
However,  All  treatment  had  no  effect  on  insulin-stimulated  glucose  uptake  or  suppression 
of  lipolysis. 
These  experiments  were  undertaken  to  test  the  hypothesis  that  AH  may  reduce  insulin 
responsiveness  at  the  cellular  level,  and  explain  why  activation  of  the  RAS  in  response  to 
dietary  sodium  restriction  is  associated  with  a  reduction  in  whole  body  insulin  sensitivity. 
The  main  sites  of  peripheral  glucose  uptake  in  vivo  are  skeletal  muscle  and  adipose  tissue, 
with  recent  evidence  proposing  that  the  contribution  of  adipose  tissue  insulin  sensitivity  to 
the  phenotype  is  considerably  more  important  than  hitherto  appreciated  (119),  (120). 
Skeletal  muscle  and  adipose  tissue  have  similar  insulin-signalling  cascades,  suggesting  that 
any  effect  seen  in  adipose  fissue  may  be  extrapolated  to  muscle.  From  a  more  practical 
standpoint,  it  is  very  difficult  to  obtain  the  volume  of  human  skeletal  muscle  necessary  to 
undertake  the  assays  described  above. 
Two  techniques  were  employed  to  confirm  the  presence  of  the  AT1  receptor  in  adipocytes 
prepared  using  my  digestion  and  isolation  protocol.  Immunoblotting  of  adipocyte 
membranes  prepared  from  fresh  adipocytes  demonstrated  that  the  protein  was  expressed  in 
these  cells.  This  did  not  however  confirm  that  the  receptor  binds  AII  under  the  conditions 
used  in  the  laboratory,  and  so  competitive  radioligand  binding  studies  were  undertaken. 
These  confirmed  that  adipocytes  do  indeed  bind  AH,  and  that  this  is  displaced  by  losartan, 
implying  specific  binding  to  the  ATI  receptor. 
188 The  finding  that  human  adipose  tissue  expresses  constituents  of  the  RAS  is  not  novel,  as 
there  is  now  considerable  evidence  to  suggest  that  a  locally  regulated  RAS  is  present  in 
adipose  tissue(364).  In  particular,  Crandall  et  al  (204)  undertook  detailed  binding  studies  in 
human  subcutaneous  adipocytes,  using  similar  methods  to  those  employed  in  this  thesis, 
and  demonstrated  ATI  receptor  binding  with  a  mean  maximum  binding  capacity  of  27.3  ± 
9.3  fmol  AH/mg  protein,  and  an  IC50  for  losartan  of  1.614-  0.45  x  10's.  Competitive  binding 
studies  using  the  AT2  receptor  blocker  PD  123  319  suggested  no  binding  at  this  receptor. 
This  binding  capacity  is  similar  to  the  findings  described  in  the  present  chapter.  The 
combination  of  my  own  studies  with  data  from  other  groups  (204)  provides  firm  evidence 
of  the  presence  of  the  AT1  receptor  in  human  adipose  tissue,  and  confirms  that  adipose 
tissue  is  a  suitable  tissue  in  which  to  investigate  my  hypothesis. 
The  notion  that  AH  may  have  a  direct  effect  on  cellular  insulin  sensitivity,  mediated  at  the 
level  of  intr-Acellular  second  messengers,  was  proposed  in  two  papers.  The  first  of  these 
found  that  in  cardiac  myocytes  from  animals  injected  with  AR  2  minutes  prior  to  excision, 
insulin  stimulated  activation  of  PI3'-Idnase  was  reduced  by  40%  (314).  This  effect  of  All 
was  mediated  via  the  ATI  receptor,  and  involved  the  recruitment  of  the  intracellular  Janus 
Kinase-2  enzyme.  The  second  paper  studied  the  nature  of  the  intracellular  crosstalk  in 
rodent  aortic  vascular  smooth  muscle  cells.  Again,  AH  reduced  insulin  stimulated  IRS-I 
associated  PI3'-Idnase  activity  by  60%  (315),  though  in  these  cells  blocldng  the  ATI 
receptor  did  not  diminish  this  action.  This  effect  was  mediated  by  crosstalk  between 
intracellular  AII  and  insulin-signalling,  involving  the  phosphorylation  of  serine/threonine 
residues  on  the  regulatory  subunit  of  P13'-Idnase. 
189 There  are  no  published  data  investigating  the  effects  of  AII  on  insulin  stimulated  glucose 
transport  in  human  tissue.  Baba  et  al  (322)  did  examine  the  effect  of  AH  on  insulin 
stimulated  tyrosine  kinase  activity  in  isolated  human  adipocytes,  and  found  no  effect. 
Patiag  et  al  (365)  inv  estigated  the  effect  of  AII,  and  AII  receptor  blockade,  in  cultured 
myoblasts  and  again  showed  that  AII  co-incubation  did  not  alter  insulin  sensitivity  at  the 
cellular  level. 
Thus,  this  work  is  the  first  to  consider  the  potentially  important  effect  of  AH  on  insulin 
regulated  cellular  processes  in  human  tissue.  I  have  found  no  effect  of  AII  on  insulin- 
stimulated  glucose  transport  or  suppression  of  lipolysis.  In  the  crosstalk  studies,  the 
concentration  of  AIII  that  inhibited  P13'-Idnase  activation  was  lOOnM.  I  have  used  AII 
doses  of  between  InM  and  IuM  and  found  no  effect.  It  is  possible  that  I  have  missed  an 
effect  of  AH  at  very  high  or  low  doses,  though  this  seems  unlikely  given  the  range  of  doses 
that  I  have  tested.  It  may  be  that,  despite  demonstrating  that  AT1  receptors  are  present  in 
adipocytes  i9olated  using  my  protocol,  other  important  components  of  the  signalling 
machinery  necessary  to  generate  this  crosstalk,  such  as  JAK2,  are  expressed  at  insufficient 
levels  in  adipocytes  compared  with  myocytes.  Were  this  the  case,  however,  an  effect  would 
be  anticipated  in  myoblasts,  and  this  is  not  the  case  (365). 
It  seems  more  likely  that  this  crosstalk  in  response  to  AH  and  insulin  does  occur  in 
metabolically  active  cell  lines,  however  the  reduction  in  IRS-1  associated  P13'-kinase 
activity  is  not  translated  into  effects  on  glucose  transport  or  lipolysis.  This  raises  questions 
about  the  absolute  requirement  for  IRS-1  associated  P13'-Idnase  activity  in  cellular  insulin 
action,  and  has  support  from  some  of  the  published  literature.  In  insulin  resistant 
adipocytes,  IRS-1  associated  P13'-kinase  activity  is  reduced,  however  IRS-2  associated 
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mice,  though  the  animals  are  growth  retarded  and  hypertriglyceridaernic,  they  are  not 
diabetic.  In  contrast,  mice  lacking  IRS-2  do  indeed  develop  diabetes  at  an  early  age  (89). 
Thus  there  are  situations,  manufactured  and  natural,  in  which  a  reduction  in  IRS-1 
associated  P13'-Icinase  is  not  associated  with  a  reduction  in  glucose  transport,  and  so 
perhaps  the  effect  of  AH  on  IRS-1  associated  P13'-Idnase  is  compensated  similarly  by 
altemative  metabolic  pathways. 
No  effect  of  AH  was  seen  on  glucose  transport  in  the  absence  of  insulin,  though  incubation 
times  were  of  a  relatively  short  duration  (though  long  enough  to  demonstrate  binding).  It 
addition,  a  relatively  small  effect  on  glucose  transport  cannot  be  excluded  as  this  may  be 
beyond  the  sensitivity  of  the  assay  system. 
I  was  not  able  to  demonstrate  a  statistically  significant  effect  of  AH  on  the  release  of  NEFA 
from  isolated,  adipocytes,  however  it  is  suggested  in  the  concentration  response  curves,  both 
with  and  without  isoproterenol  and  adenosine  (figure  5.9.1  and  5.9.2)  that  there  may  be  a 
modest  effect  to  increase  release  of  NEFA.  AH  has  been  reported  to  stimulate  the  release  of 
prostaglandins  from  isolated  rat  adipocytes  (210),  using  arachidonic  acid  as  a  substrate 
derived  from  cellular  phospholipid  breakdown,  though  not  triacylglycerol  lipolysis.  The 
reagents  in  the  NEFA  assay  detect  the  presence  of  arachidonic  acid,  and  so  this  modest 
increase  in  NEFA  at  high  AII  doses  may  represent  the  liberation  of  arachidonic;  acid  rather 
than  triglyceride  lipolysis.  Angiotensin  H  may,  however,  play  a  relatively  minor  role  in  the 
regulation  of  lipolysis,  as  suggested  in  a  recent  publication  which  found  no  effect  of 
infusing  subpressor  or  pressor  concentrations  of  angiotensin.  II  on  whole  body  lipolysis  in 
healthy  volunteers  (366).  My  own  data  would  largely  support  this. 
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messengers  does  not  result  in  a  reduction  in  insulin  regulated  cellular  processes  is  of 
relevance  to  the  local  adipose  tissue  microcirculation,  as  well  as  the  systemic  circulation. 
Adipose  tissue  has  a  highly  developed  local  RAS  and  is  capable  of  producing  AH, 
independent  of  the  activity  of  the  circulating  RAS.  The  local  production  of  AH  seems  to  be 
important  mainly  in  cellular  differentiation  and  growth  (213,216).  The  observation  made  in 
Chapter  4,  that  dietary  sodium  restriction  activates  the  renin-angiotensin  system  and 
reduces  insulin  sensitivity,  in  combination  with  the  demonstration  of  intracellular  crosstalk 
between  second  messengers  of  the  angiotensin  III  and  insulin-signalling  cascades,  raises  the 
possibility  that  the  local  RAS  may  in  addition  modify  insulin  sensitivity.  The  results 
presented  herein,  however,  would  refute  this. 
In  summary,  I  have  found  no  inhibition  of  insulin  sensitivity  by  AII  in  isolated  human 
adipose  tissuý,  despite  confirming  binding  at  the  ATI  receptor.  Any  reduction  in  insulin 
sensitivity  seen  in  response  to  AII  may  be  mediated  in  alternative  tissues,  or  through 
alternative  mechanisms. 
192 Chapter  6:  Glucocorticoids  and  insulin  sensitivity:  dissociation  of  insulin's  metabolic 
and  vascular  actions 
6.1  Introduction 
In  chapter  4,1  demonstrated  that  dietary  sodium  restriction  is  associated  with  a  reduction  in 
insulin  sensitivity.  This  reduction  in  metabolic  insulin  sensitivity  was  not  associated  with 
any  difference  in  the  circulating  levels  of  markers  of  endothelial  function,  suggesting  that 
despite  the  association  of  metabolic  insulin  resistance  and  endothelial  dysfunction, 
manipulation  of  one  variable  did  not  necessarily  alter  the  other.  In  the  present  chapter,  I 
have  investigated  this  relationship  fin-ther,  using  systemic  exposure  to  glucocorticoids  as  a 
model  of  reduced  metabolic  insulin  sensitivity.  There  is  reasonable  scientific  evidence,  on  a 
background  of  considerable  clinical  evidence,  to  suggest  that  glucocorticoids  reduce 
metabolic  insulin  sensitivity-,  it  remains  unclear  if  this  metabolic  defect  is  an  isolated 
response  or  alternatively,  whether  there  may  a  reduction  in  sensitivity  to  insulin  action  in 
the  vasculature.  While  there  are  some  data  suggesting  that  metabolic  and  vascular  insulin 
sensitivity  are  coupled  (i.  e.  the  most  metabolically  insulin  responsive  subjects  exhibit  the 
greatest  vasodilation  in  response  to  insulin)  (177)  ý367,368),  there  are  few  data 
demonstrating  alteration  of  both  in  response  to  one  stimulus.  To  show  this  in  vivo  would 
suggest  there  being  a  defect  common  to  both  metabolic  and  vascular  tissues.  One  such 
defect  may  be  at  the  level  of  the  intracellular  signalling  intermediates  that  are  shared 
between  both  tissue  types;  the  classical  metabolic  pathway  of  insulin  stimulating  the  insulin 
receptor  and  insulin  receptor  substrate  proteins  through  a  series  of  tyrosine  phosphorylation 
events  culminating  in  the  activation  of  P13'-Idnase  seems  also  to  be  the  case  in  endothelial 
193 cells.  It  is  of  importance,  therefore,  to  bear  in  mind  that  the  predominant  mechanisms 
through  which  glucocorticoids;  induce  insulin  resistance  in  peripheral  tissues  appears  to  be 
mediated  at  the  level  of  GLUT4  trafficIdng  and  subcellular  distribution(336,338).  As  such, 
this  model  of  insulin  resistance  is  one  in  which  the  impairment  in  insulin-stimulatcd 
glucose  uptake  is  most  likely  due  to  a  defect  beyond  the  level  of  the  insulin-signalling 
cascade. 
In  addition,  it  has  been  suggested  (369)  that  excessive  tissue  exposure  to  glucocorticoid 
action  as  a  result  of  dysregulation  of  the  119  hydroxysteroid  dehydrogenase  enzymes  (types 
I  and  II),  may  play  a  part  in  the  aetiology  of  the  insulin  resistance  or  metabolic  syndrome.  If 
this  is  indeed  the  case,  then  the  metabolic  and  vascular  features  of  the  metabolic  syndrome 
might  be  expected  to  develop  during  dexamethasone  treatment. 
194 6.2  Methods 
6.2.1  Study  Protocol 
A  double-blind,  randomised,  placebo-controlled  crossover  trial  with  a  four  week  washout 
period  was  utilised  to  compare  the  effect  of  dexamethasone,  lmg  twice  daily  for  six  days 
with  matching  placebo.  The  Ethics  Committee  of  the  West-  Glasgow  Hospitals  University 
NHS  Trust  approved  the  protocol.  Twenty  volunteers  were  recruited  as  described  in 
Chapter  2.  Exclusion  criteria  were  BMI  L>27kg/m2,  blood  pressure  >150/85  mmHg,  fasting 
glucose  >6.0  mmol/I  and  any  history  of  intercurrent  illness  or  drug  therapy.  Volunteers 
were  asked  not  to  smoke  or  drink  alcohol  during  the  two  study  phases.  On  the  fifth  day  of 
dexamethasone  or  placebo,  volunteers  attended  fasted  for  a  gluteal  biopsy  (Chapter 
2.2.2.3.3).  A  technician,  blinded  to  the  study  phase  and  the  result  of  metabolic 
investigations,  dissected  small  resistance  vessels  from  the  biopsy  for  vascular  studies  using 
the  Mulvany  wire  myograph  method  (Chapter  2.2.2.5).  For  the  next  24  hours,  the 
volunteers  collected  urine  for  measurement  of  urinary  free  cortisol.  The  following  morning 
volunteers  underwent  fasting  serum  lipid  measurements  followed  by  a  euglycaemic 
hyperinsulinaemic  clamp. 
195 Figure  6.1:  Study  protocol 
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6.2.2.1  Euglycaemic  hyperinsulinaemic  clamp 
Insulin  sensitivity  was  assessed  using  the  hyperinsulinaernic  euglycaernic  clamp  (10) 
(Chapter  2.2.2.3.1).  At  time  0  minutes  of  the  clamp  protocol,  serum  samples  were 
withdrawn  from  the  left  antecubital  fossa  for  lipid  profile.  The  methods  for  all  peripheral 
blood  analysis  are  described  in  Chapter  2. 
6.2.2.2.  Vascular  studies 
i)  Gluteal  Biopsy 
Subjects  were  invited  to  attend  the  Clinical  Investigation  and  Research  Unit  at  0830, 
having  fasted  from  midnight.  A  gluteal  biopsy  was  obtained  as  described  in  Chapter 
2.2.2.3.3 
ii)  Myography  studies 
Resistance  arteries  were  dissected  from  the  biopsy;  these  underwent  myography  studies  as 
described  in  full  in  Chapter  2.  In  brief,  four  vessels  were  obtained  where  possible  from  each 
volunteer  during  both  study  phases.  After  the  initial  nonnalisation  protocol,  vessels 
underwent  a  cumulative  concentration  response  curve  to  norepinephrine  (NE),  then  pre- 
constriction  with  norepinephrine  followed  by  an  acetylcholine  relaxation  phase,  then 
insulin  (InM,  100pM,  lOpK  pre-incubation  followed  by  a  further  norepinephrine 
concentration-response  curve.  Where  sufficient  vessels  remained  viable  after  the  insulin 
NE  concentration  response  curve,  30  minute  incubations  were  undertaken  with  L-NMMA 
(IILNI)  prior  to  repeating  the  NE  concentration  response  curve  in  the  presence  of  insulin 
lOpM-InM. 
197 Wherever  possible  one  vessel  was  used  as  a  time  control.  This  vessel  underwent  an 
identical  protocol  to  the  others,  except  no  insulin  incubation  was  undertaken,  allowing 
analysis  of  the  effect  of  time  alone  on  contractile  response  in  vessels. 
6.2.3  Statistical  analysis 
i)  Comparisons  of  insulin  sensitivity  (M-value),  lipids  and  circulating  markers  of 
endothelial  function  between  phases  were  made  using  a  paired  West. 
ii)  For  myography  studies,  two  parameters  were  used  for  comparison  of  either 
concentration  response  curves  with  baseline  curves,  or  between  phase  comparisons.  First, 
the  pD2,  which  is  the  negative  log  of  the  NE  concentration  at  which  the  half  maximal 
response  is  seen  (EC5o),  was  calculated.  This  has  also  been  referred  to  as  the  sensitivity 
value.  In  addition,  the  maximum  active  effective  pressure  (mN/mm2,  calculated  from  the 
radius  and  the  wall  tension  using  the  Law  of  LaPlace  P=T/r,  where  P  is  the  active  effective 
pressure,  T  is  the  wall  tension  and  r  is  the  internal  radius)  was  calculated,  allowing 
comparison  of  the  maximal effect  of  agonist.  Baseline  NE  concentration  response  curve 
and  NE  concentration  response  curve  following  insulin  were  compared  between  placebo 
and  dexamethasone  phases  using  these  parameters.  Where  subjects  had  undergone  two 
biopsies,  a  paired  t-test  was  used,  whereas,  when  comparing  data  that  included  subjects 
with  only  one  successful  myography  result,  an  unpaired  t-test  was  used.  In  assessing  the 
effect  of  L-NMMA  on  insulin-mediated  vasodilation,  a  paired  t-test  was  used  to  compare 
pD2between  the  insulin  pre-treated  NE  concentration  response  curve  and  the  equivalent 
insulin  concentration  +  L-NMMA. 
198 6.3  Results 
Twenty  volunteers  were  recruited  to  the  study,  with  one  failing  to  attend  for  the  second 
study  phase  due  to  work  commitments.  The  study  protocol  was  well  tolerated  by  all  of  the 
subjects,  the  only  complication  being  four  minor  infections  at  the  biopsy  site.  Sixteen 
volunteers  had  at  least  one  successful  biopsy,  with  twelve  having  full  myography  data.  An 
absence  of  vessels  of  suitable  diameter  was  the  reason  for  failure  to  obtain  vessels  from  the 
biopsies  with  no  myography  data.  'Me  baseline  characteristics  of  the  subjects  are  detailed  in 
Table  6.1. 
63.1  Blood  pressure,  body  weight  and  insulin  sensitivity 
No  significant  change  in  blood  pressure  or  weight  was  observed  between  phases  (Table 
6.2).  Insulin  sensitivity,  measured  by  the  euglycaemic  hyperinsulinaemic  clamp,  was 
significantly  reduced  following  six  days  of  dexamethasone  (mean  fall  of  29%  (95%CI  8. 
50%))  (Table  6.1,  Figure  6.2).  In  addition,  fasting  serum  insulin  was  higher  during  this 
phase  (Table  6.2,  Figure  6.3).  There  was  no  between  phase  difference  in  serum  insulin  at 
any  time  point  during  the  clamps  (Figure  6.3),  and  in  particular,  there  was  no  difference  in 
the  mean  serum  insulin  during  steady  state  (115+  36  AU/ml  (SD)  during  placebo  vs.  123:  E 
36AU/ml  (SD)  during  dexamethasone  p=0.33). 
199 Table  6.1:  Baseline  characteristics  of  recruits 
All  values  are  expressed  as  mean  and  one  standard  deviation 
Mean  (A:  S.  D.  ) 
Number  20 
Age  (years)  24.3-±4.1 
Weight  (kg)  76.1±  9.2 
BMI  (kg/m7)  23.9±  3.1 
Blood  Pressure  (mm/Hg)  129d--10.4/66+-8.6 
Total  Cholesterol  (mmol/1)  4.3+-0.98 
Triglycerides  (mmol/1)  1.49±0.84 
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6.3.2.1  Analysis  of  the  effect  of  time  on  control  vessels 
Comparison  of  the  norepinephrine-induced  vasoconstriction  between  vessels  after  the  first 
and  third  concentration  response  curves  to  norepinephrine  demonstrated  no  change  in  pD2 
(pD2  for  first  NE  concentration  response  curve  7.14±0.1  vs  7.13±0.13  for  third  NE 
concentration  response  curve,  p=0.91)  when  all  17  available  results  were  examined  (Figure 
6.4).  When  these  were  examined  according  to  study  phase,  there  was  no  difference  in  pD2 
between  these  curves  during  placebo  (n--6,  p=0.84)  or  dexamethasone  phases  (n=1  1, 
p=0.88).  Having  demonstrated  that  there  was  no  effect  of  time  on  vessel  response,  further 
comparisons  of  the  effect  of  insulin  or  acetylcholine  on  NE  induced  vasoconstriction  were 
made  for  each  vessel  versus  the  first  curve  in  response  to  NE  alone,  on  the  same  vessel. 
6.3.2.2  Dexamethasone  and  norepinephrine  induced  vasoconstriction 
For  this  analysis,  data  were  obtained  from  12  volunteers,  accounting  for  32  arteries  studied 
I 
in  each  phase.  All  volunteers  contributed  between  two  and  four  arteries  to  the  final  analysis 
and  each  volunteer  contributed  the  same  number  of  arteries  in  each  phase.  In  volunteers 
where,  for  example,  two  arteries  were  available  from  one  phase  and  three  from  the  other, 
the  vessel  used  to  subsequently  study  insulin  lOnM  was  discarded  arbitrarily.  To  achieve 
greater  statistical  accuracy,  only  subjects  with  data  from  both  phases  were  studied,  and  the 
pD2  of  NE  induced  vasoconstriction  compared  using  a  paired  West.  The  results  are  shown 
in  Figure  6.5.  There  was  no  statistically  significant  change  in  the  pD2  of  NE  induced 
vasoconstriction  between  phases  (pD2  during  placebo  6.86±0.08  vs  pD2  during 
dexamethasone  7.0±0.05,  p=O.  1). 
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Data  were  available  from  eleven  subjects  during  the  placebo  phase  and  thirteen  subjects 
during  the  dexamethasone  phase.  There  was  no  difference  in  the  pD2  of  acetylcholine- 
mediated  vasodilation  between  phases,  as  shown  in  figure  6.6  (pD2  for  acetylcholine 
mediated  vasodilation  during  placebo  6.87-±0.09  vs.  7.04±0.11  during  dexamethasone, 
P=0.5).  In  addition,  on  comparing  the  ten  volunteers  with  data  from  both  phases,  again  no 
difference  in  acetylcholine-mediated  vasodilation  was  observed. 
63.2.4  Insulin-mediated  attenuation  of  NE  induced  vasoconstriction 
i)  placebo  phase 
Figures  6.7.1-3  and  table  6.3  demonstrate  the  effect  of  pre-incubation  of  vessels  with 
insulin  on  NE-mediated  vasoconstriction,  during  the  placebo  phase.  Vessels  were  pre- 
incubated  with  insulin  InM  (Figure  6.7.1),  100pM  (Figure  6.7.2)  and  1OpM  (Figure  6.7.3). 
A  significant  rightward  shift  in  the  NE  concentration  response  curve  (reduction  in  pD2)  was 
seen  at  insuli  ,n  concentrations  of  100pM  and  lOpM.  No  significant  change  in  pD2  was  seen 
in  association  with  insulin  InM.  In  response  to  insulin  InM  and  IOOpM,  a  significant 
reduction  in  the  calculated  maximum  active  effective  pressure  was  observed.  No  change  in 
maximum  active  effective  pressure  was  observed  in  response  to  insulin  I  OpM. 
ii)  dexamethasone  phase 
Figures  6.8.1-3  and  table  6.3  demonstrate  the  effect  of  pre-incubation  of  vessels  with 
insulin  on  NE-mediated  vasoconstriction  during  the  dexamethasone  treatment  phase. 
Vessels  were  pre-incubated  with  insulin  ln.  M  (Figure  6.8.1),  IOOpM  (Figure  6.8.2)  and 
lOpM  (Figure  6.8.3).  A  significant  rightward  shift  in  the  NE  concentration  response  curve 
was  seen  at  insulin  concentrations  of  InM  and  IOOpM.  In  addition,  a  significant  reduction 
in  calculated  maximum  active  effective  pressure  was  observed  at  insulin  concentrations  of 
202 InM  and  100pM.  There  was  no  significant  effect  on  the  pD2  or  maximum  active  effective 
pressure  in  response  to  insulin  I  OpM. 
6.3.2.5  Comparison  of  insulin  action  during  dexamethasone  and  placebo  phases 
Figures  6.9.1-2  and  table  6.4  illustrate  the  results  of  NE  concentration  response  curve  and 
corresponding  insulin  pre-treated  NE  concentration  response  curve  during  placebo  and 
dexamethasone  phases  for  InM  (n=1  1)  and  100pM  (n--10)  insulin.  In  both  of  these  graphs, 
only  data  from  volunteers  with  two  sets  of  myography  results  (i.  e.  on  placebo  and 
dexamethasone  treatment  phases)  were  included.  Importantly,  there  was  no  difference  in 
the  pD2  or  maximum  active  effective  pressure  for  the  baseline  NE  concentration  response 
curves  when  placebo  and  dexamethasone  phases  were  compared.  Similarly,  no  between 
phase  difference  in  pD2  or  calculated  maximum  active  effective  pressure  was  seen  at  either 
insulin  dose.  These  data  are  also  represented  in  figure  6.10.1-4,  comparing  the  pD2  and 
calculated  maximum  active  effective  pressure  between  phases  after  incubation  with  insulin 
I  nM  (n7-1  1)  ýnd  1  OOpM  (n--  10).  The  data  from  1  OpM  insulin  were  not  analysed  due  to  low 
numbers  of  matched  results.  To  absolutely  exclude  a  confounding  effect  of  dexamethasone 
on  the  NE  concentration  response  curve  between  phases,  after  correcting  for  the 
corresponding  NE  concentration  response  curve  by  expressing  pD2  ins/  pD2  baseline  and 
maximum  active  effective  pressure  ins/maximum  active  effective  pressure  baseline  for  each 
individual,  still  no  effect  of  dexamethasone  was  observed. 
6.3.2.6  Insulin-mediated  vasodilation-the  effect  of  nitric  oxide  synthase  inhibition 
Figures  6.11.1-3  and  6.12.1-2,  and  table  6.5,  demonstrate,  during  placebo  and 
dexamethasone  phases  respectively,  the  effect  of  L-NMMA  pre-incubation  on  insulin- 
mediated  attenuation  of  NE  induced  vasoconstriction.  Numbers  are  lower  due  to  some 
203 protocols  being  abandoned  at  a  stage  where  vessels  were  clearly  non-viable,  limiting 
conclusions  that  can  be  drawn  from  these  data.  Despite  this,  the  impression  is  that 
inhibition  of  the  endothelial  isoform,  of  nitric  oxide  synthase  abrogates  most  of  the  insulin 
effect  during  both  phases.  During  both  placebo  and  dexamethasone  phases,  L-NMMA  had 
a  significant  effect  on  insulin  action  (figures  6.11.1-3  and  6.12.1-2,  table  6.5) 
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204 Figure  6.2:  Insulin  sensitivity  after  placebo  and  dexamethasone  phases. 
Insulin  sensitivity  after  placebo  and  dexamethasone  study  phases  was  measured  and 
compared  using  the  euglycaernic  hyperinsulinaemic  clamp.  There  was  a  significant 
reduction  in  insulin  sensitivity  after  six  days  of  dexamethasone  exposure  compared  with 
placebo  (p<0.001).  Values  shown  illustrate  the  mean  for  each  phase. 
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205 Figure  6.3:  Serum  insulin  during  the  euglycaemic  hyperinsulinnemic  clamp 
Fasting  and  steady-state  serum  insulin  concentrations  during  euglycaernic 
hyperinsulinaemic  clamp  were  compared.  Fasting  insulin  was  significantly  greater  during 
the  dexamethasone  study  phase  (p<0.05),  however  serum  insulin  was  no  different  at  any 
point  during  the  clamp,  and  in  particular  during  the  final  40  minutes.  Error  bars  represent 
standard  errors. 
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0  30  60  90  120  150  180 
time  (minutes) Figure  6.4:  The  effect  of  time  and  norepinephrine-Induced  vasoconstriction. 
The  effect  of  time  on  NE  induced  vasoconstriction  in  human  resistance  vessels  was 
compared  during  placebo  and  dexamethasone  phases  (p=0.91  for  comparison  of  pD2,  n=17 
vessels).  Error  bars  represent  standard  errors. 
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.9  .8  -7  .6  .5  Norepinephrine  (log  M Figure  6.5:  Norepinephrine-induced  vasoconstriction  during  placebo  and 
dexamethasone. 
NE  induced  vasoconstriction  in  human  resistance  vessels  (n=32)  dissected  from  subjects 
(n--12)  after  five  days  of  dexamethasone  was  compared  with  that  after  an  equivalent  period 
of  matched  placebo.  No  statistically  significant  difference  in  the  pD2  for  NE  induced 
vasoconstriction  was  observed  (p=O.  1).  Error  bars  represent  standard  errors. 
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.9  -8  -7  -6 
Norepinephdne  (logM) Figure  6.6:  Acetylcholine-mediated  vasodilation  during  dexamethasone  and  placebo. 
Acetylcholine-mediated  vasorelaxation,  in  human  resistance  vessels  was  compared  during 
placebo  (n=11)  (complete  line)  and  dexamethasone  (n--13)  (interrupted  line).  Values  are 
expressed  as  a  percentage  of  the  contraction  generated  by  incubation  with  norepinephrine 
lOgM.  No  difference  in  the  pD2  of  acetylcholine  action  was  observed  between  phases. 
Error  bars  represent  standard  errors. 
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74 Table  6.2:  Metabolic  characteristics  of  subjects  during  both  study  phases 
All  values  are  expressed  as  mean  and  one  standard  deviation 
Placebo  Dexamethasone  p-value 
(paired  t- 
test) 
Weight  (kg)  76.0±9  76.7±9  0.18 
Systolic  blood  pressure  (mmHg)  120.6±10  120.3±14  0.92 
Diastolic  blood  pressure  (mmHg)  60±9  61.7±9  0.45 
Fasting  insulin  (AU/ml)  17.4±9  26.1±11  0.001 
Insulin  sensitivity  (M-mg/kg/min)  10.13±2  7.2±2  <0.001 
Urinary  free  cortisol  (/mol 
creatinine) 
6.8  ±4  0.33  ±  0.3  <0.00  1 
Serum  cortisol  (nmol/l)  322.5 
(median) 
<27  (median) 
Total  cholesterol  (mmol/1)  4.0±  0.9  4.1±  0.9  0.22 
Triglycerides  (mmol/1)  1.0±  0.7  1.2::  h  0.8  0.04 
HDL  cholesterol  (mmol/1)  1.13±  0.2  1.3±  0.2 
1 
0.003 
216 Table  6.3:  Insulin-mediated  vasodilation  in  human  resistance  vessels  during  placebo 
and  dexamethasone  phases 
Errors  represent  standard  error  of  the  mean 
Placebo  Dexamethasone 
pD2  p 
value 
vs 
control 
Maximum 
active 
effective 
pressure 
p 
value 
vs 
control 
pD2  p 
value 
vs 
control 
Maximum 
active 
effective 
p  ure 
p 
value 
vs 
control 
Control  6.8±0.1  31.1±1.6  31.3±2.4 
Insulin 
10-9 
6.6±0.4  0.15  28.711.6  <0.01  6.7±0.2  0.02  29.2±2  0.02 
Control  6.8±0.1  33.8±1.2  6.9±0.1  33.3±2.6 
Insulin 
10-10 
6.6±0.1  <0.01  30.7±1.5  <0.001  6.7±0.1  0.01  3  1.14.6  0.02 
Control  6.810.1  36.8±5.3  7.1±0.1  33.5±4.2 
Insulin  6.4±0.1  <0.01  32.8±5.1  0.21 
- 
6±0.2  0.1  31.5±3.8  0.08 
217 Table  6.4:  Comparison  of  insulin-mediated  vasodilation  during  placebo  and 
dexamethasone  phases 
Errors  represent  standard  error  of  the  mean. 
Parameter  Placebo  Dexamethasone  p  value 
Insulin 
10-9 
pD2 
Maximum  active  effective  pressure 
6.6±0.1 
28.7±2 
6.7±0.1 
29±2 
0.75 
0.64 
Insulin 
0-10 
pD2 
Maximum  active  effective  pressure 
6.6±0.1 
30.7±2 
6.7±0.1 
31.4±1 
0.45 
0.91 
218 Table  6.5:  The  effect  of  L-NMMA  on  insulin-mediated  vasodilation  during  placebo 
and  dexamethasone  phases 
Errors  represent  standard  error  of  the  mean 
Placebo  Dexamethasone 
pD2  P  Maximum  P  pD2  P  Maximum  P 
value  active  value  value  active  value 
effective  effective 
pressure  pressure 
NE  +  6.5:  0.2  0.2  28:  ý2.5  0.04  6.6±0.1  0.02  30.1±3  0.4 
Insulinle  I  I  I 
NE+  6.8±0.2  31+-3  7.0-+0.2  31.7.  +3.4 
Insulin10-9 
+  L- 
NMMA 
NE+  6.4±0.1  0.08  29.9±3  <0.0  1  6.5±0.1  0.14  36±3  0.31 
Insulin10"o 
NE+  6.  T±5.1  33±3  6.7±0.1  37±3 
Insulin10-10 
+  L- 
NMMA 
+  6.4:  LO.  I  0.2  34±3  0.4 
InsulInIO"' 
NE+  6.6±0.1  36±2 
insulinIO'll 
+  L- 
NMMA 
219 6.4  Discussion 
In  this  chapter  I  have  demonstrated  that  six  days  of  dexamethasone  treatment  was 
associated  with  a  29%  reduction  in  metabolic  insulin  sensitivity,  measured  by  the 
euglycaemic  hyperinsulinaemic  clamp.  Despite  this,  there  was  no  associated  reduction  in 
insulin  action  in  small  resistance  arteries,  measured  using  wire  myography.  Thus  metabolic 
and  vascular  insulin  responses,  in  this  model,  do  not  appear  to  be  coupled.  This  observation 
may  be  of  importance  in  unravelling  the  relationship  between  insulin's  metabolic  and 
vascular  actions. 
That  glucocorticoids  reduce  insulin  sensitivity  is  not  a  novel  observation,  though  the 
underlying  mechanisms  are  unclear.  Ri=  et  al  (325)  suggested  that  the  defect  lies  in  both 
peripheral  and  hepatic  insulin  action,  and  is  located  downstream  of  the  insulin  receptor. 
Candidate  "hepatic"  mechanisms  include  an  increase  in  phosphoenolpyruvate 
carboxyIdnase  (PEP-CK)  activity,  the  rate-limiting  step  in  hepatic  gluconeogenesis(326),  a 
reduction  inpancreatic  9-cell  insulin  secretion  (327)  and  an  increase  in  a-cell  glucagon 
secretion  (328).  The  defect  in  "peripheral"  tissues  may  be  secondary  to  an  increase  in 
circulating  free  fatty  acids,  or  a  more  direct  cellular  effect  on  insulin  binding  at  the  plasma 
membrane  (330),  (331)  or  the  insulin-signalling  cascade  (335)  (370).  It  has  also  been 
proposed  by  several  groups  that  the  reduction  in  insulin-stimulated  glucose  transport  is 
secondary  to  abnormalities  of  GLUT4,  either  in  its  amount  (338)  or  distribution  (336), 
(337),  (371)  within  the  cell. 
Rooney  and  colleagues  (326)  confirmed  that  a  28-hour  cortisol  infusion  reduced  both 
hepatic  and  peripheral  insulin  sensitivity  by  nearly  50%.  Similarly,  Paquot  et  at  (329) 
observed  a  51.5%  reduction  in  glucose  uptake  in  healthy  volunteers  during  a 
220 hyperinsulinaemic  euglycaemic  clamp,  and  a  54%  reduction  in  glucose  oxidation  after  2 
days  of  dexamethasone  1mg  bd.  In  the  present  study,  a  29%  reduction  in  peripheral  insulin 
sensitivity  was  observed,  in  association  with  an  elevation  in  fasting  insulin.  The  reason  for 
this  more  modest  reduction  is  unclear;  compliance  with  study  medication  was  good  as 
evidenced  by  all  volunteers  reducing  serum  cortisol  to  <27nmol/l  and  suppressing  urinary 
free  cortisol  during  the  dexamethasone  phase.  It  may  be  of  relevance  that  the  population 
studied  consisted  of  young  healthy  volunteers  who  were  largely  insulin  sensitive. 
Clearly  there  was  no  attempt  in  this  work  to  identify  the  mechanism  responsible  for  the 
reduction  in  insulin  sensitivity,  however  it  is  of  note  that  there  was  no  change  in  either  body 
weight  or  blood  pressure  between  phases. 
There  is  good  evidence  to  support  a  relationship  between  insulin  sensitivity  and  lipid 
profile.  In  conditions  associated  with  insulin  resistance  such  as  obesity  and  type  2  diabetes, 
insulin  resisiance  is  associated  with  elevated  senun  triglycerides  and  reduced  HDL- 
cholesterol,  while  even  in  the  healthy  population,  there  is  a  continuous  relationship  between 
insulin  resistance  and  triglycerides,  and  an  inverse  relationship  with  HDL-cholesterol.  As 
such,  the  observation  that  dexamethasone  exposure  was  associated  with  insulin  resistance, 
an  increase  in  triglycerides  and  an  increase  in  HDL-cholesterol  is  intriguing.  There  is  no 
obvious  explanation  for  this  elevation  in  HDL.  This  is  most  likely  a  direct  effect  of 
dexamethasone  that  has  "overridden"  the  endogenous  mechanism  coupling  insulin 
sensitivity  and  lipid  profile.  It  may,  of  course,  also  be  a  chance  observation.  It  is  not  in 
keeping  with  the  notion  that  tissue  corticosteroid  levels  may  be  involved  in  the 
development  of  the  metabolic  syndrome. 
221 It  is  now  accepted  that  insulin  acts  in  the  vasculature  as  an  endothelium  dependent 
vasodilator  (described  more  fully  in  Chapter  1),  the  action  of  which  is  mediated  at  least 
partly  by  activation  of  the  endothelial.  isoform,  of  nitric  oxide  synthase.  This  process  may  be 
effectively  inhibited  by  the  addition  of  the  stereospecific  substrate  inhibitor  of  eNOS  -  L- 
NMMA.  Several  authors  have  demonstrated  a  relationship  between  insulin  resistance  and 
endothelial  function.  Petrie  (177)  showed  a  correlation  between  metabolic  insulin 
sensitivity  and  basal  nitric  oxide  production  (measured  by  the  reduction  in  forearm  blood 
flow  following  intra-arterial  infusion  of  L-NMMA).  Using  similar  techniques,  Cleland  et  al 
(185)  extended  this  observation  across  groups  with  varying  phenotype,  comparing  three 
groups  -  healthy  normotensives,  non-diabetic  hypertensives  and  type  2  diabetics  -  and 
found  a  relationship  between  metabolic  insulin  sensitivity  and  endothelial  function  on 
combining  the  data  from  all  three  groups.  Thus,  using  these  techniques,  those  with  the 
lowest  metabolic  response  to  insulin  seem  also  to  have  the  lowest  vascular  insulin  response. 
Observations  in  obese  (176)  hypertensive  (180),  and  diabetic  (176)  cohorts  have  shown  that 
acetylcholine,  -mediated  vasodilation  is  also  impaired,  suggesting  that  a  more  generalised 
endothelial  dysfunction  is  present  in  these  metabolically  insulin  resistant  groups. 
Despite  these  observations,  much  remains  unknown  about  the  nature  of  this  relationship,  in 
particular  the  molecular  mechanisms  that  mediate  endothelial  dysfunction  an&  insulin 
resistance.  The  culture  of  human  endothelial.  cells  has  led  to  a  greater  understanding  of 
insulin  action  in  vascular  cells.  Zeng  et  al  (186)  demonstrated  an  insulin-stimulated 
increase  in  NO  release  from  cultured  HUVECs,  and  found  properties  that  were  shared  with 
the  better-characterised  insulin  signal  in  muscle  and  adipose  cells;  insulin-stimulated 
release  of  NO  was  reduced  by  inhibition  of  P13'-kinase.  Similar  findings  were  subsequently 
reported  in  bovine  aortic  endothelial.  cells  (187),  where  insulin  stimulated  increases  in 
222 eNOS  activity  were  sensitive  to  P13'-Idnase  inhibitors.  Furthermore,  overexpression  of 
insulin  receptors  into  HUVECs  (188)  results  in  an  increase  in  insulin  stimulated  NO 
production.  Thus,  insulin  acts  as  an  endothelium-dependent  vasodilator,  acting  via  the 
insulin  receptor  and  activation  of  P13'-kinase.  Thus  there  are  clear  parallels  with  the  insulin 
signal  in  metabolically  active  tissue,  such  as  muscle  and  fat.  This  raises  the  possibility  that 
there  may  a  single  proximal  signalling  defect  in  both  vascular  and  metabolic  cells  which 
would  account  for  two  of  the  fundamental  components  of  the  insulin  resistant  phenotype- 
insulin  resistance  and  vascular  dysfunction.  In  keeping  with  this,  in  vascular  tissue  from 
animal  models  of  insulin  resistance  (189),  insulin  stimulated  tyrosine  phosphorylation  of 
the  insulin  receptor,  IRS-  I  and  -2  is  reduced. 
Analysis  of  the  myography  data  supports  the  role  of  insulin  as  an  enclothelium  dependent 
vasodilator.  Significant  vasodilation  was  observed  at  physiological  insulin  concentrations 
during  both  placebo  and  dexamethasone  phases.  In  addition,  the  effect  of  insulin  was  at 
least  partially  reversed  by  the  preincubation  of  vessels  with  IuM  L-NMMA.  The  objective 
of  this  study  was  not  to  define  the  mechanism  of  insulin  action  in  the  vasculature;  however, 
these  data  are  in  keeping  with  recent  observations  that  while  insulin  action  in  partly  NO 
mediated,  there  may  be  other  endothelial  relaxant  factors  that  mediate  insulin  action  in  the 
vasculature;  in  a  recent  publication  it  was  even  suggested  that  the  main  vasorelaxant  in 
resistance  arteries  is  independent  of  nitric  oxide(372).  Indeed,  the  investigators 
demonstrated  that  only  20%  of  acetylcholine  mediated  vasodilation  may  be  nitric  oxide 
mediated,  and  proposed  a  considerable  contribution  from  an  endothelial  dependent 
hyperpolarizing  factor,  possibly  an  arachidonic  acid  metabolite. 
223 The  primary  hypothesis  of  this  study  was  to  determine  whether  the  metabolic  reduction  in 
insulin  sensitivity  that  may  accompany  dexamethasone  treatment  would  be  associated  with 
a  reduction  in  vascular  insulin  responsiveness.  Clearly,  if  this  were  to  be  the  case,  this 
would  be  of  fundamental  importance  in  attempting  to  clarify  the  nature  of  the  relationship 
between  insulin  response  in  vascular  and  metabolic  tissue,  as  it  would  reinforce  the 
coupling  of  the  two  variables,  even  after  pharmacological  manipulation,  and  would  support 
a  common  mechanism.  Despite  the  29%  reduction  in  metabolic  insulin  sensitivity 
associated  with  dexamethasone  exposure,  I  demonstrated  no  reduction  in  insulin  action  in 
the  vasculature,  implying  uncoupling  of  these  two  mechanisms.  This  may  be  explained  by 
several  possibilities.  Firstly,  previous  studies  examining  insulin-mediated  vasodilation  have 
been  undertaken  in  vivo,  with  vascular  response  to  insulin  measured  using  forearm 
plethysmography.  While  this  technique  also  reflects  small  vessel  responses,  there  are  no 
data  comparing  these  techniques;  future  studies  need  to  address  the  correlation  between 
measurements  of  insulin  action  in  the  vasculature,  comparing  wire  myography  with  forearm 
plethysmography.  In  the  only  published  study  to  have  examined  the  vascular  and  metabolic 
effects  of  dexamethasone,  Tappy  and  colleagues  (373)  showed  that  48  hours  of 
dexamethasone  2mg  b.  d.  reduced  metabolic  insulin  sensitivity,  and,  in  association, 
demonstrated  no  increase  in  calf  blood  flow,  measured  by  venous  occlusion 
plethysmography,  that  would  normally  accompany  the  hyperinsulinaemic  clamp. 
Mechanistically,  it  was  suggested  that  the  main  metabolic  defect  was  in  glucose  oxidation, 
and  the  main  site  of  insulin  resistance  was  peripheral  rather  than  hepatic.  As  discussed 
above,  the  conflicting  nature  of  these  results  with  my  own  may  reflect  the  different 
techniques  used  to  measure  increases  in  flow;  it  must  also  be  considered  that  the 
phenomenon  of  dexamethasone  action  in  the  endothelium  may  be  evanescent  and  so  an 
effect  may  be  missed  in  ex  vivo  models  such  as  the  one  used  in  this  chapter. 
224 An  effect  of  dexamethasone  on  vascular  responsiveness  was  also  considered  as  a 
confounding  factor  that  may  have  masked  differences  in  insulin  sensitivity.  No  difference 
in  either  measurement  of  vessel  contraction  was  observed  between  the  NE  concentration 
response  curves  during  placebo  and  the  dexamethasone  phase,  allowing  the  use  of  pD2  and 
maximum  active  effective  pressure  to  compare  insulin  action  between  phases. 
This  is  one  of  the  first  studies  to  test  the  hypothesis  that  an  exogenous  stimulus  can  alter 
insulin  response  in  more  than  one  insulin  responsive  tissue.  It  may  be  that  the  coupling  of 
endogenous  insulin  sensitivity  is  the  result  of  a  more  complex  interplay  of  circulating  and 
tissue-based  factors  that  is  overwhelmed  by  the  crude  insult  dealt  to  the  metabolism  by 
administering  pharmacological  glucocorticoid  doses.  Finally,  it  must  be  acknowledged  that 
despite  the  clear  vasodilatory  effect  of  insulin  in  this  vessel  system,  its  effect  was  modest, 
and  so  subtle  changes  in  vascular  insulin  response  may  not  have  been  detected.  The 
sensitivity  of'vessels  to  acetylcholine-mediated  vasodilation  was,  however,  also  measured; 
again  there  was  no  difference  between  phases.  Acetylcholine  had  a  more  marked 
vasodilatory  action  than  insulin  in  these  vessels,  and  as  such,  more  minor  changes  in 
endothelial  function  would  perhaps  be  more  evident  between  phases  in  response  to  this 
vasodilator.  This  was  not,  however,  the  case. 
By  convention,  myography  studies  comparing  two  groups  have  required  groups  of  16 
subjects.  While  20  subjects  were  recruited  to  this  study,  paired  values  of  insulin  action  at  a 
given  dose  were  only  available  in  11  subjects.  No  difference  was  observed  between  phases, 
as  was  also  the  case  on  analysis  of  unpaired  data  (maximum  n--14  on  dexamethasone  phase, 
n--13  on  placebo  p=ns  for  difference  in  pD2  or  maximum  active  effective  pressure).  Thus, 
225 one  criticism  of  the  study  is  that  it  may  be  underpowered  to  detect  a  small  difference  in 
insulin  action  in  the  vasculature;  in  defence  of  this,  the  crossover  design  of  the  study  does 
permit  the  analysis  of  paired  data  and  as  such  increases  statistical  power. 
The  results  of  this  trial  are  against  the  notion  that  cortisol  excess  underpins  the  insulin 
resistance  syndrome  based  on  the  observations  that  vascular  insulin  resistance  was  not 
demonstrated  and  that  the  lipid  profile  did  not  change  in  the  typical  pattern  associated  with 
this  syndrome.  There  is  no  doubt  however  that  the  metabolic  effects  of  exogenous 
glucocorticoid  are  considerable,  as  encountered  in  patients  with  syndromes  of  cortisol 
excess. 
In  summary,  glucocorticoid  exposure  for  five  days  was  associated  with  a  reduction  in 
metabolic,  although  not  vascular  insulin  sensitivity,  thus  raising  further  questions  about  the 
nature  of  the  vascular  insulin  resistance. 
226 Chapter  7:  Conclusion 
Insulin  sensitivity,  defined  as  a  subnormal  biological  response  to  insulin  at  physiological 
concentrations,  is  the  classical  feature  of  type  2  diabetes.  In  addition,  many  authors  have 
also  described  reduced  insulin  action  in  conditions  such  as  hypertension,  dyslipidaemia  and 
obesity,  all  of  which  are  clustered  with  insulin  resistance  in  large  epidemiological  studies, 
even  on  exclusion  of  subjects  with  type  2  diabetes.  As  such,  the  study  of  insulin  sensitivity, 
and  factors  that  may  determine  or  modify  this  biological  variable,  assumes  increasing 
importance  from  both  a  basic  scientific  and  clinical  standpoint.  In  this  thesis  I  have  used 
several  techniques  to  measure  insulin  action  in  the  whole  body  and  in  isolated  tissues,  and 
considered  endogenous  factors  that  may  modify  insulin  sensitivity. 
Initial  studies  were  undertaken  in  isolated  subcutaneous  adipocytes.  Insulin  sensitivity, 
measured  as  the  suppression  of  isoproterenol-induced  lipolysis,  was  measured  in  a  small 
cohort  of  healthy  females.  The  most  phenotypically  insulin  resistant  subjects,  characterised 
primarily  by  their  body  habitus  though  also  by  fasting  serum  insulin  and  lipid  profile, 
showed  the  least  response  to  insulin  in  isolated  cells.  While  this  observation  seems 
intuitive,  it  has  considerable  relevance  to  current  scientific  debate  within  this  area.  Some 
groups  propose  that  resistance  to  insulin-stimulated  glucose  uptake  may  be  largely 
influenced  by  the  supply  of  substrate  to  that  particular  vascular  bed.  In  addition, 
measurements  of  in  vivo  insulin  sensitivity  may  be  influenced  by  circulating  and  locally 
secreted  factors,  providing  a  further  confounding  effect  on  insulin  sensitivity  at  the  cellular 
level.  The  fundamental  observation  in  Chapter  3,  that  the  behaviour  of  adipose  tissue  after 
227 dissection  and  digestion  continues  to  reflect  the  host  phenotype,  suggests  that  there  is  a 
defect  present  at  the  cellular  level,  perhaps  in  the  insulin-signalling  cascade. 
This  assay  was  then  used  in  association  with  clinical  studies  of  dietary  sodium  restriction  to 
investigate  the  role  of  the  renin  angiotensin  system  in  determining  insulin  sensitivity.  While 
several  publications  have  investigated  the  effect  of  dietary  sodium  restriction  on  insulin 
sensitivity,  the  lack  of  uniformity  in  their  findings  is  a  reflection  of  the  variation  in 
methodology  employed.  As  such,  a  randomised,  placebo-controlled,  double-blinded 
crossover  study  was  designed,  which  included  careful  monitoring  of  urinary  sodium 
excretion,  and  measurement  of  insulin  sensitivity  using  the  gold  standard  euglycaemic 
hyperinsulinaernic  clamp.  A  modest,  though  significant,  reduction  in  insulin  sensitivity  was 
observed  in  association  with  activation  of  the  renin  angiotensin  system.  Even  a  small 
reduction  in  insulin  sensitivity  may  have  an  important  role  in  determining  future 
cardiovascular  morbidity  and  mortality;  the  IRAS  investigators  demonstrated  a  continuous 
relationship  between  insulin  resistance  and  intima  media  thickness  of  the  internal  carotid 
artery.  As  such,  any  reduction  in  insulin  sensitivity  may  be  anticipated  to  translate  into 
cardiovascular  morbidity  and  mortality.  This  observation  seems  at  odds  with  the  vogue  for 
sodium  restricted  diet;  there  seems  little  doubt  that  sodium  restriction  is  an  effective  non- 
pharmacological  means  of  reducing  blood  pressure,  however  until  there  is  good  clinical 
trial  evidence  of  a  reduction  in  mortality  in  association  with  sodium  restriction,  the 
possibility  of  creating  an  adverse  metabolic  environment  will  continue  to  hamper  efforts  to 
introduce  widespread  sodium  restriction. 
In  an  attempt  to  explain  the  reduction  in  insulin  sensitivity  associated  with  sodium 
restriction  and  activation  of  the  renin  angiotensin  system,  the  effect  of  angiotensin  Il  on 
228 insulin  action  in  human  adipocytes  was  then  studied.  Previous  studies  have  shown  that  AH 
may  interfere  with  insulin  action  at  the  level  of  intracellular  second  messengers,  thereby 
providing  a  mechanism  through  which  activation  of  the  renin-angiotensin  system  would 
reduce  insulin  sensitivity  in  isolated  tissue.  Despite  confirming  that  angiotensin  II  does 
indeed  bind  to  adipocytes,  there  was  no  change  in  insulin  action  when  adipocytes  were  co- 
incubated  with  angiotensin  IL  This  implies  that  if  angiotensin  H  is  responsible  for  the 
reduction  in  insulin  sensitivity  seen  in  the  clamp  experiments,  the  mechanism  is  not 
mediated  in  adipose  tissue.  There  is  some  evidence  to  suggest  that  a  reduction  in  IRS-1 
associated  P13'-Idnase  activity  induced  by  angiotensin  II  may  be  compensated  for  by  a 
heightened  intracellular  role  of  IRS-2.  Alternatively,  other  components  of  the  RAS,  such  as 
aldosterone,  may  have  an  effect  on  insulin  sensitivity  at  the  cellular  level. 
In  the  final  results  chapter,  the  effects  of  a  short  period  of  glucocorticoid  exposure  on  the 
metabolic  and  vascular  action  of  insulin  are  described.  Despite  data  suggesting  that  the 
action  of  insulin  in  these  tissues  is  coupled,  in  this  system,  a  29%  fall  in  the  metabolic 
action  of  insulin  was  not  associated  with  any  change  in  insulin  action  in  the  vasculature. 
Interpretation  of  these  findings  may  offer  insight  into  the  nature  of  insulin  action  in 
different  tissues.  They  support  the  intriguing  possibility  that  the  coupling  of  insulin  action 
lies  in  the  commonality  of  the  proximal  insulin-signalling  cascade;  there  may  be  shared 
mechanisms  of  disrupted  activation  of  such  key  intermediates  as  PIYkinase  that  transcend 
tissue  type.  An  example  of  this  is  the  IRS-  1  '4'  mouse  which  displays  both  metabolic  insulin 
resistance  and  endothelial  dysfunction.  In  contrast,  it  seems  that  dexamethasone  induced 
insulin  resistance  at  the  cellular  level  may  be  the  result  of  defects  that  lie  further 
downstream,  such  as  the  trafficking  of  GLTJT4.  This  type  of  abnormality  may  be  more 
tissue  specific,  and  result  only  in  metabolic  abnormalities.  Clearly  this  hypothesis  requires 
229 further  investigation,  however  one  potential  model  may  be  that  of  intracellular  crosstalk 
between  such  circulating  factors  as  TNF-ci  and  insulin-signalling;  if  this  relationship  is 
mediated  at  the  level  of  IRS-1/2,  then  wider  effects  than  those  seen  in  the  dexamethasone 
model  be  manifest. 
In  summary,  I  have  measured  insulin  action  in  the  whole  body,  adipose  tissue  and  vascular 
tissue.  Insulin  sensitivity  in  isolated  tissues  is  closely  related  to  the  clinical  phenotype, 
however  activation  of  endocrine  systems  such  as  the  RAS  and  the  hypothalamic  pituitary 
adrenal  axis  result  in  insulin  resistance.  In  addition,  while  endogenous  insulin  action  is 
coupled  in  different  tissues,  this  delicate  relationship  may  be  disrupted  by  activation  of  such 
systems.  As  reduced  insulin  sensitivity  has  a  relationship  with  type  2  diabetes, 
hypertension,  obesity  and  dyslipidaemia,  these  results  may  have  important  clinical 
implications  for  the  assessment  and  management  of  patients  at  risk  of  developing  vascular 
disease. 
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